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resumo 
 
 
A Doença de Alzheimer (DA) é uma doença multifactorial e progressiva do sistema 
nervoso central. Apresenta uma incidência mundial de 2-7% em indivíduos com 
mais de 65 anos e de cerca de 50% em indivíduos acima dos 85 anos de idade. As 
principais alterações histopatológicas observadas nos doentes são a presença de 
tranças neurofibrilhares intracelulares e depósitos extracelulares de um peptídeo 
de 4 KDa denominado Abeta, que é o principal componente das placas de 
amilóide. Apesar da sua etiologia multifactorial, há uma correlação bem descrita 
entre esta patologia e o Abeta (peptídeo neurotóxico). O Abeta deriva fisiológica e 
proteoliticamente de uma glicoproteína transmembranar com características de 
receptor: a Proteína Percursora de Amilóide de Alzheimer (PPA). As possíveis 
funções fisiológicas da proteína PPA, o seu destino e vias de processamento 
celulares, conjuntamente com possíveis proteínas celulares que com ela interajam, 
são assim tópicos de interesse e áreas de investigação científica mundial. A PPA 
possui na sua estrutura primária sequências consenso para fosforilação, quer no 
seu ectodomínio quer no seu domínio intracelular, já descritas como sofrendo 
fosforilação “in vitro” e “in vivo”. Mais ainda, em alguns casos esta fosforilação está 
associada a estados de doença. Assim sendo, 7 dos 8 aminoácidos que 
hipoteticamente podem ser fosforilados no seu domínio intracelular encontram-se 
fosforilados em cérebros de doentes de DA, nomeadamente, Tyr653, Ser655, Thr668, 
Ser675, Try682, Thr686, Tyr687. O último pertence ao domínio funcional NPTY que é 
um sinal típico de endocitose em receptores associados à membrana e um local 
consenso para a endocitose. Várias proteínas interagem com este domínio 
intracelular da PPA, a maioria possui múltiplos domínios de interacção permitindo a 
formação de multi-complexos de sinalização entre a PPA e proteínas celulares. 
Existe assim a possibilidade dessas proteínas funcionarem como proteínas 
adaptadoras direccionando a PPA para vias de sinalização específicas. A 
interacção da PPA com essas proteínas de ligação parece ser regulada por 
fosforilação proteica, uma vez que a ligação da PPA à FE65 só ocorre quando a 
Thr668 está desfosforilada.  
O uso de proteínas de fusão PPA-GFP permitiu avaliar a função do domínio NPTY, 
através da mimetização do estado fosforilado (Y687E) e desfosforilado (Y687F) da 
Tirosina 687. Resultados contrastantes foram observados na localização subcelular
destas proteínas. A proteína Y687E-PPA-GFP foi detectada na membrana 
plasmática mas não foi eficientemente incorporada em vesículas de tranferrina e 
apresentou uma diminuição significativa na produção de Abeta. Em contraste, a 
proteína Y687F-PPA-GFP é facilmente endocitada, tal como a proteína selvagem, 
e produziu mais Abeta, ou seja ocorreu um favorecimento da clivagem pela via da 
β-secretase. Os resultados obtidos indicam que este resíduo é importante para o 
direccionamento subcelular da proteína PPA e para o seu processamento nas 
diferentes vias, nomeadamente secretória e endocítica. A localização subcelular da 
PPA pode ser mediada por ligação a proteínas específicas. Um desses exemplos é 
a ligação da PPA à RTN3-B, uma vez que ambas co-localizam no retículo 
endoplásmico. 
Adicionalmente, os resultados apontam no sentido de que as interacções entre a 
PPA e as suas proteínas parceiras de ligação estejam dependentes do seu estado 
de fosforilação. Com este propósito o papel da Tirosina 687 no estabelecimento 
dessas interacções foi avaliado. Os resultados demostram que ambas as proteínas
mutantes ligam FE65 e que esta última é a proteína que medeia a conexão entre a 
PPA e a PP1γ. As implicações destas observações na DA e em novas aplicações 
terapêuticas para a doença são subsequentemente discutidas. 
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abstract 
 
Alzheimer’s disease (AD), the most common age-related dementing illness, is a 
progressive multifactorial neurodegenerative disorder of the central nervous 
system affecting individuals worldwide with an incidence of 2-7% of post-65 
and 50% of post-85 years old. The pathological hallmarks of AD are the 
presence of intracellular neurofibrillary tangles and extracellular deposits of a 
4kDa amyloid beta peptide (Abeta) forming amyloid plaques in the cerebral 
cortex. This disease is multifactorial in its etiology but central to its pathology is 
the neurotoxic Abeta peptide. Abeta arises from the proteolytic cleavage of a 
larger ubiquitous glycophosphoprotein, APP (Alzheimer Amyloid Precursor 
Protein), whose short cytoplasmic domain contains several phosphorylatable 
amino acids. The latter can be phosphorylated ‘in vitro’ and ‘in vivo’, and in 
some cases phosphorylation appears to be associated with the disease 
condition. Furthermore, it was demonstrated that 7 of the 8 potentially 
phosphorylatable residues in the intracellular domain of APP were 
phosphorylated in AD patients, namely Tyr653, Ser655, Thr668, Ser675, Tyr682, 
Thr686 and Tyr687. The latter lies within the NPTY domain, a typical 
internalization signal for membrane-associated receptor proteins, as well as a 
consensus sequence for coated-pit mediated internalization. Several proteins 
interact with the above mentioned cytoplasmic domain of APP, most of them 
possessing multiple protein-protein interacting domains, thus forming large 
multimolecular APP complexes. It appears therefore that these proteins 
function as adaptor proteins directing APP to specific molecular pathways. The 
interaction of APP with these binding proteins appears to be regulated by 
protein phosphorylation as has been described for FE65 binding, for example. 
Using APP-GFP fusion proteins to monitor intracellular pathways, the role of 
the NPTY domain was addressed by mimicking Tyr687 constitutive 
phosphorylation (Y687E) and dephosphorylation (Y687F), respectively. 
Contrasting effects on subcellular APP distribution were observed. Y687E-
APP-GFP was targeted to the membrane but could not be detected in 
transferrin containing vesicular structures, and exhibited a concomitant and 
dramatic decrease in Abeta production. In contrast, Y687F-APP-GFP was 
endocytosed similarly to wild-type APP, but was relatively favoured for beta-
secretase cleavage. Overall, Tyr687 appears to be a critical residue determining 
APP targeting and processing via different pathways, including secretory, 
endocytic and retrograde transport. Significantly, from a disease perspective, 
mimicking Tyr687 phosphorylation resulted in a hitherto undescribed inhibition of 
Abeta production. Our results provide novel insights into the role of direct APP 
phosphorylation on APP targeting, processing and Abeta production. Targeting 
of APP is most likely mediated by binding to specific proteins. One such novel 
interaction identified was RTN3-B. These two proteins colocalize in the ER. 
Additionally, our conclusions so far, favour the model that interaction of APP 
with the binding proteins may also be mediated by the phosphorylation state of 
APP itself and with this proposal the role of Tyr687on protein-protein interactions 
was investigated. We demonstrated that FE65 binds to both Tyr687 mutants and 
also that FE65 is the bridging protein between APP and PP1γ. 
Our results provide novel insights into the role of direct APP phosphorylation on 
processing and Abeta production, pointing towards potential intervention 
strategies for the treatment of Alzheimer’s disease. 
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CHAPTER I 
 
GENERAL INTRODUCTION 
 
 
 
1.1 ALZHEIMER’S DISEASE 
 
Alzheimer’s disease (AD), the most common age-related dementia, is 
characterized by progressive and insidious neurodegeneration of the central nervous 
system leading to gradual decline in cognitive function that ultimately leads to 
dementia. AD represents more than 50% of all dementia cases and is the most 
frequent human disorder featuring accumulation of abnormal proteins in the brain. It 
was first described by Alois Alzheimer in 1906 after characterization of a patient 
named Auguste D., who suffered from strong jealousy towards her husband, 
increased memory impairment, disorientation, hallucinations and aggressive 
behaviour. After four and half years of rapid deteriorating mental illness, August D. 
died in a completely demoted state. This disease, bearing his name, largely remained 
an enigma until the end of the 20th century.   
United Nations population projections estimate that the number of people older 
than 80 years will be 370 million by the year 2050. Currently, it is estimated that 50% 
of people over the age 85 are afflicted with AD. Therefore, if these predictions hold 
true, in 50 years, more than 100 million people worldwide will suffer from this 
dementia. The vast number of individuals requiring constant care and other services 
will severely strain medical, monetary and human resources (Chang and Suh 2005). 
Nowadays AD affects 20 million people worldwide (Selkoe and Schenk 2003), and it is 
estimated that approximately 55 000 people are affected in Portugal. 
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1.2 NEUROPATHOLOGICAL HALLMARKS OF AD  
 
Brains of AD patients are characterized by cortical atrophy in the form of gyral 
shrinkage, widening of the sulci and enlargement of the ventricles. The first regions to 
be affected are the hippocampus and the entorhinal cortex (Figure 1; Braak and Braak 
1994).  
 
 
Figure 1. Normal brain (A) and Alzheimer’s brain (B) (taken from 
http://images.google.pt). 
 
 
Moreover, with disease progression, a pronounced neurodegeneration occurs in 
the temporal and parietal lobes. The frontal and occipital lobes may also be affected in 
some patients. The key neuropathological features of AD detected by microscopy are: 
the presence of intracellular neurofibrillary tangles (NFTs), extracellular amyloid 
plaques, neuronal cell death and synaptic degeneration. The origin and the role of the 
neurofibrillary tangles and amyloid plaques are quite different, although both lead to 
degeneration.  
 
 
 
 
 
 
 
B A 
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The NFTs are composed of paired helical filaments (PHFs), aggregates of 
abnormally phosphorylated tau protein which accumulate in the cytoplasmic 
compartment of neurons and are primarily found in the pyramidal regions of 
amygdala, hippocampus and neocortex (Figure 2). Tau is a microtubule-associated 
protein that regulates cytoskeleton structure. When highly phosphorylated, tau is 
sequestered into paired helical filaments and causes disruption of microtubules, that 
ultimately leads to cell death.  
 
 
 
Figure 2.Neurofibrillary tangles (NFTs). The NFTs are composed of paired helical 
filaments (PHFs) ( taken from http://images.google.pt).  
 
 
In brains of AD patients, neurofibrillary tangles can also appear as ghost cells, 
having the shape of dead neurons. The density of NFTs correlates well with the loss of 
cells and synapses and also with the neuropathological disease stage. Tau, belonging 
to the family of microtubule-associated proteins is required for initiation and 
stabilization of neuronal microtubules through tubulin binding. More than 40 different 
phosphorylation sites on tau have been identified, mainly on serine and threonine 
residues followed by proline (Grundke-Iqbal et al. 1986).These sites are 
phosphorylated by several kinases (e.g. glycogen synthase kinase 3β, GSK-3β) and 
seem to confer different functional properties to tau. Furthermore, phosphorylation of 
tau by protein kinases such as the neuron-specific cyclin dependent kinase 5 (cdk5) 
precedes the formation of PHFs that causes neurodegeneration (Noble et al. 2003). In 
AD, tau is hyperphosphorylated, causing impaired microtubule function and leading to 
a fatal breakdown of the neuronal cytoskeleton. 
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The classical amyloid plaques (APs; Figure 3), can also be called as senile 
plaques. They consist of a central amorphous core that can be identified by 
histopathological stains such as Congo red and Thioflavin T. The core is surrounded by 
neuronal and glial processes. Moreover, amyloid plaques are found diffusely 
throughout the brain, but notably in the central cortex and hippocampus of AD 
patients (El Khoury 1996; Noble et al. 2003)  
 
 
  Figure 3. Amyloid plaque (AP). The major component of the AP is the Abeta peptide 
(taken from http://images.google.pt).  
 
 
The major proteinaceous component of these deposits is a 40-42 amino acid 
aggregated polypeptides termed Abeta (Abeta1-40 and Abeta1-42), derived by 
proteolytic cleavage from the larger Alzheimer’s Amyloid precursor protein (APP) 
(Glenner and Wong 1984; Masters et al. 1985). The majority of Abeta peptides are 40 
amino acids long (Abeta1-40), soluble and apparently less neurotoxic, whereas the 
more hydrophobic peptides (less soluble) are 42 amino acids long (Abeta1-42) and 
although they are less prevalent, overall they predominate in the protein core of 
plaques (Jarrett et al. 1993; Jarrett and Lansbury 1992). Diffuse plaques, which are 
focal diffuse deposits of amyloid without accompanying dystrophic neurites, and that 
may represent an early stage of AD plaques, contain predominantly Abeta1-42 and low 
levels of Abeta1-43 rather than Abeta1-40 (Gowing et al. 1994; Iizuka et al. 1995; 
Iwatsubo et al. 1995; Iwatsubo et al. 1994; Lemere et al. 1996).  
The term “soluble Abeta” generally is applied either to the newly generated, 
cell-secreted Abeta or to the fraction of tissue or synthetic Abeta that is taken into 
aqueous phase of a non-detergent-containing extraction buffer. “Misfolded” and 
aggregated” Abeta are terms used to describe very early, nonspecific changes in Abeta 
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folding states or solubiltity sates, respectively. “Oligomeric” Abeta refers to peptide 
assemblies with limited stoichiometric (e.g. dimmers, trimers, etc.), while protofibrils 
(PFs) are structures of intermediate orther between aggregates and fibrils. The term 
“Abeta-derived diffusible ligands” (ADDLs) is also applied to pre-protofibrillar 
intermediates (Figure 4). Indded, oligomers, PFs and ADDLs are believed to be the 
assembly states of Abeta with the most potent toxicity and also that are the proximate 
mediatotors of Abeta induced neurotoxicity, specially in neuronal cultures models 
(Kayed et al. 2004; Klein et al. 2001). The final assemblies, called fibrils, are the basic 
building blocks of the amyloid plaque (Figure 3) and are so named because of their 
characteristic ultrastructural appearance. 
 
 
 
Figure 4. Different assembly (biophysical) states of Aβ. The assembled forms obtained 
from incubation of synthetic Aβ are highly sensitive to preparation and incubation. Widely 
differing proportions of insoluble fibrils (A), soluble PFs (B), and oligomers (C), also known as 
ADDLs are revealed by atomic force microscopy. Scale bars: 200 nm. (Adapted from Gandy 
2005). 
 
 
Several other components, such as proteoglycans, inflammatory molecules and 
apolipoprotein E have also been identified in plaques.  
Amyloid vs NFTs. Evidence points to amyloid deposition preceding and 
leading to the formation of NFTs in some patients, with Abeta preceding Tau 
aggregation. In agreement with this, Tau deposition in transgenic mice is influenced 
by Abeta (Lewis et al. 2001; Stalder et al. 1999). In young Down’s syndrome patients, 
Abeta deposits exist in the absence of NFTs, notably in areas of the brain most 
affected by AD (Gouras et al. 2000b; Iwatsubo et al. 1995; Leverenz and Raskind 
1998). Typically, these two aggregates (APs and NFTs) constitute the neuropathologic 
criteria confirming AD. Post-mortem brain autopsy is still the most accurate and 
       A                                     B                                     C 
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definitive means of diagnosing AD (Crimson and Eggert 1999) but the patient’s death 
often occurs long after the onset of the dementia. Consequently, the relationship 
between the pathology and the actual mechanism of the disease remains unclear. 
 
 
1.3 GENETICS OF ALZHEIMER’S DISEASE 
 
It is now widely accepted that genes play an essential role in predisposing to 
AD onset and in modifying the progression of the disease. Thus, AD can be classified 
into several subgroups. Familial (FAD) versus sporadic AD are grouped according to 
the occurrence or absence of other demented persons in the family. AD has also been 
divided into early versus late-onset AD, depending on whether the patient presented 
the first symptoms before or after the age of 65 years. However, the pathological 
hallmarks of different forms of AD seem to be the same, inspite the the difference in 
the genetic background. Approximately 10% of all familial Alzheimer’s disease cases 
are inherited in an autossomal dominant Mendelian pattern (Selkoe and Podlisny 
2002). Other familial cases and sporadic AD have more complex modes of inheritance. 
Besides age as the main risk factor, a number of susceptibility genes were found 
which contribute to the occurrence of sporadic AD.  
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A. Early-onset AD: 
 
 
B. Late-onset AD: 
 
 
Figure 5. Scheme of contribution and interaction of the known and putative AD 
related genes. A. Mutations in the early-onset AD genes: APP, PSEN1 and PSEN2 all lead to an 
increase in Abeta production. B. Representation of the interaction of known and proposed late-
onset AD genes. These risk-factor genes are each likely to affect one or more of the known 
pathogenic mechanisms resulting in neurodegeneration. Their effects are further influenced by 
gene-gene interactions and the contribution from non-genetic risk-factors (Adapted from 
Bertram and Tanzi 2004). 
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Altered Abeta production 
Neurodegeneration 
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To date, three genes responsible for familial AD have been identified: APP 
gene, Presenilin 1 gene (PSEN1) and Presenilin 2 gene (PSEN2) (Table 1 and Figure 
5A). Pathogenic mutations in these genes account for up to 50% of familial cases of 
early-onset AD. If one of the genes is mutated, the gene product leads to the 
development of AD with almost always 100% penetrance. Together, these mutations 
are estimated as less than 1% of the total number of AD cases (Delacourte et al. 
2002). 
 
Table 1. Overview of Alzheimer’s disease genes, their incidence and functional 
relevance to AD pathogenesis. Chromo., Chromosome location 
Gene 
 
Chrom. 
location 
Mode of 
inheritance 
Number of 
pathogenic 
mutations 
Mean  
Familial 
onset age 
Revelance to 
AD 
pathogenesis 
APP 21q21.3 
Autossomal-
dominant 
18  
51.5 years 
 
Increase in Aβ: 
(Aβ42/Aβ40 ratio) 
 
PSEN1 14q24.3 
Autossomal-
dominant 
142  
44.1 years 
 
Increase in Aβ: 
(Aβ42/Aβ40 ratio) 
PSEN2 1q31-42 
Autossomal- 
dominant 
10  
57.1 years 
 
Increase in Aβ: 
(Aβ42/Aβ40 ratio) 
APOE 
(ε4-allele) 
19q13.32 
Complex 
(risk increased) 
n.a. 
Onset-age 
modifier 
Increase in Aβ 
Aggregation 
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1.3.1 APP hereditary mutations 
 
So far, 18 mutations of the APP gene (Table 1; chromosome 21) have been 
described in AD families with early onset and autosomal dominant inheritance from 
different parts of world (Alzheimer Disease and Frontotemporal Dementia Mutation 
Database, available at http://www.molgen.ua.ac.be/AD). The first mutation 
discovered in the APP gene was Glu22 to Gln within the Abeta sequence and was 
termed the “Dutch mutation” (Figure 6) (Hardy and Allsop 1991). Synthetic peptides 
containing this mutation were shown to have an increased propensity to aggregate 
(Clements et al. 1993; Wisniewski et al. 1991). Furthermore, some British families 
with early-onset AD were found to have pathogenic mutations at positions 642 of APP 
(APP695 numbering) resulting in a change from Val642 to Ile, Gly or Phe (Figure 6; 
(Chartier-Harlin et al. 1991; Goate et al. 1991; Murrell et al. 1991). This mutation was 
named the “London mutation”. These APP mutations were all shown to result in an 
increase in the relative amounts of long Abeta1-42 compared with Abeta1-40 (increased 
Abeta1-42/Abeta1-40 ratio). Being that synthetic Abeta1-42 aggregates more readily in 
vitro than Abeta1-40 (Burdick et al. 1992), suggests that these mutations directly affect 
amyloid deposition, in this case by diverting the proteolytic processing of APP towards 
the production of the longer, more amyloidogenic forms of Abeta. The Swedish double 
mutation (Lys595 and Met596 are mutated to Asn and Leu; Figure 6) resulting in 
increased secretion of Abeta, presumably through enhanced cleavage at the β-
secretase site (Cai et al. 1993; Citron et al. 1992).Thus, familial pedigrees have been 
identified worldwide, and the geographical origin of the initial discovery is often used 
to name the mutant molecule. A recently discovered pathogenic mutation, found in AD 
patients from northern Sweden, near the Arctic circle, was named of Artic mutation 
and effectivelly decreases the levels of total Abeta production and the molecules that 
are generated have increased propensity to oligomerize (Nilsberth et al. 2001; Paivio 
et al. 2004). The number of carriers of the various mutations may differ across clinical 
populations. In the general population, not more than 0.5% of early-onset AD patients 
carry a mutation in the APP gene (Sleegers and Van Duijn 2001). Amoung all AD 
patients, not more than 0.005% carry a mutation in APP. 
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Figure 6. APP mutations. Abeta region showing the pathogenic APP mutations 
(residues are numbered according to APP695 or the Abeta position). 
 
 
1.3.2 PSEN hereditary mutations 
 
Mutations in two other genes have been found to lead to early-onset autosomal 
dominant forms of AD (Table 1). The presenilin-1 (PSEN1) and presenilin-2 (PSEN2) 
genes were localized using linkage analysis (Levy-Lahad et al. 1995; Sherrington et al. 
1995). These genes encode proteins that are involved in the normal cleavage of the 
APP protein, increasing the production of Abeta1-42 (Citron et al. 1997; Xia et al. 
1997).However, the PSEN1 sequence does not point to a specific enzymatic activity for 
this protein, it may play a role as chaperone in the γ-secretase complex that includes 
other proteins like nicastrin. This molecule was identified in association with PSEN1 
and influences APP metabolism (Yu et al. 2000). A total of 142 mutations have been 
found in PSEN1 in 281 families (Table 1; http://molgen-www.uia.ac.be/AD 
Mutations/). This is the gene with highest number of pathogenic mutations in AD. For 
PSEN2, 10 mutations have been found in 16 families (Table 1). In the general 
population, mutations in the presenilin genes explain about 7.5% of early-onset AD 
(6.5% for PSEN1 and 1% for PSEN2). When considering all patients, both early and 
late onset, sporadic and familial cases, the presenilin genes explain less than 0.075% 
of the cases (Sleegers and Van Duijn 2001). PSEN mutations may disturb protein 
AbetaN CAPP
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1 40
N L - Swedish
G - Flemish
Q - Dutch
K - Italian
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interactions in the complex through subtle conformational alterations (Cruts et al. 
1998). The effects of PSEN1 and PSEN2 mutations on Abeta levels have been analysed 
in cellular models and in biological samples from patients. Overproduction of Abeta1-42 
was found in the media of several cell types co-transfected with PSEN1 and APP cDNA 
in wild-type or mutated form. The expression of mutated PSEN1 or PSEN2 leads to a 
1.5-5 fold increase in the concentration of Abeta1-42 in the media compared to cells 
expressing wild-type PSEN1 and 2. 
 
 
1.3.3 APOE 
 
Apolipoprotein E (APOE) was identified as a risk factor or a susceptibility gene 
for AD in 1993 (Table 1; Strittmatter et al. 1993). APOE plays a major role in 
lipoprotein metabolism and cholesterol homeostasis in the brain (Mahley 1988). The 
relationship between APOE and AD has been confirmed in more than 100 studies 
conducted in diverse ethnic backgrounds (Farrer et al. 1997). There are three isoforms 
of the protein: E2, E3 and E4, which are encoded by three different alleles ε2, ε3 and 
ε4 (Kowalska et al. 1998). Carriers of the APOE ε4 allele are at higher risk of 
developing AD in a dose dependent manner (Kowalska et al. 2003). Thus, 
homozygotes for the APOE ε4 allele usually develop AD at an earlier age than 
heterozygotes (Corder et al. 1993). However, the presence of the APOE ε4 allele is 
neither necessary nor sufficient to develop AD. Moreover, there is a strong evidence of 
the role of APOE in AD. This gene has been implicated in different pathophysiological 
pathways leading to neurodegeneration, including Abeta1-42 deposition and 
antioxidative stress (Lahiri and Greig 2004). Neuropathological studies using brain 
tissues in AD patients have shown a higher density of neuritic plaques and 
neurofibrillary tangles in APOE ε4 carriers (Tiraboschi et al. 2004). Biochemical studies 
have demonstrated that the APOE protein can bind both the Abeta1-42 and tau protein. 
Furthermore, transgenic knock-out mice expressing human APOE ε4 have an 
imparment in cognitive function and also show neuropathological changes. Finally, 
higher levels of APOE expression have been associated with AD in several studies 
(Strittmatter et al. 1993). However, the exact mechanism by which the APOE gene 
increases the risk of AD remains to be determined. On the population level, the APOE 
ε4 allele plays an important role, explaining up to 17% of all patients. 
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It has been suggested that as much as 50-60% of all AD cases might be 
genetically influenced by different susceptibility genes, such as IL-1, tumor necrosis 
factor and α2-macroglobulin (Daw et al. 2000). Recently new susceptibility loci for late 
AD have been identified on chromosomes 1, 9, 10, 12 and 13 (Figure 5B; Bertram and 
Tanzi 2004; Blacker et al. 2003). 
 
 
1.4 THE “AMYLOID CASCADE” OF AD ETIOLOGY 
 
The “amyloid cascade hypothesis” of AD (Figure 7), which is now widely 
accepted, describes the pathogenesis of this disease as a cascade of several steps, 
from the initial generation of the Abeta peptide to cognitive impairment and neuronal 
loss. Thus, several lines of evidence suggest that the small pepide Abeta is central to 
the progression of the disease. Firstly, genetic studies in cases of familial AD have 
demonstrated that over 150 mutations in three autosomal dominant genes: APP, 
PSEN1 and PSEN2 are associated with increased production of Abeta peptides by 
altering the proteolytic processing of APP (Robakis and Pangalos 1994). Secondly, 
Down’s syndrome (trisomy 21) patients with three copies of APP, deposit increased 
levels of Abeta peptide resulting in amyloid plaque deposition and dementia (Holtzman 
et al. 2000). Thirdly, the APOE ε4 genotype is a significant risk factor for developing 
late-onset AD, and has been shown to modulate both levels of Abeta peptide and the 
aggregation state and clearance of the peptide (Walsh et al. 2002). Finally, multiple 
reports have demonstrated the neurotoxic effects of fibrillar and soluble oligomeric 
species of Abeta peptides both in vitro and in vivo (Lammich et al. 1999). Irrespective 
of the cause (or toxic Abeta species), it is likely that during the disease process the 
balance between Abeta production and Abeta catabolism is altered, resulting in the 
slow accumulation of toxic Abeta species, amyloid deposition in the brain, and 
ultimately neuronal dysfunction and degeneration. 
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At the molecular level, diffuse neurocentric amyloid deposits would progress 
over time and eventually become neuritic amyloid plaques. One hypothesis is that 
deposition of Abeta1-42 may form a “precipitation core” to which soluble Abeta1-40 could 
aggregate, in an AD-specific process. The “in vivo” aggregation of Abeta may 
precipitate a chronic and destructive inflammatory process in the brain, occurring in 
the immediate vicinity of amyloid plaques in AD patient brains (Eikelenboom et al. 
1994). Some of the proinflammatory molecules thereby produced may be locally toxic 
to neuronal processes in the vicinity of the amyloid plaque, such as complement, 
cytokines, reactive oxygen and nitrogen intermediates. They also produce factors, 
such as Interleukin-1 (IL-1), which stimulate APP synthesis, leading to a vicious cycle 
of reciprocal activation and growth, which potentiates a local inflammatory cascade. 
These would culminate in the neurodegenerative process possibly via free radical 
production by microglia cells and/or complement lysis of neuronal membranes (Allsopp 
2000). Although it is not clear if Abeta accumulation is a cause or effect in AD, its 
production nonetheless plays a central role. 
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Figure 7. The sequence of pathogenic events leading to AD was proposed as amyloid 
the cascade hypothesis. The cascade is initiated when the Abeta1-42 is generated. In familial 
early onset AD, the Abeta1-42 is overproduced as a result of pathogenic mutations. In sporadic 
AD, various factors can contribute to an increased load of Abeta1-42 oligomers and their 
aggregation (Adapted from Citron 2004; Hardy and Selkoe 2002). 
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1.5 THE ALZHEIMER’S AMYLOID PRECURSOR PROTEIN 
 
 
1.5.1 Gene family 
 
APP and related family members, amyloid precursor like protein-1 and -2 
(APLP-1 and APLP-2), are homologous type-I transmembrane proteins (Selkoe 2001) 
that are similarly post-translationally modified and processed, as well as having 
overlapping expression in brain (Bayer et al. 1999). The nearest relative to APP is 
APLP-2, sharing 50% homology. Thus, these three proteins are well-conserved in 
evolution, functionally and structurally related, and probably share similar functions 
(Bayer et al. 1999; Coulson et al. 2000). Moreover, knockout mice studies reveal a 
functional redundancy among APP family members but knockout of all three genes 
simultaneously, or of APLP-2 and APP, is lethal in utero (Heber et al. 2000). 
Structurally, the mammalian APP family members possess a single transmembrane 
domain, as well as a large extracellular domain and short intracellular domain. Of note 
is that APLP-1 and APLP-2 share homology at the amino acid sequence, domain 
structure and protein organization with APP, but lack the Abeta domain. Moreover, 
because of the high degree of homology in the N-terminal region between APLP’s and 
the amyloidogenic APP isoforms, some N-terminal antibodies recognizes both APP and 
APLP’s (Slunt et al. 1994; Webster et al. 1995). 
Other members of the APP superfamily have been identified in non-mammalian 
species and include APPL in Drosophila (Luo et al. 1992; Rosen et al. 1989), APL-1 in 
C. elegans (Daigle and Li 1993) and an APP homologue protein in Xenopus (Okado 
and Okamoto 1992). 
 
 
1.5.2 Isoforms 
 
The APP gene is located on human chromosome 21 (21q21.2-3) and contains 
18 exons (GenBank A.N. D87675), with the Abeta sequence divided between exons 
16 and 17 (Figure 8). The sequence of the Abeta peptide starts at residue 597 (except 
when otherwise indicated, numbering is according to the APP695 isoform) and spans 
the extracellular and membrane domains. At least eight APP isoforms have been 
described, numbered according to their length in amino acids: L-677, 695, L-696, 
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714, L-733, 751, L-752, 770 (Kitaguchi et al. 1988; Ponte et al. 1988). These 
isoforms arise from alternative splicing of exons 7, 8 and 15 of the APP mRNA (Kosik 
1993) and differ only in size of the extracellular domain. Analysis of APP mRNA 
expression levels revealed that APP can be detected in almost all tissues examined, as 
well as in cultured cells. It is ubiquitously expressed in mammalian cells (Golde et al. 
1990; Neve et al. 1988; Sisodia and Price 1995; Tanzi et al. 1987; Tanzi et al. 1988) 
with a broad tissue distribution. The tissue-specific pattern of APP mRNA splicing was 
studied by RT-PCR analysis (Sandbrink et al. 1994a). The less abundant L-APP 
isoforms, lacking exon 15, are mainly expressed in leukocyte cells, such as T-
lymphocytes, macrophages and microglial cells. They are also ubiquitously expressed 
in rat tissues, including brain, but not in neurons (Ohgami et al. 1993; Sandbrink et 
al. 1994a). 
 
 
Figure 8. Exon structure of the full length APP transcript and the final eight isoforms. 
The alternatively spliced exons are indicated in colour: yellow, exon 7; green, exon 8; orange, 
exon 15. The Abeta sequence is indicated in red. 
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The three major APP isoforms were found to be the 695, 751 and 770 (Figure 
8). Of these, APP695 is the only one lacking exon 7. The exon 7-containing APP mRNA 
isoforms (751 and 770) are predominantly expressed in peripheral tissues. Brain 
tissue expresses little APP770 and, depending on the animal species and brain region 
analysed, low, intermediate or high levels of APP751 (Kang and Muller-Hill 1990; Konig 
et al. 1989; Neve et al. 1988; Tanaka et al. 1989). However, the exon 7-containing 
isoforms predominate in cultured astrocytes (Gray and Patel 1993a; Gray and Patel 
1993b; Rohan de Silva et al. 1997), with the 695:751:770 ratio being 1:4:2 (Gray and 
Patel 1993a; Gray and Patel 1993b). A number of studies have indicated that 
alternative splicing of exons 7 and 8 changes in brain with aging and in AD, but results 
obtained are still inconsistent and controversial to consider altered alternative splicing 
as an AD risk factor (Moir et al. 1998; Panegyres et al. 2000; Rockenstein et al. 1995; 
Sandbrink et al. 1994b). Conversely to the 751 and 770 isoforms, the 695 is the APP 
isoform predominantly produced in the mammalian brain, with the 695:751:770 
mRNA ratios being approximately 20:10:1 (Tanaka et al. 1989). Furthermore, APP695 
is most highly expressed in neurons, representing 95% of total neuronal APP (LeBlanc 
et al. 1991; Tanzi et al. 1987; Weidemann et al. 1989), and is therefore often referred 
to as the “cerebral” or “neuronal” isoform. In conclusion, as APP695 is the isoform 
predominantly produced in the brain, and predominates within the CNS (Neve et al. 
1988; Tanzi et al. 1993), this isoform has received the most attention in AD research. 
 
 
1.5.3 Functional domains 
 
APP exon 7 encodes a 56-amino acid (aa) stretch with homologies to the 
Kunitz-type protease inhibitors (KPI) that inhibits proteases, such as trypsin or 
plasmin, and blood coagulation factors (Kitaguchi et al. 1988; Ponte et al. 1988; Van 
Nostrand and Cunningham 1987; Wagner et al. 1992). Exon 8 encodes a 19-aa 
domain with homologies to the MRC OX-2 antigen found on the surface of neurons and 
certain immune cells such as thymocytes (Clark et al. 1985; Kitaguchi et al. 1988; 
Tanzi et al. 1988). In adition to KPI and OX-2, several other structural features have 
been identified within the APP ectodomain (Figure 9).  
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Figure 9. APP functional subdomains (APP770 numbering). Pink, signal peptide (1-17); 
yellow, heparin-binding domains (28-123; 174-185; 391-412); violet, copper-binding domain 
(135-155); green, zinc-binding domain (181-188); dark blue, KPI domain; grey, OX-2 domain; 
“RERMS”, putative growth-promoting motif (403-407); orange, gelateinase A (matrix 
metalloproteinase) inhibitor (407-417); black, collagen-binding site (523-540); red, Abeta; 
“RHDS”, integrin-binding motif (aa 5-8 of Abeta); “VHHQK”, heparin-binding motif (aa 12-16 of 
Abeta).  
 
Two subdomains (328-332 and 444-612) were deduced to have a 
neuroprotective function. The “RERMS” sequence with putative growth-promoting 
properties (Ninomiya et al. 1993). Several heparin-binding domains (Small et al. 
1994), a collagen-binding site (Beher et al. 1993 ), an integrin-binding motif (amino 
acid sequence RHDS at residues 5-8 of Abeta) (Ghiso et al. 1992) and N-linked 
carbohydrate attachment sites (Weidemann et al. 1989) were also found in this 
region. Indeed, APP has been shown to bind laminin, collagen, and heparin sulphate 
proteoglycans (Breen et al. 1991; Kibbey et al. 1993). The ectodomain also contains 
two binding-sites for metals such as zinc (Bush et al. 1993; Bush et al. 1994) and 
copper (Hesse et al. 1994; Multhaup et al. 1996).  
 
 
1.5.4 Proteolytic processing 
 
APP is processed by three different proteases named α-, β-, and γ-secretase 
(Esler and Wolfe 2001) (Figure 10). Their cleavage sites were therefore named α-, β- 
and γ-sites. In its simplest form, APP proteolytic processing was described as occurring 
via two distinct pathways, one being non-amyloidogenic and the other amyloidogenic. 
N C 
“RERMS” “RHDS” 
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This classification arose as α- and β-cleavages appear to be mutually exclusive events, 
with one precluding and the other leading to Abeta production (Nunan and Small 
2000; Small and McLean 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. APP is processed by either α-secretase or β-secretase, which cleave at two 
different sites in the extracellular domain. Cleavage of APP by α-secretase (TACE and ADAM10) 
results in formation of C83, which precludes Abeta formation. After α-secretase cleavage of C83, 
a small peptide fragment called p3 is produced. Alternativelly, by the sequential action of β-
secretase (BACE1) and γ-secretase, the Abeta peptide is produced. AICD, APP intracellular 
domain (Adapted from Kerr and Small 2005).  
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α-secretase 
 
The predominant pathway by which APP is processed does not give rise to 
Abeta fragments and involves the cleavage of APP by the α-secretase, and it is 
referred to as the non-amyloidogenic pathway (Figure 10). Moreover, once cleaved by 
α-secretase, APP can no longer be processed to form Abeta by other enzymatic 
pathways. This suggests that the processing of APP by this pathway not only does not 
lead to AD, but may also be neuroprotective. The α-secretase cleaves APP within the 
Abeta sequence, between lysine 16 and leucine 17 and produces a secreted form of 
APP (sAPPα) of 105-125 KDa and an 83-residue fragment called C83, an 
approximately 10 KDa C-terminal fragment, which remains membrane associated. 
Further processing of C83 by γ-secretase yields a p3 fragment (approximately 3 KDa) 
and a γ-cleaved C-terminal fragment (γCTF), also known as the APP intracellular 
domain (AICD). The p3 peptides are not generally found in the amyloid cores of 
classical plaques or in amyloid deposits in cerebral vasculature. Both sAPPα and p3 are 
secreted by a variety of cultured cells and are found in human brain as well as in CSF 
(Oltersdorf et al. 1990; Palmert et al. 1989a; Palmert et al. 1989b; Schubert et al. 
1989a; Schubert et al. 1989b; Selkoe et al. 1988; Weidemann et al. 1989). The 
trafficking of APP mainly follows the constitutive secretory route which involves α-
secretase in the trans-Golgi network (Kuentzel et al. 1993; Sambamurti et al. 1992) 
and at the cell surface (Sisodia 1992). 
In order to explore the upregulation of α-secretase activity as a therapeutical 
target for AD, it is essencial to identify the protease responsible for the α-secretase 
activity. In 1999 it was indicated that a disintegrin and metalloproteinase-10 
(ADAM10) has α-secretase activity in vitro and in cultured cells (Lammich et al. 1999). 
Purified ADAM10 cleaved APP derived peptides at the α-secretase cleavage site and 
overexpression of ADAM10 in several cell lines resulted in increased α-secretase 
activity. Consistently, expression of mutated ADAM10 significantly decreased 
endogenous α-secretase activity. Finally, it was possible to stimulate the α-secretase 
activity of ADAM10 with phorbol esters, and to inhibit it by hydroxamic acid-based 
inhibitors for metalloproteinases. In vivo studies using transgenic mice which 
overexpress either ADAM10 or the catalytic inactive ADAM10 mutant have shown that 
a moderate overexpression of ADAM10 in mice transgenic human APP [V717I] 
increased the release of the neurotrophic N-terminal APP domain (sAPPα), reduced the 
formation of Abeta1-40 and Abeta1-42, and prevented their deposition in plaques. 
Functionally, impaired long-term potentiation and cognitive deficits were alleviated. 
Thus, ADAM10 has been found to possess both a constitutive and a regulated 
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secretase activity and so has been proposed as the major APP-processing enzyme in 
the brain (Postina et al. 2004). 
A transmembrane glycoprotein, tumor necrosis factor α-converting enzyme 
(TACE) or ADAM17 is another member of the ADAM family that shows α-secretase 
activity in cellular systems. 
 
 
β-secretase 
 
A second pathway for the proteolysis of APP, referred to as the amyloidogenic 
pathway, involves a first cleavage by β-secretase (Figure 10). β-secretase cleaves APP 
at the N-terminal side of Asp1 of the Abeta sequence. This is the major cleavage site 
for β-secretase, although some cleavage adjacent to Glu11 can also occur. Cleavage at 
Asp1 results in the production of a N-terminal fragment of APP (sAPPβ) that is released 
from the membrane (Schubert et al. 1993) and a C-terminal membrane associated 
fragment called C99 (Figure 10). The C99 is processed by γ-secretase to generate 
predominantly Abeta1-40 (90%) and Abeta1-42 (10%) fragments (Haass et al. 1992; 
Seubert et al. 1992). Abeta species from 1-39 to 1-43 amino acids long can also be 
produced, with fragments appearing to be more amyloidogenic with increasing length. 
Moreover, using C99 as a substrate, the additional product of γ-secretase processing is 
a short 59/57 amino acid long C-terminal peptide, named the APP intracellular domain 
(AICD) or γCTF. However, gamma CTF is very unstable “in vivo” and difficult to be 
detected both in brain or cell lysates (Kimberly et al. 2005; Pinnix et al. 2001; Zheng 
et al. 2003). In fact, the CTF gamma/C59 AICD is rapidly degraded (half-life of 
approximately 5 min) by a mechanism that is not inhibited by endosomal/lysosomal or 
proteasome inhibitors (Cupers et al. 2001). By sequence analysis of the AICD 
fragment, researchers have found that γ-secretase cleaves APP at an additional site (ε-
site) (Sastre et al. 2001), a few amino acids downstream of the γ-site (Figure 11). 
Although both cleavages are independent of one another, they may occur nearly 
simultaneously (for review see Selkoe and Kopan 2003). This ε-site cleavage is 
thought to occur for better AICD membranar release, and as both cleavages render an 
AICD peptide of 50 aa long, it was unknown which AICD peptide (C59/57 or C50) was 
physiologically functional (Selkoe and Kopan 2003). Nonetheless, evidence points to 
the C50 AICD as the physiologically functional peptide (von Rotz et al. 2004). 
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Figure 11. Schematic representation of the progressive cleavage of APP by α, β, γ-
secretases. The fragments generated by proteolytic activity of the different secretases are 
represented (adapted from Russo et al. 2005).  
 
 
Additional reports have revealed that APP can also be proteolytic processed at 
its C-terminus by caspases, like caspase-3 (Gervais et al. 1999), caspase-6 and -8 
(Pellegrini et al. 1999), or caspase-9 (Lu et al. 2000). The target residue for the 
caspase-directed APP cleavage is Asp622 (Gervais et al. 1999; Weidemann et al. 1999; 
Zambrano et al. 2004). The resulting C-terminus C31 peptide is a potent inducer of 
apoptosis, and this cleavage was shown to reduce APP internalization and to have 
varying effects on the secreted levels of Abeta (Lu et al. 2000; Pellegrini et al. 1999; 
Soriano et al. 2001).  
The generation of Abeta is initiated by β-secretase cleavage of APP (Golde et al. 
1992; Seubert et al. 1993). The endoprotease catalyzing this cleavage at the N-
terminus of Abeta peptide has been identified as β-site APP cleaving enzyme (BACE-1) 
(Hussain et al. 1999; Sinha et al. 1999; Sinha and Lieberburg 1999; Vassar et al. 
1999; Yan et al. 1999). The enzimatically active BACE-1 protein derives from cleavage 
of a pro-peptide within the endoplasmic reticulum (Bennett et al. 2000) and 
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undergoes complex N-glycosilation during the maturation process (Capell et al. 2000; 
Haniu et al. 2000; Huse et al. 2000). Since the enzymatic activity of BACE1 is a 
prerequisite for the generation of Abeta peptides, BACE-1 appears to be a promising 
pharmacological target to reduce the formation of amyloid plaques in AD brains. In 
brain, BACE-1 is primarily expressed by neurons (Bigl et al. 2000) and has been 
localized in known subcellular structures of Abeta generation, i.e. to the Golgi complex 
and to endossomes (Vassar et al. 1999). BACE-1 mRNA and protein levels are rather 
stable during aging of mice and humans (Bigl et al. 2000; Irizarry et al. 2001), 
whereas increased BACE-1 enzimatic activity was detected in several species during 
aging (Fukumoto et al. 2004). In AD, however, increases in both BACE-1 protein 
concentrations and enzymatic activities have been reported (Fukumoto et al. 2002; 
Holsinger et al. 2002). 
In humans, another β-secretase gene has been identified, referred to as BACE-
2, however only BACE-1 is significantly expressed in brain. The therapeutic potential 
of BACE-1 inhibition was demonstrated by findings that BACE-1 knockout mice 
develop normally, but the production of Abeta was completely abolished, suggesting 
that BACE-1 is the principal β-secretase in neurons (Luo et al. 2001; Roberds et al. 
2001; Westmeyer et al. 2004). Developing specific BACE inhibitors has been difficult, 
in part, because there appears to be a non-linear relationship between decreased 
BACE activity in vivo, and reduced Abeta in brain. Studies using heterozygous BACE-1 
knockout animals have shown that a 50% decrease in BACE activity leads to a much 
smaller decrease (~15%) in brain Abeta levels. A further difficulty is the low brain 
penetration of most inhibitors, probably due to the fact that many are substrates for 
glycoproteins, plasma membrane proteins that actively extrude a wide range of 
amphiphilic and hydrophobic drugs from cells, and this is an important mechanism in 
preventing the accumulation of several drugs in the brain. Finally, crystallography of 
BACE-1 has revealed a large catalytic domain making it more difficult to identify small 
molecule transition-state analogues. This problem is further exacerbated if active 
BACE is a dimmer, with a potentially even larger substrate-binding pocket (Paganetti 
et al. 2005). Nevertheless, a number of small molecule inhibitors are close to entering 
clinical trials and should provide much needed efficacy and reliability information. 
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γ-secretase 
 
The C-terminal fragments of APP, C83 and C99, which result from cleavage by 
the α- and β-secretases, remain associated with the membrane and can be further 
processed by a third enzyme, γ-secretase, to produce p3 and Abeta, respectively 
(Figures 10 and 11). The site of γ-secretase cleavage is variable, creating several 
Abeta peptides of different lengths. Although γ-secretase cleavage and the production 
of Abeta are involved in AD pathogenesis, they are also associated with the normal 
processing of APP (Estus et al. 1992; Haass et al. 1992). It is generally accepted that 
a complex of proteins is responsible for γ-secretase cleavage, but the active site of the 
enzyme has not yet been determined unequivocally. Proteins known as PSEN1 and 
PSEN2 are essential for γ-secretase activity (Zhang et al. 2000) and, therefore, could 
possess the active site. A complex containing PSEN1 and PSEN2, the transmembrane 
glycoprotein nicastrin, APH-1, and PEN-2 has been proposed as forming the complete 
γ-secretase complex (Esler et al. 2002; Francis et al. 2002; Lee et al. 2002; Li et al. 
2000a; Li et al. 2000b; Steiner et al. 2002; Wolfe et al. 1999). Their simultaneous 
expression in yeast, an organism that lacks any endogenous γ-secretase activity, 
results in reconstitution of γ-secretase complex formation and activity, demonstrating 
that these four (PSEN1/PSEN2, Nicastrin, APH-1 and PEN-2) membrane proteins are 
the core components of the complex (Edbauer et al. 2003). γ-secretase activity 
depends on the presence of two conserved aspartate residues in either the PSEN1 or 
PSEN2, two polytopic membrane proteins with a partially redundant function (Haass 
2004). Presenilins constitutively undergo endoproteolysis, leading to the generation of 
N- and C-terminal fragments which remain bound to each other and apparently 
constitute the catalytic site of the γ-secretase. The active site aspartate residues of the 
presenilins reside within their TMDs 6 and 7, in agreement with an intramembrane 
cleavage mechanism. The TMD 7 aspartate is located within a highly conserved 
sequence motif GxGD (Steiner et al. 2002), which is also found in other 
intramembrane cleaving proteases, the bacterial type 4 prepilin peptidases and signal 
peptide peptidases. These data strongly suggest that the presenilins are the 
proteolytically active components of the γ-secretase complex. In contrast, the role of 
the other three subunits is less well understood. The type I glycoprotein nicastrin and 
the polytopic membrane protein APH-1 might form a precomplex to which first 
presenilin holoprotein is added (Takasugi et al. 2003).  
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Moreover, studies aimed at understanding the functional activity of nicastrin led 
to the evidence that PSEN1 and nicastrin require each other to become fully mature 
(reviewed in Selkoe and Kopan 2003), and the two can be released from the 
endoplasmic reticulum and be sorted to the plasma membrane where the complex 
PSEN1-nicastrin is biologically active (Kaether et al. 2004; Kaether and Haass 2004; 
Kaether et al. 2002).  
 
 
 
Figure 12.  Topology of the 4 components that comprise the high molecular weight γ-
secretase complex. Black bar represents the cleavage site for processing of the zymogen form 
of PS1 into the amino and carboxyterminal fragments that self associate and form the active 
enzyme (adapted from Gandy 2005).  
 
Because of its large extracellular domain, it was speculated that the role of 
nicastrin within the γ-secretase complex would be to recognize the substrate by 
measuring the length of the membrane-inserted stub (Struhl and Adachi 2000). It has 
been recently demonstrated that nicastrin functions as a γ-secretase substrate 
receptor (Shah et al. 2005), since it binds specifically to the N-terminal side of the APP 
and Notch C-terminal stubs, but not the full length proteins generated upon 
proteolysis at the extracellular domains, and recruits these substrates within the γ-
secretase complex for further cleavage.  
APH-1 and PEN-2 were isolated as part of the γ-secretase complex in two 
genetic screens in C. elegans (Francis et al. 2002; Goutte et al. 2000). These studies 
showed that APH-1 and PEN-2 are required for Notch signalling and Abeta formation 
(Francis et al. 2002). In turn, APH-1 is required together with presenilin for the correct 
localization of the mature form of nicastrin at the cell surface (Goutte et al. 2000). 
Interestingly, these studies also reported that APH-1 exists in more than one isoform, 
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that can be variably involved in the formation of the γ-secretase complex, with the 
form APH-1a being the one mostly involved in Notch signalling and the processing of 
APP (Serneels et al. 2005; Shirotani et al. 2004). Furthermore, it was proposed that 
the physiological significance of PEN-2 together with APH-1 within the γ-secretase 
complex is to stabilize mature presenilin and nicastrin (Steiner et al. 2002), and to 
regulate the endoproteolysis of presenilin leading to the formation of the active 
heterodimer (Hu and Fortini 2003; Luo et al. 2003). Moreover, Prokov et al. (2004) 
showed that the C-terminal domain of PEN-2 is involved in the maturation of nicastrin 
and the formation of presenilin heterodimer. From these observations it could be 
speculated that PEN-2 associates with the complex nicastrin/ PSEN1 in the ER, 
regulating its maturation and sorting to the plasma membrane. 
So far, it is not clear how these four elements (PSEN1, Nicastrin, APH-1 and 
PEN-2) orchestrate γ-secretase activity and so these aspects are under intense 
investigation. Although the catalytic activity of the γ-secretase complex resides in the 
two aspartate residues of PSEN1, these four proteins indeed participate in the 
regulation of one another’s activation and/or maturation, associated with the active γ-
secretase complex and are required to reconstitute γ-secretase in mammalian cells 
(Kimberly and Wolfe 2003) and in yeast (Edbauer et al. 2003). 
The β- and γ-secretases are obvious targets for drug development for 
prevention and treatment of AD, but these proteases have a widespread tissue 
distribution and multiple substrates including Notch1 for presenlin/γ-secretase (Selkoe 
and Kopan 2003). Thus, protease inhibitors may engender toxic side effects. 
 
 The role of the NPTY functional domain on APP trafficking and processing 43 
 
 
1.5.5 Cellular functions of APP and APP fragments 
 
Several functions have been attributed to APP, including a role in brain 
development and signal transduction. As discussed previously, APP is processed to 
produce distinct proteolytic fragments, which in turn have been associated with 
specific functions, different from the holo protein. Some of these putative functions 
are discussed below. 
 
 
Memory 
AD is associated with dementia, so it is perhaps not surprising to find evidence 
for a specific role of APP in long term memory (Doyle et al. 1990; Flood et al. 1991; 
Huber et al. 1993). Specifically, APP knockout mice show impaired behavioral 
performance (Muller et al. 1994; Zheng et al. 1996). Additionally, blocking the 
extracellular domain of APP by intracerebral and intracerebroventricular administration 
of anti-APP antibodies targeted against various isoforms of APP, differentially impairs 
behaviour and memory in rats (Chan et al. 2002; Doyle et al. 1990; Huber et al. 
1993; Turner et al. 2003). Conversely, exposure of hippocampal slices to sAPPα 
results in altered frequency of LTD and an increase in LTP (Ishida et al. 1994), 
strengthening a role for APP in learning and memory processes. Indeed, infusion of 
sAPPα and the RERMS sequence enhances memory formation (Meziane et al. 1998) 
and prevent APP anti-sense induced memory loss (Mileusnic et al. 2000). 
 
 
Brain development 
It has been suggested that the APP protein family has a role in the reelin 
signalling pathway, and may participate in neuronal migration and positioning during 
brain development (Bothwell and Giniger 2000; Ishida et al. 1994). Supporting the 
hypothesis for APP involvement in cell differentiation and synaptogenesis, APP isoform 
levels were found to reach their maximum peak during the second postnatal week of 
the rat, the time which coinsides with brain maturation and completion of synaptic 
connections (Loffler and Huber 1992). Also of note is the finding that APP can be 
regulated by cholinergic mechanisms (Bayer et al. 2001).  
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Cell surface receptor 
The analogy of the secondary structures and proteolytic processing profiles 
between Notch and APP predicts that APP could function as a cell surface receptor 
similar to Notch (reviewed in Selkoe and Kopan 2003). Supporting this hypothesis, 
Bruce Yankner’s group reported that the Abeta peptide could bind APP and thus be a 
candidate ligand for APP (Lorenzo et al. 2000). Evidence from Ho and Sudhof (2004) 
showed that the APP extracellular domain binds to F-spondin, a neuronally secreted 
glycoprotein, and this interaction regulates Abeta production and downstream 
signalling (Ho and Sudhof 2004). Similarly, Nogo-66 receptor was recently shown to 
interact with the APP ectodomain and this interaction affects Abeta production (Park et 
al. 2006).  
 
 
Cell adhesion 
Data linking cell surface APP with cell-substratum and cell-cell adhesion are 
perhaps particularly convincing. The exon 1 and 2 regions have been shown to interact 
with extracellular matrix proteins and heparin sulphate proteoglycans (reviewed in 
Small and McLean 1999), supporting a role in cell-substratum adhesion. The same 
sequences have also been implicated in cell-cell interactions. Specifically, X-ray 
analysis revealed that the exon 2 domain of APP could form antiparallel dimers (Wang 
and Ha 2004). Such structure has the potential to function in trans-cellular adhesion. 
Cell culture studies addressing the homo- or hetero-dimer formation of the APP family 
members, and the trans-dimerizations have shown that this level of organization 
promotes cell-cell adhesion (Soba et al. 2005). However, this activity appears to be 
mediated by the exon 1 domain. Downstream of the exon 1 and exon 2 regions, a 
“RHDS” motif (Figure 9) in the extracellular domain of APP within the Abeta sequence 
also appears to promote cell adhesion. It is believed that this region acts in an 
integrin-like manner by homology to the “RGD” sequence (Ghiso et al. 1992). In this 
regard, it is interesting that APP colocalizes with integrins on the surface of axons and 
at sites of adhesion (Storey et al. 1996; Yamazaki et al. 1997). 
 
 
Neurite outgrowth and synaptogenesis 
A neurotrophic and synaptogenic role for APP is perhaps the most consistently 
documented and arguably the best established, further this function may be linked to 
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its adhesive properties described above. A number of publications have supported 
such a role for the APP extracellular domain in this context, both as holo protein and 
as sAPP following ectodomain shedding. Consistently, APP may exert these activities 
both in an autocrine and paracrine fashion. Thus, APP expression is upregulated during 
neuronal maturation and differentiation (Bibel et al. 2004; Hung et al. 1992). The 
latter is also induced after traumatic injury both in mammals and in Drosophila 
(Leyssen et al. 2005; Murakami et al. 1998; Van den Heuvel et al. 1999). Moreover, 
APP undergoes rapid anterograde transport and is targeted to synaptic sites (Koo et 
al. 1990; Lyckman et al. 1998; Sisodia et al. 1993; Yamazaki et al. 1995), where the 
levels of secreted APP coincide with synaptogenesis (Moya et al. 1994). The crystal 
structure of the exon 1 domain shows similarities to known cysteine-rich growth 
factors, known as the growth factor like domain (GFLD, Rossjohn et al. 1999). 
Previous indications of this APP function came from the observation that assessing 
fibroblasts treated with an antisense APP construct grew slower and the growth 
retardation could be restored by treatment with sAPP (Saitoh et al. 1989). The active 
domain was subsequently mapped to a pentapetide motif “RERMS” in the E2 domain 
(Ninomiya et al. 1993). The activity is not restricted to fibroblasts because the infusion 
of this pentapeptide or sAPP in brain resulted in increased synaptic density and 
improved memory retention in animals (Meziane et al. 1998; Roch et al. 1994), while 
the injection of APP antibodies directly into the brain led to impairment in behavioural 
tasks in the adult rat (Meziane et al. 1998). This result is in agreement with reports 
showing that reduction of APP is associated with impairment of neurite outgrowth and 
neuronal viability in vitro and synaptic activity in vivo (Allinquant et al. 1995; Herard 
et al. 2006; Perez et al. 1997). A recent report demonstrated that the growth 
promoting property is mediated by the ability of the sAPPα to down regulate Cdk5 and 
inhibit tau hyperphosphorylation (Han et al. 2005). Finally, Caille et al. (2004) has 
identified the binding sites for sAPP in epidermal growth factor (EGF)-responsive 
neural stem cells, in the subventricular zone of the adult rodent brain. Furthermore, 
sAPPα acts as a cofactor with EGF to stimulate the proliferation of these cells both in 
neurospheres in culture and in vivo. Because the levels of sAPP have been reported to 
be reduced in individuals with AD (Palmert et al. 1990), this result raises the 
possibility that the loss of the trophic activity of sAPP, and the reduction of other 
growth factors in the brain, may contribute to the neurodegeneration in AD. 
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Axonal transport 
The neuron is unique in cellular morphology with a long axon and a rich 
dendritic arbour. Elaborated protein trafficking exists in neurons for selected proteins 
to reach their designed compartments and to be transported back to the cell soma. 
Protein processing and modifications are known to take place during the transit along 
axons. APP is transported in axons via fast anterograde transport machinery, a 
process that requires kinesin molecular motors, and at least one documented source 
of amyloid deposits originates from the synaptically released Abeta pool (Lazarov et al. 
2002; Sheng et al. 2002). The anterograde transport of APP is proposed to be 
mediated by binding of APP to the Kinesin light chain (KLC) subunit, a component of 
the kinesin-1 transport machinery (Kamal et al. 2000). However, recent evidence is 
more consistent with the view that the interaction is mediated indirectly through 
adaptor proteins, of which JIP-1, a member of the JNK-interacting protein family (JIP), 
is a likely candidate as it is known to interact with both KLC and APP (Sisodia 2002). 
Unresolved by this model is how APP is initially sorted into a particular class of 
vesicles. The potential importance of the initial sorting of APP is underscored by the 
report that BACE-1 and Presenelins are contained within the same Kinesin-1 
dependent APP transport vesicles (Kamal et al. 2001). This finding suggests that not 
only is APP required for the delivery of the enzymatic machinery necessary for Abeta 
production, but Abeta generation also occurs from the cell body to the nerve terminals 
within the transport cargo that is required by APP. However, the report that APP is a 
kinesin-1 receptor and a common vesicular compartment carrying all the processing 
machinery necessary for Abeta generation has not been confirmed by others (Lazarov 
et al. 2005). Nevertheless, KLC deficient animals when crossed with APP transgenic 
mice, showed axonal pathology manifested by axonal swellings and increased amyloid 
levels and deposits in brain (Stokin et al. 2005). The latter argue that perturbations of 
the axonal transport during aging may predispose to the development of AD 
pathology. 
 
 
Cell signalling 
In addition to the γ-secretase that yields Abeta1-40 and Abeta1-42, PSEN-
dependent proteolysis also occurs at other positions including the ε-site (Abeta1-49) 
downstream of the γ-site proximal to the membrane-intracellular boundary (Figure 11; 
Sabo et al. 2003; Sastre et al. 2001; Weidemann et al. 2002; Zhao et al. 2004). 
Recent data provide support for a sequential cleavage model in which ε-cleavage 
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serves as the initial cutting site, followed by δ- and γ-processing within the membrane 
(Kakuda et al. 2006; Qi-Takahara et al. 2005; Zhao et al. 2004). Thus, ε-cleavage of 
APP may represent the primary PSEN-dependent processing event. The importance of 
the latter event is significant being that it releases an APP intracellular domain (AICD) 
that is highly reminiscent of the release of the Notch intracellular domain (NICD) after 
γ-secretase processing, the latter being an obligatory step in Notch mediated signalling 
(reviewed in Selkoe and Kopan 2003). Moreover, PSEN-dependent AICD has been 
shown to translocate to nucleus and could function as a transcriptional regulator 
(Cupers et al. 2001; Gao and Pimplikar 2001; Kimberly et al. 2001). AICD is very 
labile but can be stabilized by FE65 (Cupers et al. 2001). Using a heterogenous 
reporter system, AICD is shown to form a transcriptionally active complex, presumably 
in the nucleus with FE65 and Tip60 (Cao and Sudhof 2001; Gao and Pimplikar 2001). 
However, further studies have revealed that the previous model may be too simplistic 
and incomplete. Firstly, follow up studies showed that nuclear translocation of AICD is 
not required but signalling may be indirect through FE65 (Cao and Sudhof 2004). 
Secondly, PSEN-dependent AICD production is not required for APP signalling activity 
because it happens normally in either PSEN null cells or using a PSEN inhibitor (Haass 
and Yankner 2005). Furthermore, the authors provide an alternative pathway for this 
activity that involves the Tip60 phosphorylation. Finally, a recent report has shown 
that the proposed signalling activity is executed by FE65 and that APP is not required 
(Yang et al. 2006). Overall, a potential nuclear signalling activity remains to be clearly 
established. 
In spite of the unclear nature of how AICD may activate signalling pathways, a 
trans-activating role of APP/FE65/Tip60 complex has been consistently documented, at 
least in overexpression systems. Accordingly, downstream targets have been 
identified. Two genes have been proposed, KAI1, a tumor suppressor gene, and 
neprilysin, a neural endopeptidase with Abeta degrading activity. The latter pathway is 
particularly interesting because it suggests that γ-secretase release of AICD can 
regulate the degradation of Abeta in the extracellular space.  
The proposed AICD signalling has also been implicated in phosphoinositide-
mediated calcium signalling and cell cycle regulation (Leissring et al. 2002) and 
reviewed in (Neve and McPhie 2006). Specifically, fibroblast cells lacking APP exhibit 
calcium signalling defects which can be rescued by expressing AICD. 
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Cell migration and synapse remodeling 
In addition to stabilizing AICD and modulating nuclear signalling, the binding of 
APP to FE65 has been implicated in the regulation of cell motility and growth cone 
dynamics. In H4 neuroglioma and MDCK cells, APP is found to be associated with FE65 
and a mammalian homolog of Enabled (Sabo et al. 2001; Sabo et al. 2003), a 
cytoskeletal protein expressed in actin remodelling areas, such as lamellipodia and 
growth cones (reviewed in Bearer 2001). The functional role of this complex was 
demonstrated using a wound healing assay in MDCK cells where the authors showed 
increased rate of cell migration and wound closure by overexpressing APP and FE65. 
This process appears to be partially dependent on the Mena/actin complex (Sabo et al. 
2001). Further studies by the same group showed that in primary neurons, APP and 
FE65 are concentrated in actin-rich area of the growth cones, supporting the idea for 
an active role of the APP/FE65 complex in growth cone dynamics and synapse 
remodelling (Sabo et al. 2003). 
 
 
Apoptosis 
Interestingly, there is a lengthy history regarding the cytotoxic properties of 
APP, especially when APP or the β-cleaved C-terminal fragment of APP (C99 or C100) 
are overexpressed (Yankner et al. 1989; Yoshikawa et al. 1992). Indeed, 
overexpression of C100 is associated with neuronal degeneration in brain (Oster-
Granite et al. 1996), perhaps by perturbing APP signal transduction. Another pathway 
by which APP CTF is cytotoxic may be through AICD. Specifically, the cytotoxicity of 
APP CTF appears to require an intact caspase site within the cytoplasmic tail (Lu et al. 
2003). In this culture model, loss of this caspase site by mutating the aspartate 
residue at position 622 to alanine (D622A) resulted in a loss of C100 associated 
cytotoxicity. It has been proposed that release of smaller fragments (C31 and jcasp) 
from AICD after cleavage at position 622 results in the generation of new cytotoxic 
APP related peptides (Figure 11). Indeed, in an APP transgenic mouse line in which the 
caspase site is mutated to render APP noncleavable, the predicted Abeta-related 
phenotypes in brain, including synaptic, behaviour, and electrophysiological 
abnormalities, were absent in spite of abundant amyloid deposits in the brain. 
Therefore, release of C99 may result in the activation of genes that contribute to cell 
death in a γ-secretase dependent manner. In essence, there are at present several 
potential mechanisms whereby APP may contribute to neurotoxicity: via γ-secretase 
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cleavage to release AICD or via alternative cleavage of the APP C-teminus to release 
other cytotoxic peptides. 
 
 
1.5.6 APP C-terminus domains and APP-binding proteins  
 
Whereas the APP ectodomain contains many potential functional domains, 
previously described, the short cytoplasmic tail possesses few regions capable of 
interacting with intracellular proteins. Most of these interacting proteins possess 
multiple protein-protein interacting domains, which in turn form complexes with other 
proteins, suggesting that the latter function as adaptor proteins bridging APP to 
specific molecular pathways. The number of APP binding proteins thus far identified is 
quite vast and can be loosely divided into two overlapping categories: signal 
transduction and subcellular localization (da Cruz e Silva et al. 2004b). For both there 
is an emerging consensus that the APP C-terminus is critical in these interactions. 
Examples of APP binding proteins involved in signal transduction are: c-Abl, Disabled-1 
protein (mDab-1), Fe65 and Fe65-like proteins, SET protein, X11 family proteins, 
Numb, and G0. Fewer APP binding proteins involved in APP targeting have been 
described and include APPBP2 (or PAT1) and the X11 family proteins, important in 
microtubule association. Moreover, X11 was also found to potentially function as an 
APP vesicle coat-protein (Hill et al. 2003). Recent contributions have brought to light 
two other proteins putatively involved in APP traffic: the neuronal sorting receptor 
sorLA/LR11 (Andersen et al. 2005), and a novel sorting nexin (SNX30) (Lichtenthaler 
et al. (2005)). The APP-G0 binding (Nishimoto et al. 1993) may also have a role in APP 
targeting, as G0 was found to be located at subcellular membrane domains specialized 
in the sorting of trafficking proteins (Qian et al. 2003). Other known APP binding 
proteins involved in trafficking are the Kinesin Light Chain (KLC) and JIP-1 [Jun N-
terminal kinase (JNK) interacting protein 1]. Further, examples exist where the 
binding to APP has not been clarified, as in the case of caveolin (Ikezu et al. 1998; 
Nishiyama et al. 1999).  
The function of all the APP binding proteins has yet to be completely elucidated, 
but considerable contributions have already been made. For review on APP binding 
proteins involved in APP signal transduction see da Cruz e Silva et al. (2004b). Several 
other APP binding proteins have been described that appear to have very diverse roles 
such as in Abeta clearance and/or aggregation, as for example APOE.  
Proteins which bind the N-terminus of APP have not been extensively 
documented, but examples include fibulin-1, whose binding blocks neural stem cells 
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sAPP-mediated proliferation (Ohsawa et al. 2001), and F-spondin, which may mediate 
APP CAM (cellular adhesion molecule) and neurite outgrowth functions (Ho and Sudhof 
2004). In fact, almost all known APP binding proteins bind to its C-terminus, and 
specifically at one of two APP domains: 653YTSI656 and 682YENPTY687 (Table 2 and Table 
3). Recently, it was reprted that Pin1 binds to Thr668 located in the third domain 
(667VTPEER672). These domains can be classified according to their attributed functions 
and are thought to be involved in regulating APP rate of secretion, endocytosis, and 
Abeta production (Ando et al. 2001; Ando et al. 1999; da Cruz e Silva et al. 2004b; 
Iijima et al. 2000; Mueller et al. 2000; Roncarati et al. 2002; Sabo et al. 2001). 
Of particular interest is the YENPTY motif at the C-terminus of APP, because it 
is the only region in the cytoplasmic domain that is completely conserved from C. 
elegans to humans (King et al. 2003). The NPTY motif was first identified in the low-
density lipoprotein (LDL) receptor as a requirement for the transmembrane receptor 
internalization and was subsequently identified in APP (Chen et al. 1990). The 
682YENPTY687 motif binds phosphotyrosine-binding (PTB) domains of adaptor proteins 
(Wolf et al. 1995). However, the binding of PTB domais to the NPTY sequence has 
been reported to be largely independent of phosphorylation (Borg et al. 1996).  
Internalization of APP and trafficking through the endocytic pathway are an 
important step in APP proteolysis. Several studies have demonstrated that disruption 
of this process substantially reduces the secretion of Abeta (Koo and Squazzo 1994; 
LeBlanc and Gambetti 1994; Perez et al. 1999). The internalization of transmembrane 
proteins in clathrin-coated vesicles is a multistep process requiring the initial binding 
of adaptor proteins to the cytoplasmic domain and subsequent assembly of clathrin-
coats and vesicle formation (Schmid 1997). Thus, this motif is thought to function 
through interaction with various known APP binding protein that are described below 
and summarized in Table 2.  
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Table 2. YENPTY domain interacting proteins. YENPTY dependent APP interacting 
proteins are indicated as well as their putative role and subcellular localization. ND, not 
determined. 
APP BINDING 
PROTEIN 
PUTATIVE ROLE SUBCELLULAR 
LOCALIZATION 
REFERENCE 
FE65 
FE65L1 
FE65L2 
− Regulation of APP 
secretion 
− Regulation of cell 
movement 
− Promotion of gene 
transactivation  
− Cytoplasm and Nucleus 
− In AD colocalizes with 
tau protein in NFTs 
− Synaptic sites and in 
neuronal growth cones, 
specially in actin-rich 
lamellopodia 
− Fiore et al., 1995 
− Breesler et al., 1996 
− Guenette et al., 1999 
− Kimberly et al., 2001 
− Sabo et al., 2001 
−Kinoshita et al., 2002 
X11α 
X11 family 
− APP trafficking  
− APP coat vesicle protein 
− APP synaptic localization 
− Regulation of APP 
processing and 
metabolism 
−Cytosolic/Golgi adaptor 
protein 
−APP/Mint/Cask 
complexes are localized in 
neuronal processes and in 
the Golgi 
− Borg et al., 1996 
− McLoughlin and Miller, 
1996 
− Sastre et al., 1998 
− Mueller et al., 2000 
− Hill et al., 2003 
− King et al., 2003, 2004 
Dab1 
Dab2 
− Neuron migration (cell 
movement) 
− Links APP to signal 
transduction processes 
− Neuronal development 
− Co-localizes with APLP1 
in membrane ruffles and 
vesicular structures 
− Trommsdorf et al., 1998 
− Homayouni et al., 1999 
− Mishra et al., 2002 
− Yun et al., 2003 
c-Abl 
− Abl active form 
phosphorylates APP at 
Y682  
− Forms a trimeric 
complex with APP and 
Fe65 
− APP internalization 
− Cytoplasm and nucleus 
− Russo et al., 2001 
− Zambrano et al., 2001 
− Tarr et al., 2002 
 
Numb 
− Link between APP and 
Notch signalling pathways 
− Endocytosis 
− Neurons cytoplasm, 
dendritic and axonal 
processes; excluded from 
nuclei  
− Roncarati et al., 2002 
− Berdnick et al., 2002 
− Santolini et al., 2000 
JIP-1b 
− Scaffolds APP with c-
Jun Kinase (JNK) 
− Links APP to stress 
kinase signalling 
pathways 
− Involved in APP axonal 
trafficking 
− APP and JIP-1b exhibit 
similar subcellular location: 
cytoplasmic significantly 
overlapped staining  
− Matsuda et al., 2001 
− Scheinfeld et al., 2002 
− Sisodia, 2002 
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Shc 
− Tyrosine kinase-
mediated signal 
transduction 
− ShcA upregulated in AD 
brains 
− Cytoplasm 
− Russo et al., 2001 
− Zambrano et al., 2001 
− Tarr et al., 2002 
− Russo et al., 2002 
Grb2 
− Mediated signal 
transduction 
− Grb2 upregulated in AD 
brains 
− ND 
− Zhou et al., 2004 
− Venezia et al., 2004 
 
ARH − APP internalization − Plasma membrane − Noviello et al., 2003 
UV-DDB 
− ND − cytosolic fraction (PC12 cells) − Watanabe et al., 1999 
 
 
FE65 
Y2H screens have revealed that the FE65 family of adaptor proteins, including 
FE65, FE65L1 and FE65L2, can bind to the YENPTY sequence of APP (Borg et al. 1996; 
Duilio et al. 1998; Fiore et al. 1995; Guenette et al. 1996). Both FE65 and APP 
colocalized in human neuroglioma cells (Sabo et al. 1999) and they are expressed 
during neuronal development (Kesavapany et al. 2002). Members of FE65 proteins 
contain several protein interacting domains, including two PTB domains and a WW 
region. Furthermore, the WW domain binds to MENA (mammalian enabled) which 
binds actin and thus links FE65 and APP to cytoskeletal dynamics and cellular motility 
and morphology (Ermekova et al. 1997). The PTB1 domain of FE65 binds either the 
transcription factor complex CP2-LSF-LBP-1c, or the low density lipoprotein receptor-
related protein (LRP). The PTB2 domain of FE65 binds the APP C-terminus, providing a 
potential scaffold between APP and LRP (Kinoshita et al. 2001). The interaction 
between APP and FE65 involves binding of YENPTY sequence and dephosphorylated 
Thr668 residue in APP to the PTB domain closest to the C-terminus of FE65 (Ando et al. 
2001; Borg et al. 1996)  
The C-terminal product of γ-secretase cleavage, AICD, has been shown to also 
bind to FE65 and translocate to the nucleus to form a transcriptionally active complex 
with Tip60 (Cao and Sudhof 2001; Kimberly et al. 2001). The initial binding of FE65 to 
AICD occurs before the APP fragment dissociates from the membrane, and the three 
functional domains of FE65 have to be intact (Cao and Sudhof 2001; Cao and Sudhof 
2004). Furthermore, it was reported that FE65-mediated transcriptional activation by 
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APP, upregulates the expression of many genes including APP and BACE (von Rotz et 
al. 2004). This suggests that γ-secretase proteolysis of APP, which regulates AICD, 
may result in the up-regulation of the amyloidogenic processing.  
The effect of FE65 expression on APP processing is unclear and may be 
dependent on both the cell type in which expression occurs and the FE65 family 
member. FE65 can increase secretion of Abeta and sAPP from cells expressing APP 
(Sabo et al. 1999), and overexpression of FE65L1 leads to a decrease in cellular C83 
and increased secretion of Abeta1-40 resulting from increased processing through the γ-
secretase pathway (Chang et al. 2003). FE65L1 has also been shown to enhance the 
maturation and secretion of APP (Duilio et al. 1998; Guenette et al. 1999). The 
remaining family member, FE65L2, has been demonstrated to increase secretion of 
Abeta without affecting the production of other proteolytic products of APP (Tanahashi 
and Tabira 2002).  
The binding of FE65 to APP has also been reported to promote formation of 
receptor complexes. It was demonstrated by Pietrzik et al. (2004) a complex similar to 
that proposed by Trommsdorff et al. (1998), consisting of APP and LDL receptor-
related protein (LRP) linked through their binding to separate PTB domains of FE65. 
This finding is of particular interest for AD, because one allelic form of the LRP ligand, 
apolipoprotein E (APOE ε4), is a risk factor to develop late-onset AD. Thus, the APP-
FE65-LRP complex formation is responsible for the alteration of APP processing 
(Pietrzik et al. 2004), suggesting that APOE may influence Abeta production, and 
therefore AD pathology, via the APP-LRP receptor complex. 
 
X11α and X11 family (Mint family) 
Members of the X11 family of adaptor proteins also interact with the YENPTY 
motif of APP (Borg et al. 1996; Tanahashi and Tabira 1999a; Tomita et al. 1999). This 
family consists of three proteins, X11α, -β and -γ (or Mint1, -2, -3, respectively), all of 
which possess both PTB and PDZ domains. The N-terminal domains of X11α and X11β 
contain a munc18-interacting domain (MID), and the PDZ domain may interact with 
several different proteins, including PSEN1 (Lau et al. 2000). X11α contains an 
additional mLin-2/CASK interacting domain (CID; Borg et al. 1998). Whereas X11γ 
expression is ubiquitous, X11α and X11β are considered neuron specific and are 
expressed only in the brain (Okamoto and Sudhof 1998). The binding between the 
X11 PTB domain and an APP C-terminal peptide containing the YENPTY motif was 
shown to be of high affinity (Zhang et al. 1997), and deletion of this sequence 
completely abolished the interaction (Tomita et al. 1999). 
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X11α coexpression with APP has been shown to delay the maturation, 
trafficking and processing of APP, thus increasing cellular levels of APP and reducing 
the secretion of amyloidogenic peptides (Borg et al. 1998; King et al. 2003; Sastre et 
al. 1998). Although an overall slowing of APP processing was demonstrated in these 
studies, the interaction between X11α and APP is also reported to block the action of 
the γ-secretase processing of APP selectively (King and Scott Turner 2004). These 
results suggest that the X11 family, and X11α in particular, may function as regulators 
of cellular processing and metabolism of APP. 
 
Dab1 and Dab2 
Another protein that is potentially involved in APP internalization is Dab2, a 
member of the Disabled family. The PTB domain of Dab2 binds to the NPTY motif in 
APP (Yun et al. 2003). Evidence supports the involvement of the latter protein in 
endocytosis, firstly given its localization at the plasma membrane and secondly its 
capacity to bind both clathrin and AP-2 (Mishra et al. 2002). Furthermore, both co-
immunoprecipitation and yeast two-hybrid (Y2H) screens have revealed that the PTB 
domain of an additional Disabled family member, Dab1, can bind the YENPTY motif 
(Homayouni et al. 1999; Trommsdorff et al. 1998). However, Dab1 binds stronger to 
APLP1 than APP695 (Homayouni et al. 1999). Dab1 is involved in neuronal migration to 
cortical layers during development and has been implicated in neuronal development.  
 
c-Abl  
The Src homology 2 (SH2) domain of Abl (Zambrano et al. 2001) may interact 
with APP when the tyrosine in the YENP sequence is phosphorylated, also suggesting a 
role for APP in tyrosine kinase-mediated signal transduction. 
 
Numb 
The APP cytoplasmic domain also interacts with Numb, an adaptor protein that 
was originally identified for its role in Notch signalling (Roncarati et al. 2002). The 
binding of Numb to Notch promotes its internalization, inhibiting its signal transduction 
from the cell surface and consequently influencing Notch-mediated cell-fate decisions 
during differentiation (Berdnik et al. 2002). Numb may be involved in endocytosis 
because it binds to endocytic vesicles (Table 2; Santolini et al. 2000). 
 
 
 The role of the NPTY functional domain on APP trafficking and processing 55 
 
 
JIP1b  
APP can bind to the JNK interacting protein 1b (JIP1b) (Matsuda et al. 2001; 
Taru et al. 2002). However, the affinity of the Jip1b PTB domain for APP is lower than 
for the X11, Dab1 and FE65 PTB domains (Matsuda et al. 2001). The Jip1b-APP 
interaction may enhance in vitro phosphorylation of APP at Thr668 by JNK (Inomata et 
al. 2003). The role of this interaction is unclear, although coexpression of APP and 
Jip1b has been shown to reduce the secretion of Abeta (Taru et al. 2002). The binding 
of Jip1b to APP may be involved in the cellular sorting of APP. Jip1b reportedly 
enhances the association of APP to KCL1 (Inomata et al. 2003), which is a component 
of the axonal transport machinery. 
 
SHC  
Shc A and Shc C are members of a family of cytoplasmic adaptor proteins, that 
also includes ShcB, whose PTB domain binds to the YENPTY APP motif (Russo et al. 
2002; Tarr et al. 2002). However, unlike the other PTB-containing proteins that 
interact with APP, ShcA and ShcC seem to associate with APP only when the tyrosine 
is phosphorylated, suggesting a role of APP in tyrosine kinase-mediated signal 
transduction. Interestingly, the expression level of ShcA is increased in AD brains as 
compared to normal, non-demented brains (Russo et al. 2002). 
 
Grb2  
Grb2 directly interacts with APP reqiring the phosphorylation of APP Tyr682  
(Venezia et al. 2004). Un like other interacting proteins that bind the YENPTY motif via 
their PTB domain, Grb2 binds to YENPTY via its SH2 domain (Zhou et al. 2004). 
Moreover, the Grb2-APP complex is detectable in human brains and its amount 
apparently increases in AD brains.  
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ARH 
The functional significance of adaptor protein interactions is suggested for the 
autosomal recessive hypercholesterolemia (ARH). A disorder of defective 
internalization of the LDL receptor caused by mutations in the SRH gene (Garcia et al. 
2001). The ARH protein directs the internalization of the LDL receptor through the 
binding of its PTB domain to the NPTY sequence. The ARH protein has also been 
shown to bind to APP YENPTY motif (Noviello et al. 2003). Moreover, inhibition of this 
interaction resulted in an increased level of APP at the cell surface supporting a role 
for ARH in internalization (Table 2; Noviello et al. 2003). 
 
UV-DDB  
The UV-damaged DNA-binding (UV-DDB) protein was demonstrated to bind the 
APP cytoplasmic tail, and this binding is dependent on an intact YENPTY sequence 
(Watanabe et al. 1999). 
 
 
The previously mentioned amino acid sequence 653YTSI656 forms a 4-residue 
tyrosine-based characteristic internalization and/or basolateral sorting signal (YXXI) 
(Haass et al. 1995; Lai et al. 1995; Zheng et al. 1998b). When transplanted to the 
cytoplasmic domain of the transferrin receptor (TR), this sequence promoted the 
internalization of a TR-YTSI chimera in COS-1 cells and seemed to be partially 
responsible for its post-Golgi degradation (Lai et al. 1995). This domain has received 
less attention and until now only one protein (APPBP2) was shown to specifically bind 
to it. As the exact site of APP binding to the KLC protein is still unknown, the binding 
of KLC to the 653YTSI656 domain is speculative and supported only by KLC homology to 
APPBP2. Nonetheless, this is a domain that could contribute to the targeting of APP to 
correct plasma membrane subdomains and be involved in APP signalling functions. 
The characteristics of both the putative and known 653YTSI656 domain binding proteins 
are described below (Table 3). 
 
 
 
 
 
 
 The role of the NPTY functional domain on APP trafficking and processing 57 
 
 
Table 3. Putative and known YTSI domain binding proteins. The YTSI dependent APP 
interacting proteins are indicated as well as their putative role and subcellular localization. 
APP BINDING 
PROTEIN 
PUTATIVE ROLE SUBCELLULAR 
LOCALIZATION 
REFERENCE 
APPBP2  
(or PAT1) 
− Translocation of APP 
along microtubules toward 
the cell surface  
− Involved in nuclear gene 
transactivation/repression  
 
− Nucleus, cytoplasm and 
membrane  
− Golgi and in filamentous 
cytoplasmic structures 
emanating from the Golgi, 
where it co-localizes with 
APP 
− Zheng et al., 1998 
− Gao and Pimplikar, 2001 
− Richards et al., 2003 
− Zhang et al., 2004 
KLC (?) 
− Axonal transport of APP 
containing vesicles 
(anterograde and 
retrograde) 
− Cellular cytoskeleton/ 
Microtubules 
− Kaether et al., 2000 
− Kamal et al., 2000; 2001 
SET (?) 
− Transactivation of the 
KAI1 gene 
(AICD/SET/Fe65/ Tip60 
complex) 
− Mediation of APP C-
terminal-induced apoptosis 
− Co-localizes with AICD at 
the nucleus (on the kai1 
gene promoter) 
− Madeira et al., 2005; 
− Telese et al., 2005 
 
 
Several other cytoplasmic proteins (Table 4) have been identified that bind the 
intracellular domain of APP. A putative G-protein (G0) interacting domain has been 
identified in the cytoplasmic domain (Nishimoto et al. 1993), indicating a possible role 
for APP in signal transduction from the plasma membrane. Another APP binding 
protein, named APP-binding protein (APPBP1) was described and has a putative role in 
apoptotic signalling pathways (Chen et al. 2003; Chow et al. 1996). Also of note is the 
recent report that the Pin1 protein binds to the phosphorylated Thr668 APP (Pastorino 
et al. 2006) and this binding regulates isomerization between the cis- and trans-
conformations, affecting APP processing. Pin1 is a prolyl-isomerase that binds to and 
isomerizes specific phosphorylated S/T-P motifs (for review see Lu et al. 1999) been 
proposed that Pin1 catalyses the APP conformational change helping the prevention of 
its amyloidogenic processing, thus preventing the pathogenic mechanisms that lead to 
AD pathology (Pastorino et al. 2006). It was also shown both in vivo and in vitro that 
the ablation of Pin1 gene resulted in increased Abeta secretion, as well as increased 
sAPPβ and decreased sAPPα secretion in an age-dependent fashion. Furthermore, Pin1 
promotes the accumulation of intracellular Abeta1-42 at a neuronal level, suggesting 
that Pin1 favors the amyloidogenic over the non-amyloidogenic processing of APP. 
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Table 4. Other APP binding proteins. Other C-terminus dependent APP interacting 
proteins are indicated, as well as their putative role and subcellular localization. ND, not 
determined. 
APP BINDING 
PROTEIN 
PUTATIVE ROLE SUBCELLULAR 
LOCALIZATION 
REFERENCE 
G0 
− APP cellular signalling  
− APP targeting  
− Co-localizes with APP at 
neuronal growth cones 
− Co-localizes with APP at  
neuronal membrane 
microdomains 
−Strittmatter and Fishman, 
1991  
−Nishimoto et al., 1993  
−Okamoto et al., 1995  
−Qian et al., 2003 
APPBP1 
− Apoptotic signalling 
pathways 
− ND 
− Chow et al., 1996 
− Chen et al., 2003 
Hsc73 
− APP/AICD traffic  
− APP/AICD proteasomal 
or lysosomal degradation  
− Mainly cytosol, 
lysosomal membrane, also 
in nucleus 
− Kouchi et al., 1999 
AIDA-1a 
− Modulator of APP 
processing 
− Diffuse localization with 
some nuclear accumulation  
− Ghersi et al., 2004 
hARD1 − ND − ND − Asaumi et al., 2005 
Pin1 
− Regulation of Thr668 APP 
isomerization between the 
cis- and trans-
conformations 
− Regulate tau function,  
dephosphorylates 
phosphorylated tau 
− ND 
− Lu et al., 1999 
− Liou et al., 2003 
− Pastorino et al., 2006 
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1.5.7 APP subcellular trafficking  
 
 
APP trafficking and maturation 
In neuronal and non-neuronal cells, APP is known to be transported via the 
secretory pathway, a continoum of separate membrane-enclosed organelles leading to 
the cell surface. Newly synthesized proteins that are destined for secretion or cell-
surface expression enter this pathway at the rough endoplasmic reticulum (RER). APP 
is known to undergo post-translational modifications that include N- and O-linked 
glycosylation and tyrosine sulfation (Oltersdorf et al. 1990; Weidemann et al. 1989). 
APP N-glycosylation starts at the ER and the carbohydrate chains are further 
processed in the cis-Golgi, with immature N-glycated APP being found at both 
locations (Tomita et al. 1998). Two residues in the APP ectodomain (Asn467 and Asn496) 
have consensus sequences for N-glycosylation, although only one appears to be N-
glycosylated “in vivo” (Pahlsson and Spitalnik 1996). APP maturation by O-
glycosylation and tyrosyl-sulfation occurs while moving through the trans-Golgi 
network (TGN) (Weidemann et al. 1989). Maturation of all metabolic labelled APP cell-
associated proteins reached maximum intensity after 30 min of chase (Peraus et al. 
1997).  
 
 
Figure 13. APP secretory pathway. APP in the classical secretory pathway. APP is 
subjected to N-glycosylation in the ER, O-glycosylation in the Golgi apparatus, and then reaches 
the plasma membrane. N, Nucleus, ER, Endoplasmic reticulum; PM, Plasma Membrane 
(adapted from Suzuki et al. 2006). 
PM 
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O-glycosylation does not depend on correct APP N-glycosylation to precede it 
but, as it is performed at the TGN, is a subsequent process (Pahlsson and Spitalnik 
1996). Inhibition of APP O-glycosylation does not appear to affect APP biosynthesis or 
secretion (Pahlsson and Spitalnik 1996). Nonetheless, the majority of APP cleavage by 
secretases occurs after O-glycosylation, as shown by using HEK293 cells expressing 
mutant APP defective in O-glycosylation (Tomita et al. 1998). This mutant 
accumulated in subcellular reticular compartments and exhibited decreased cleavage 
to αCTFs or to Abeta1-40/1-42.  
Mature APP (N-,O-glycated and sulfated) is therefore located in compartments 
from the trans-Golgi to the plasma membrane (Tomita et al. 1998). Most APP resides 
in the Golgi complex (Caporaso et al. 1994), but a small pool is carried into post-TGN 
secretory vesicles that carry it to the plasma membrane (Koo et al. 1996; Peraus et al. 
1997; Yamazaki et al. 1996). In SH-SY5Y cells, the pool of TGN mature APP that is 
targeted to the plasma membrane takes 30 to 45 min to reach this cellular destination 
following APP translation (Cai et al. 2003). At the cell surface, APP can be cleaved or 
undergo re-internalization as a holoprotein via endocytosis, to be recycled back to the 
membrane, retrogradely delivered to the TGN or incorporated into secondary 
endosomes. Secondary endosomes target APP for complete degradation at the 
lysosomes or to be recycled back to the TGN/Golgi (Koo et al. 1996; Tagawa et al. 
1993; Yamazaki et al. 1996). In central and peripheral neurons a pool of APP 
molecules is also transported from the cell body down axons by fast axonal transport 
(Ferreira et al. 1993; Kaether et al. 2000; Koo et al. 1990). Presynaptically targeted 
full-length APP (and APLP2) occurs in its mature form (syalated and N- and O-
glycosylated) (Lyckman et al. 1998). APP was also detected in both pre- and post-
synaptic sites, in the axoplasm of myelinated and unmyelinated nerve fibres, within 
vesicular structures in axonal, dendritic and synaptic compartments, as well as on the 
surface of axons and dendrites (Allinquant et al. 1994; Caporaso et al. 1994; Ferreira 
et al. 1993; Schubert et al. 1991; Simons et al. 1995). Of note is that APP was 
suggested to be up-regulated in synapses with increased membrane activity, such as 
in synapses subject to high transmission rates or during synaptogenesis (Schubert et 
al. 1991).  
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Figure 14. A. Association of APP with the kinesin-I motor. APP binds to KLC 
through an association with JIP1b, but does not bind to KLC directly. Thus, APP serves as a 
cargo-receptor via JIP1b B. APP trafficking. Anterograde transport of APP vesicles and 
metabolism of APP. APP can be cleaved during axonal transport (1), at the plasma membrane 
(2), or during the endocytic cycle (3), generating neurotoxic Abeta (adapted from Suzuki et al. 
2006). 
 
 
In addition, pools of unprocessed synaptic APP are also transported 
retrogradely (transcytotic movement) from axonal synaptic compartments to neuronal 
cell bodies and dendrites (Simons et al. 1995; Yamazaki et al. 1995). In rat forebrain 
and PC12 cells, APP was observed in Rab5-containing endocytic organelles that derive 
from an endocytic pathway distinct from the one involved in synaptic vesicle recycling 
(Ikin et al. 1996; Marquez-Sterling et al. 1997). Further, cell-surface APP was initially 
internalized with membrane proteins of recycling synaptic vesicles, but subsequently 
sorted away from these vesicles and retrogradely transported to the soma (Marquez-
Sterling et al. 1997). 
 
 
 
 
 
 
 
APP vesicle 
(3) 
Anterograde 
motor 
(2) 
(1) 
A B
PM 
Microtubule 
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APP processing and its intracellular trafficking  
Through the use of radioactivity-based techniques, the half-life of total cellular 
APP was estimated to be of approximately 1 h (Koo et al. 1996; Weidemann et al. 
1989). Nascent and immature (only N-glycosylated) APP can be degraded to a high 
degree by the proteasome, probably via the smooth ER (Kouchi et al. 1999; Yang et 
al. 1998). Additionally, immature APP may be cleaved by secretases at a low rate in 
the ER or the cis-Golgi but, as explained above, the majority of these cleavages occur 
after APP maturation complete. Mature APP is processed rapidly (turnover of 45 min) 
as it is transported to or from the cell surface via the secretory or endocytic pathways 
(Cook et al. 1997; De Strooper et al. 1993; Haass et al. 1992; Hartmann et al. 1997; 
Kuentzel et al. 1993; Marambaud et al. 1997b; Sambamurti et al. 1992; Shoji et al. 
1992). In several types of cultured cells, part of the TGN/Golgi APP pool was observed 
to be locally cleaved by α-secretase. β-secretases can also cleave a fraction of Golgi 
APP but to a lesser extent. Approximately 30% of surface APP is cleaved to sAPP (Koo 
et al. 1996), with 20% being cleaved within 10 min (Lai et al. 1995). The remaining 
full-length APP and the cleavage products (CTFs) are re-internalized via coated pits 
and vesicles by receptor-mediated endocytosis (Yamazaki et al. 1996). The net result 
of cell surface APP proteolytic cleavage and endocytosis is the rapid removal of cell 
surface APP. Indeed, the estimated half-life for surface-expressed APP is less than 10 
min (Koo et al. 1996). Consequently, only minor amounts of APP (as compared to the 
total cellular pool) are detected at the cell surface (Kuentzel et al. 1993). The half-life 
of internalized APP was calculated to be ∼30 min (Koo et al. 1996), with a pool of 
endosomal APP being delivered to lysosomes. The remaining cell surface CTFs may be 
subsequentially cleaved by γ-secretase to AICD, at the cell surface or upon 
endocytosis in endosomes, or further degraded in lysosomes (Chen et al. 2000; 
Kaether et al. 2006b; Mathews et al. 2002). CTFs produced at the TGN/Golgi are 
thought to be cleaved locally or to be delivered to lysosomes for degradation (Chen et 
al. 2000). In neurons, sAPP may also be generated and released at the synaptic 
terminals via α-secretase cleavage (McLaughlin and Breen 1999). 
During the APP secretory pathway, the majority of Abeta fragments are thought 
to be generated in the late Golgi, from where these peptides are packaged into post-
TGN vesicles destined for extracellular secretion (Gouras et al. 2000a; Xia 2001). This 
Abeta production seems to occur at the TGN and does not need post-TGN vesicle 
formation (Xu et al. 2001). At the TGN, the absolute levels of both Abeta1-40 and 
Abeta1-42 are high and the ratio Abeta1-42 to total Abeta is 0.05-0.16 (Greenfield et al. 
1999). A minority of Abeta peptides (1-40, 1-42 and x-42) is thought to be generated 
in the ER (Greenfield et al. 1999; Xia 2001; Xia et al. 1998), but some authors 
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arguethat the γ-secretase complex is still not formed or active in the ER (Kaether et al. 
2006a). A major portion of Abeta peptides are also generated in the endocytic 
pathway, following internalization of APP from the plasma membrane. In fact, 
mutations of the APP 682YENPTY687 domain that significantly impair APP endocytosis 
simultaneously inhibit Abeta levels (Perez et al. 1999). Recent findings locate β- and γ-
secretases within the cholesterol-enriched plasma membrane lipid rafts, but Abeta 
production at the cellular membrane was reported to occur at a lower level. APP was 
thus suggested to be potentially segregated from its proteases by the rafts lipid 
boundary (Kaether and Haass 2004). Finally, Abeta production was also reported in 
axonal vesicular compartments (Kamal et al. 2001). The putative subcellular 
localization of APP proteolytic processing is shown in Figure 16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Possible cellular trafficking of β-amyloid (Aβ). (A) In the cell body of a 
neuron, full-length β-amyloid precursor protein holoprotein (flβAPP) is generated in the 
endoplasmic reticulum (ER), transported through the Golgi complex, and carried in post-trans 
Golgi network (post-TGN) secretory vesicles to the plasma membrane. Most flβAPP resides in 
the Golgi complex, but some is also transported from the cell body down axons by fast axonal 
transport and reportedly is contained in multivesicular bodies of synaptic preparations. (B) A 
subset of flβAPP molecules are cleaved during export. A minority of Aβ peptides are generated 
in the ER, butthe majority are generated in the Golgi complex, from where most Aβ peptides are 
packaged into post-TGN vesicles destined for secretion into the extracellular space. Soluble α-
A B 
 Chapter I 
64  Sandra Rebelo 
 
  CBC/UA, 2008 
cleaved βAPP (sβAPPα) is also generatedin post-TGN vesicles and/or at the plasma membrane, 
from where it is secreted into the extracellular space. Aβ is also thought to be generated in the 
endocytic pathway following internalisation of βAPP from the plasmamembrane (taken from 
Gouras 2001). 
 
 
1.6 PHOSPHORYLATION-DEPENDENT APP REGULATION 
 
 
1.6.1 Protein phosphorylation in AD 
Several neurodegenerative disorders are the result of altered signal 
transduction pathways. One of these disorders is AD where the abnormal protein 
kinase (Jin and Saitoh 1995), as well as protein phosphatase (Gong et al. 1993), 
activities in brains were reported when compared with their normal aged controls. 
Moreover, it has been suggested that altered/abnormal signalling may lead to an 
increased neuronal Abeta load (Nitsch et al. 1992; Selkoe 1993). The overall result of 
such dysfunction is the association of neurodegenerative conditions with abnormal 
phosphorylation of key proteins, as has been reported for tau (Grundke-Iqbal et al. 
1986). Thus, this key event in cell regulation, reversible protein phosphorylation, 
consists in the transfer of a phosphate group from ATP to the substrate protein, 
altering its conformation and function. A protein kinase facilitates the transfer and a 
protein phosphatase removes the phosphate, and returns the protein to its original 
state. 
Interestingly, the brain is the mammalian tissue with the highest levels of 
protein kinases and phosphatases, indicating that protein phosphorylation is 
particularly important to brain function. Impaired balance of cellular phosphorylation 
systems has been reported to occur in AD. These abnormalities include both 
expression and activity levels of kinases and phosphatases, which result in alterations 
in the processing of APP and consequently Abeta production (da Cruz e Silva et al. 
1995; Gandy and Greengard 1994; Tian and Wang 2002). Furthermore, altered 
protein kinase C (PKC) levels and activity, decreased activity of protein phosphatases 
PP1 and PP2A, overexpression of calcineurin mRNA levels, protein tau and β-Tubulin 
hyperphosphorylation states (Bennecib et al. 2000; Gong et al. 1993; Hata et al. 
2001; Matsushima et al. 1996; Vijayan et al. 2001) have all been reported in AD. 
Several proteins associated with AD, including APP, tau, PSEN1, PSEN2 and BACE are 
phosphorylated in vivo and can be regulated by protein phosphorylation. Alterations in 
the phosphorylation state of APP C-terminal fragments were demonstrated in AD 
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patients (Lee et al. 2003b). In hippocampal pyramidal neurons phospho-APP was 
observed to accumulate inside large vesicular structures where it colocalizes with 
endossome markers and BACE-1 (Lee et al. 2003b).  
PKC levels and activity have been reported to be altered in AD brain (Cole et al. 
1988), as well as in fibroblasts derived from patients with sporadic AD, familial AD and 
Down’s syndrome (Koo 1997; Maasch et al. 2000). A significant decrease in PKC levels 
and activity was observed in the membranous fraction of AD human cortex (Cole et al. 
1988; Shimohama et al. 1993) and altered immunohistochemical distribution of some 
PKC isozymes in AD brain has also been reported (Masliah et al. 1990). Comparative 
studies on phosphatase activities in AD versus control brains (Gong et al. 1993) led to 
the findings that the activity of the Ser/Thr protein phosphatase PP1 and 
phosphotyrosyl-protein phosphatases in grey matter and of the Ser/Thr phosphatase 
PP2A in both grey and white matters were significantly lower in AD brains. In contrast, 
the mRNA of a PP2B catalytic subunit was found to be up-regulated in AD brain (Hata 
et al. 2001). The authors used cDNA microarray technology to study altered gene 
expression in an AD patient afflicted hippocampus. The most up-regulated gene in AD 
proved to be the β isoform of the catalytic subunit of calcineurin (PP2B Aβ). Indeed, in 
situ hybridization, histochemistry and RT-PCR analysis revealed that PP2B-Abeta was 
significantly up-regulated in the pyramidal neurons of AD hippocampus (Hata et al. 
2001). Interestingly, work from Ermak et al. (2001) revealed that the mRNA levels of 
a calcineurin inhibitor (DSCR1) were also overexpressed in AD and Down’s syndrome 
patients.  
 
 
1.6.2 Phosphorylation and APP processing 
Although the factors regulating APP processing and Abeta production have not 
been fully elucidated, it is now widely accepted that protein phosphorylation is 
involved. Processing of APP and Abeta production were shown to be regulated by 
phosphorylation and phosphorylation-dependent events (Ando et al. 2001; da Cruz e 
Silva and da Cruz e Silva 2003; da Cruz e Silva et al. 1995; Gillespie et al. 1992). As 
APP proteolytic processing is a necessary step in APP RIP cellular signalling and 
phosphorylation is involved in signal transduction pathways, further elucidation of the 
molecular mechanisms underlying phosphorylation-dependent regulation of APP 
processing is required. 
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Protein kinase C 
Previous studies revealed that APP levels and APP processing are regulated by 
PKC. Long-term exposure of a human glial cell line to PKC stimulating agents, such as 
the phorbol ester PMA (phorbol 12-myristate 13-acetate), increased APP mRNA levels 
and protein-binding activity to the APP promoter (Lahiri and Nall 1995; Trejo et al. 
1994). Short-term exposures to phorbol esters invariably results in a higher non-
amyloidogenic APP processing rate. Phorbol esters such as PMA or phorbol 12,13-
dibutyrate (PDBu) enhance α-secretase cleavage of APP and αsAPP production in 
several cultured cell lines (Buxbaum et al. 1990; Caporaso et al. 1992; da Cruz e Silva 
et al. 1993; Demaerschalck et al. 1993; Dyrks et al. 1994; Gabuzda et al. 1993; 
Gillespie et al. 1992; Marambaud et al. 1997a; Marambaud et al. 1997b; Mills et al. 
1997; Slack et al. 1993). The phorbol ester-induced APP processing is also evident in 
primary cultures of rat cortical neurons (Mills and Reiner 1996), and specifically in rat 
cortical synaptosomes (McLaughlin and Breen 1999). Furthermore, in vivo studies 
using rats expressing hyperactivated PKC demonstrated enhanced synaptosomal sAPP 
production and decreased levels of synaptosomal membrane-bound APP in selected 
brain regions (cortex and hippocampus) (Caputi et al. 1997). PKC-mediated 
stimulation of sAPP has been shown to be specific insofar as down-regulation of PKC 
blocked the phorbol ester-stimulated sAPP release (Buxbaum et al. 1994). 
Nonetheless, there is controversy in the effects of this α-secretase pathway induction 
and the consequential decrease in Abeta production, raising the question of 
competition between α- and β- secretases for substrate. In fact, PKC-activators or 
carbachol, which are known α-secretase pathway inducers, were reported to decrease 
Abeta secretion in cultured cells transfected with APP FAD mutant forms (Felsenstein 
et al. 1994; Gabuzda et al. 1993; Hung et al. 1993). Constitutive overactivation of 
PKC in guinea pig brain also enhanced cortical α-secretory APP processing but without 
decreasing Abeta generation (Rossner et al. 2001). The mechanisms of PKC-
dependent induction of APP α-secretase cleavage are complex and still being 
unravelled. PKC is known to be involved in the process of post-TGN vesicle formation, 
through binding and activating the phospholipase involved in vesicles scission 
(Sabatini et al. 1996; Simon et al. 1996). Activation of endogenous PKC by phorbol 
esters or addition of purified PKC increases formation of APP-containing secretory 
vesicles from the trans-Golgi network (Xu et al. 1995), and drastically reduces the 
amount of APP at the cell surface (Koo 1997). This can be explained by accelerated 
APP trafficking through the exocytotic pathway and accelerated α-secretase APP 
cleavage intracellularly and at the plasma membrane. The hypothesis that PKC 
phosphorylation at sites within the APP intracellular carboxy terminus may change the 
 The role of the NPTY functional domain on APP trafficking and processing 67 
 
 
conformation of its extracellular domain and make it a better substrate for the 
cleaving enzyme was recently advanced (Turner et al. 2003). Nonetheless, da Cruz e 
Silva et al. (1993) showed that cleavage of APP tailless constructs (with a stop codon 
at the KKK sequence) to yield sAPP was still stimulated by phorbol esters. Hence, PKC-
dependent sAPP-induction may occur as a sum of direct and indirect actions.  
 
Ser/Thr Protein Phosphatase 1 
Okadaic acid (OA), a Ser/Thr protein phosphatases type 1 (PP1) and type 2A 
(PP2A) inhibitor, was found to stimulate APP processing increasing sAPP secretory 
from COS-1 cells (da Cruz e Silva et al. 1995). APP processing and secretion 
modulation by OA was also observed in primary guinea pig neurons (Holzer et al. 
2000). da Cruz e Silva et al. (1995) were able to specifically implicate PP1 in this APP 
regulation through the use of OA and other phosphatase inhibitors with different 
inhibitory potencies against PP1/PP2A. Interestingly, PP1 is known to be involved in 
long-term potentiation (LTP) and in long-term depression (LTD), thereby influencing 
learning and memory (Genoux et al. 2002; Mulkey et al. 1994; Waddell 2003). 
Furthermore, PP1 and PP2B activities are interconnected, because PP2B is able to 
inhibit (dephosphorylate) DARPP-32 and I2, a potent PP1 inhibitor (Mulkey et al. 
1994; Yan and Mumby 1999), providing a further mechanism for PP2B modulation in 
APP processing. The mechanism by which PP1 down-regulates APP processing and/or 
sAPP secretion are not yet defined, but direct APP dephosphorylation remains a 
possibility (Oishi et al. 1997).  
 
APP secretase phosphorylation 
Another potential stage for phosphorylation-dependent regulation of APP 
proteolytic processing is through modulation of APP secretases. All three members of 
the ADAM family are synthesized as preproteins, so that their proteolytic function is 
regulated to prevent damage to other proteins, or the premature cleavage of their 
substrates, including APP (Turner et al. 2003). The TACE cytoplasmic domain contains 
potential phosphorylation sites, and the enzyme was reported to be phosphorylated at 
Ser819 after growth factor stimulation of the Erk/MAPK pathway or after PMA-induced 
PKC-activation (Black et al. 1997; Diaz-Rodriguez et al. 2002). PMA exposure did not 
alter TACE maturation or cellular distribution (Hooper and Turner 2002), suggesting 
unknown roles for this phosphorylation that may involve its enzymatic kinetics of APP 
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proteolysis (Fan et al. 2003). ADAM 10 is also stimulated after PKC activation 
(Etcheberrigaray et al. 2004). MDC9 was likewise phosphorylated after PMA activation 
of the PKC isozyme δ (Izumi et al. 1998; Roghani et al. 1999). The role of BACE-1 
phosphorylation on a cytoplasmic serine residue is better known and involves 
regulation of BACE-1 subcellular traffic. When phosphorylated on Ser498, this enzyme 
enters the recycling pathway of Golgi-retrieval after endocytosis (Walter et al. 2001). 
Phosphorylation at this serine, which is immediately upstream of the BACE-1 binding 
sequence for its vesicle coating protein GGA, was recently reported to enhance by 
three-fold the affinity of this binding (Shiba et al. 2004). 
Phosphorylation may also affect γ-secretase activity. The PSEN2 protein can be 
highly phosphorylated, whereas little phosphorylation is observed for PSEN1 (Walter et 
al. 1996; Walter et al. 1998). Casein kinases 1 and 2 (CK1, CK2) phosphorylate 
PSEN2 at three serine residues in its N-terminus before PSEN2 maturational cleavage 
by caspases, and after this cleavage its C-terminus is also phosphorylated at three 
serine residues, putatively by the same casein kinases (Walter et al. 1999).  
 
 
1.6.3 APP as a phosphoprotein 
 
APP can be phosphorylated by different kinases, which are involved in diverse 
signal transduction pathways, such that APP phosphorylation potentially represents an 
important target for therapeutical intervention. Moreover, drugs aimed at sustaining 
PKC activity could help in the prevention of AD, since APP phosphorylation by PKC 
favors the non-amyloidogenic processing of the protein. Indeed, direct APP 
phosphorylation is an essential mechanism for regulating APP binding, traffic and 
processing, and therefore worthwhile pursuing. APP is a phosphoprotein with putative 
phosphorylation sites on its extracellular and intracellular domains. Of particular note 
is the finding that AD patients exhibit altered APP phosphorylation (Lee et al. 2003b). 
APP has ten potentially phosphorylatable residues, which have been shown to be 
phosphorylated “in vitro” and/or “in vivo” (Iijima et al. 2000; Koo 1997; Minopoli et al. 
2001; Oishi et al. 1997; Standen et al. 2001; Walter et al. 2000). Two of these are 
located in the APP ectodomain and the other eight in the APP cytoplasmic domain 
(Figure 17).  
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 Figure 17. Exon localization of APP phosphorylatable residues. The extracellular 
(NH2-terminal) APP domain has two phosphorylatable residues (Ser198 and Ser206) and the 
intracellular (COOH-terminal) APP domain contains eight residues (Ser653, Thr654, Ser655, 
Thr668,Ser675, Tyr682, Thr686 and Tyr687). (adapted from da Cruz e Silva et al. 2004b). 
 
In its ectodomain APP was reported to be phosphorylated on serine residues 
(Ser198 and Ser206). Phosphorylation of the two serine residues occurs in two distinct 
cellular locations: in a post-Golgi secretory compartment (most likely within secretory 
vesicles) and at the cell surface by ectoprotein kinases (Walter et al. 1997). The 
authors also found that “in vivo” sAPP was detected exclusively in the double 
phosphorylated form. Subsequently, it was shown that ectocasein kinases 1 and 2 
were the kinases involved in the “in vivo” cell surface APP phosphorylation at residues 
Ser198 and Ser206, respectively, in a process strongly inhibited by heparin (Walter et al. 
2000). A possible role of these phosphorylations is an involvement in LTP, in neurons, 
as well as synaptogenesis. 
The Ser/Thr and Tyr cytoplasmic phosphorylatable residues are located within 
three APP functional motifs, previously mentioned and shown in Figure 17: 653YTSI656, 
667VTPEER672 and 682YENPTY687. Additionally, other potentially phosphorylatable 
residues (Tyr653, Ser675 and Thr686) were reported by (Lee et al. 2003b) but have 
received little attention.Table 5 summarises APP phosphorylatable residues located in 
the cytoplasmic domain, with their putative kinases. 
 
198
SS
206
ST
654
655
Y
682
Y
687
T
668
- CN - 5 17 18
653
Y
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675 686
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Table 5. APP C-terminal phosphorylatable residues. APP residues that can be 
phosphorylated are indicated, as well as the phosphorylation state in AD brains. The kinases 
responsible for these phosphorylations are indicated. Phospho., Phosphorylation. 
RESIDUE 
PHOSPHO. 
AD 
BRAINS 
PHOSPHO. 
CAD 
CELLS 
KINASE REFERENCE 
Y653 − Present − Present 
− Not 
determined 
− Lee et al., 2003 
T654 − Absent − Present − CaMKII 
− Gandy et al., 1988 
− Oishi et al., 1997 
− Ramelot and Nichlson, 
2001 
− Lee et al., 2003 
S655 − Present − Present 
− PKC 
− CaMKII 
− APP Kinase I 
− Gandy et al., 1988 
− Suzuki et al., 1992 
− Oishi et al., 1997 
− Ramelot and Nichlson, 
2001 
− Lee et al., 2003 
T668 − Present − Present 
− Cdk5 
− Cdc2 
− GSK-3 
− JNK-3 
− Suzuki et al., 1994 
− Aplin et al., 1996 
− Oishi et al., 1997 
− Ando et al., 2001 
− Ramelot and Nichlson, 
2001 
− Standen et al., 2001 
− Sisodia et al., 2002 
− Lee et al., 2003 
S675 − Present − Absent 
− Not 
determined 
− Lee et al., 2003 
Y682 − Present − Absent 
− TrKA, 
− c-Abl 
− Lee et al., 2003 
T686 − Present − Absent 
− Not 
determined 
− Lee et al., 2003 
Y687 − Present − Absent 
− Not 
determined 
− Lee et al., 2003 
 
 The role of the NPTY functional domain on APP trafficking and processing 71 
 
 
The amino acid sequence 653YTSI656 functions as an APP sorting signal. Central 
to the domain are two consensus residues for phosphorylation, Thr654 and Ser655, 
found to be phosphorylated in vitro and in vivo (see Table 5). The occurrence of full 
length APP phosphorylated at Thr654 or Ser655 has been reported in cultured cell lines 
and rat cortex (Gandy et al. 1988; Oishi et al. 1997).  However, in human 
hippocampus of AD patients only phospho Ser655 CTFs, and not phospho Thr654, was 
observed (Lee et al. 2003b). It is also believed that these phosphorylations may have 
a regulatory role for the 653YTSI656 APP binding proteins. 
The Thr668 residue of the 667VTPEER672 domain is found phosphorylated in rat 
brain and in several cell lines (Oishi et al. 1997). In PC12 cells immature APP is 
preferentially phosphorylated at this residue during the G2/M phase of the cell cycle 
(Oishi et al. 1997; Suzuki et al. 1994). At this phase total levels of holo APP do not 
change but the levels of secreted sAPP decrease and the levels of the CTFs increase 
(Suzuki et al. 1994). Additionally, the Thr668 precedes a proline, and can be 
phosphorylated by several proline-directed kinases, such as the cyclin dependent 
kinase cdc2, the neuronal analogue cdk5, GSK-3 and JNK. Such phosphorylation has a 
dual role regulating both neuronal development and neurodegeneration (for review 
Pastorino and Lu 2006), depending on the kinase involved phosphorylation. For 
example, cdk5 phosphorylation of Thr668 was reported to regulate either the neuronal 
differentiation (Ando et al., 1999; Iijima et al., 2000) or the amyloidogenic processing 
of APP (Lee et al. 2003b). Moreover, the GSK-3 dependent phosphorylation of APP was 
linked to neurodegeneration (Lee et al. 2004; Leroy et al. 2002) and Abeta production 
(Phiel et al. 2003). 
Additionally, it could be speculated that, in the cell, the role of APP 
phosphorylation at Thr668 could determine the exact subcellular localization of the 
protein. It has been reported that JNK dependent Thr668 phosphorylation relocates 
phosphorylated APP within the neurites, promoting their extension (Muresan and 
Muresan 2005b) probably through the formation of complexes with the JIP1 and 
kinesin1 (Muresan and Muresan 2005a) that are specifically located in vesicles at the 
neuritis and not in the cell bodies. Interestingly, it has been shown that JNK3 
dependent phosphorylation of Thr668 negatively regulates neuronal differentiation, 
which is mediated by AICD (Kimberly et al. 2005). In particular, they showed that 
when phosphorylated at Thr668, AICD is no longer stabilized by FE65, and associates 
less with FE65. Since the AICD is known to form a complex with FE65 and Tip60 that 
is directed to the nucleus and regulates transcription, it could be hypothesized that 
phosphorylation at Thr668 affects the AICD-mediated transcriptional activity due to the 
interference with association of AICD with FE65. 
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Recent experimental evidence link the phosphorylation at Thr668 to increased 
amyloidogenic processing of APP by γ-secretase (Vingtdeux et al. 2005), and to down-
regulation of FE65-mediated transcriptional activity regulated by the factor 14-3-3g, 
which was shown to bind to the 667VTPEER672 domain of AICD and facilitate FE65-
dependent gene transactivation forming a complex containing AICD and FE65 
(Sumioka et al., 2005). 
Indeed, the phosphorylation of APP at Thr668 had already been shown to affect 
the interaction between APP and FE65, probably because the phosphorylation of this 
residue induces structural changes from trans- to cis-conformations in the C-terminal 
domain of the protein (Ramelot and Nicholson 2001). Recently, it was reported that 
the Pin1 protein binds to the phosphorylated Thr668 in APP and regulates its 
isomerization between the cis-and trans-conformations, affecting the processing of 
APP (Pastorino et al. 2006). 
Another important domain is the internalization signal domain 682YENPTY687, 
that is the object of study in this thesis. Of the two tyrosine residues present in the 
domain Tyr682 phosphorylation has been demonstrated to be of functional significance 
while Tyr687 which was initially reported not to undergo phosphorylation (Haass and 
Selkoe 1993; Koo and Squazzo 1994; Minopoli et al. 2001). APP is tyrosine-
phosphorylated in cells expressing a constitutively active form of the Abl proto-
oncogene, a non-receptor tyrosine kinase similar to c-Src, which can form a stable 
complex with APP and Fe65 (Zambrano et al. 2001). Abl-dependent Tyr682 
phosphorylation appears to involve the nerve growth factor receptor TrkA, to mediate 
APP membrane internalization and to result in reduced γ-secretase APP processing 
(Koo and Squazzo 1994; Lai et al. 1995; Tarr et al. 2002). Recently, however and in 
contrast to previous findings in vivo phosphorylation of Tyr687 was reported (Lee et al. 
2003b). This renews interest on this residue and refocus the functional significance of 
Tyr687 phosphorylation. 
The key players controlling signal transduction cascades, the protein kinases 
and phosphatases, as well as their corresponding regulatory proteins, take on added 
importance and they can be key targets for therapeutic intervention. Accordingly, 
several studies have demonstrated that APP subcellular localization, proteolytic 
processing and protein-protein interaction can be regulated by protein phosphorylation 
or by phosphorylation-dependent events. APP direct phosphorylation studies that 
emerge focus on the phosphorylatable residues from the 653YTSI656, 667VTPEER672 and 
682YENPTY687 motifs, previously described. The domain 682YENPTY687 comprises a NPTY 
motif which is a typical internalization signal for membrane-associated receptor 
proteins, two tyrosine’s: Tyr682 and Tyr687 that can be phosphorylated. This domain is 
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also responsible for APP interaction with several PTB-containing adaptor proteins. So 
far, data strongly suggests an involvement of 682YENPTY687 domain and Tyr682 and 
Tyr687 in particular, on APP traffic, processing and correspondent Abeta production. Of 
particular note is the importance of both phosphorylatable residues on protein-protein 
interaction. Nonetheless, little is known about the physiological relevance of APP Tyr687 
phosphorylation including a role in signal transduction, and this will be addressed in 
the work presented here. 
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1.7. AIM OF THIS THESIS 
 
APP processing has been the subject of many studies, and our knowledge in 
this area has increased considerably with several pathways and the proteolytic 
fragments formed being unravelled. The regulatory mechanism underlying APP 
processing have been more elusive. Further, although APP is a phosphoprotein 
functional links have not been made to all its phosphorylatable residues. 
Thus, the aim of this thesis is to study the putative role of direct APP 
phosphorylation at the Tyr687 residue and the consequent protein’s cellular fate, both 
in terms of APP intracellular targeting and proteolytic processing. Understanding 
molecular mechanisms controlling these APP trafficking and processing events and 
their relevance in terms of APP function will provide us novel insights in terms the 
molecular and cellular of AD pathology. 
The central hypothesis to this thesis is that direct APP phosphorylation of the 
NPTY domain is of consequence to APP metabolism. As such, the specific aims were as 
follows: 
 
1. To develop a model system to study APP trafficking and processing; 
 
2. To analyze the effect of the Tyr687 phosphorylation on APP trafficking and 
processing by using phosphorylation/dephosphorylation mimicking mutants 
(Y687E and Y687F, respectively); 
 
3. To identify novel APP interacting proteins and to determine how the 
phosphorylation state of APP regulates multiprotein complex formation. 
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CHAPTER II 
 
DEVELOPMENT OF MODEL SYSTEMS TO STUDY APP 
TRAFFICKING AND PROCESSING 
 
 
 
During the last decade various studies have addressed APP expression, 
processing and subcellular localization, in order to identify factors that affect APP 
cellular metabolic pathways and subsequently modulate Abeta production. Among 
these studies, we can refer RT-PCR (Sandbrink et al. 1994), phosphorylation site 
mutants (Haass et al. 1995, da Cruz e Silva et al 1993), in situ hybridization 
(Rockeinstein et al. 1995), immunocytochemistry (Caporaso et al., 1994) and 
subcellular fractionation (Xia et al., 1998). Although extremely informative, these 
methods are mostly nondynamic analytical methods that may be insufficient to 
address alternative APP-processing pathways. Clearly, new approaches are needed to 
further refine our understanding of APP processing and trafficking. With this purpose, 
we developed a novel approach with the following considerations: (1) site-directed 
mutagenesis of target amino acids to mimic a constitutive 
phosphorylation/dephosphorylation state, (2) expression of Wild type and mutant APP-
GFP (green fluorescent protein) fusion proteins to facilitate visualization, (3) controlled 
low level expression to avoid ‘flooding’ cellular pathways, and (4) the use of 
cycloheximide to inhibit “de novo” protein synthesis.  
Using this methodology, we were able to detect specific differences in APP 
processing that correlated with the mimicked phosphorylation state. This approach is 
extensively described in the first manuscript (da Cruz e Silva et al. 2004) presented in 
this section. The use of this powerful methodology allows the detailed analysis of key 
control points in the cellular metabolism of specific proteins that are central to 
neurodegenerative diseases. 
Additionally, we were able to monitor a specific APP population using a different 
approach called the modified model system. The major difference between the two 
systems is that in the first cycloheximide (CHX) was added and ‘de novo’ protein 
synthesis was inhibited, whereas in the latter the CHX was removed thus allowing ‘de 
novo’ protein synthesis. APP trafficking was monitored in both cases. Consequently, 
we were able to show that CHX inhibition was reversible and well suited to monitor 
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specific stages of APP intracellular targeting. The second approach will be described in 
detail in the second manuscript (Rebelo et al. 2008, submitted).  
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ABSTRACT 
We previously described a dynamic model system to monitor a specific population of 
Alzheimer’s Amyloid Precursor Protein (APP) involving the addition of cycloheximide 
(CHX) to cells in culture to block ‘de novo’ protein synthesis. Here we show that the 
addition of CHX is non-toxic and reversible. Removal of the drug allowed cells to 
reinitiate ‘de novo’ protein synthesis and permitted the monitoring of anterograde APP 
transport. In particular, we addressed targeting of APP via the secretory pathway. The 
consensus NPTY motif in APP, typically associated with endocytosis, was mutated to 
NPTF or NPTE to mimic a constitutively dephosphorylated or phosphorylated residue, 
respectively. Our data reveals that disrupting the NPTY domain of APP not only affects 
its endocytosis, as shown previously, but also its incorporation into vesicles budding 
from the TGN. Thus, CHX can be a useful tool to study both anterograde and 
retrograde ‘in vivo’ transport of APP and other proteins. 
 
 
 
 
 
 
 
 
 
 
 
Keywords: APP-GFP, Cycloheximide, ‘de novo’ protein synthesis, monitoring, 
anterograde transport. 
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INTRODUCTION 
Monitoring intracellular targeting and processing of the Alzheimer’s Amyloid 
Precursor Protein (APP) is a challenging task, given the many pathways via which it is 
processed and the various stages at which protein cleavage can occur. Among its 
many functions, APP has been proposed to be a signal transduction molecule. This 
places it among a class of proteins which are cleaved to produce fragments that can 
mediate a process of regulated intramembrane proteolysis (RIP), with an important 
role in signaling cascades 1. APP routing in the cell entails export from the TGN (Trans-
Golgi network), via the secretory pathway, followed by insertion into the cell 
membrane. Subsequently, APP is endocytosed and can suffer several fates typical of 
this pathway. Once endocytosed, the toxic fragment Abeta can also de produced, an 
event of specific pathological interest. Both the anterograde and retrograde transport 
of APP are highly regulated events, with protein phosphorylation likely to play a 
significant modulatory role. For example, data from our laboratory (da Cruz e Silva, in 
preparation) and previous reports indicate that TGN budding is dependent on protein 
kinase C 2, as is the production of Abeta 3.  
Although APP is itself a phosphoprotein, few events regarding APP processing 
have been shown to be governed by specific phosphorylations of APP itself. Thr668, 
within the 667VTPEER672 functional domain, has been shown to be important in 
determining binding of FE65 to APP in a phosphorylation state dependent manner 4. 
Another important domain in the C-terminus of APP is 682YENPTY687, which comprises a 
typical internalization signal (NPTY) for membrane associated receptor proteins 5-7. 
Both Tyr682 and Tyr687 are phosphorylated in vivo. APP is tyrosine phosphorylated in 
cells expressing a constitutively active form of the Abl protooncogene, a non-receptor 
tyrosine kinase similar to c-Src, which can form a stable complex with APP and FE65 8. 
Abl-dependent Tyr682 phosphorylation appears to involve the nerve growth factor 
receptor TrkA, to mediate APP membrane internalization and to result in reduced γ-
secretase APP processing 6,7,9. This phosphorylation may also mediate protein-protein 
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interactions 8,9. Consequently, attention was drawn away from Tyr687, although this 
residue was reported to be phosphorylated in brain samples from AD patients 10. 
Further, this residue is important in mediating endocytosis and we have previously 
shown that the Y687E mutant, mimicking constitutive phosphorylation, produces 
significantly less Abeta 11,12. 
In order to determine the role of Tyr687 phosphorylation on APP processing, a 
model system was developed taking advantage of cycloheximide (CHX) blocking of ‘de 
novo’ protein synthesis 13. The protein was tagged with GFP and low levels of 
transfection permitted monitoring APP turnover as it disappeared from the cell. APP 
turnover is virtually complete 5 h after CHX addition. Hence we were able to address 
retrograde processing of APP. In order to analyze anterograde transport, we expanded 
the model by removing CHX from the cells in culture and following ‘de novo’ APP 
synthesis. We were able to determine that CHX, as used in this context, is not 
detrimental to the cell and that its effects are reversible. In essence, removal of CHX 
permits ‘de novo’ protein synthesis to resume and subsequently one is able to monitor 
intracellular protein targeting. The reversibility of this model is discussed, as is its 
application to unraveling APP trafficking, particularly its anterograde transport. 
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MATERIALS AND METHODS 
Production of APP-GFP fusion constructs  
The Tyr687 residue of APP695 was mutated by site directed mutagenesis to either 
glutamate or phenylalanine in order to mimic the phosphorylated and 
dephosphorylated state of the protein, respectively 13,14. Both phosphorylation 
mimicking mutants and wild-type APP were fused with GFP by inserting into the 
pEGFP-N1 mammalian expression vector (Clontech), as previously described 11,12.  
 
Maintenance and transfection of cell cultures 
Monkey kidney COS-7 cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 10% foetal bovine serum, 100 U/ml penicillin, 100 mg/ml 
streptomycin and 3.7 g/l NaHCO3 at 37ºC and 5% CO2, until 90% confluent 15. 
Transient transfections were performed at 80%-90% cell confluency using 
LipofectAMINE 2000, a cationic lipid transporter (Invitrogen Life Technologies). After 8 
hours (h), cells were divided into six-well plates with coverslips pre-treated with 100 
µg/ml polyornithine (Sigma), and left to recover for 4 h.  
 
Tracking ‘de novo’ synthesis of APP fusion constructs 
Transfected cells were then incubated in serum-free DMEM supplemented with 
50 µg/ml cycloheximide (Sigma) for five hours. Cycloheximide containing medium was 
then removed, cells were washed two times with PBS and then incubated at 37 ºC in 
DMEM supplemented with 10% foetal bovine serum for 1 h, 2 h, 3 h, 4 h and 5 h. At 
each time point the cells were washed three times with PBS and fixed in 4% 
paraformaldehyde. Following cell fixation and subsequent coverslip preparation, the 
subcellular localization of APP was directly observed by fluorescence microscopy using 
an Olympus IX-81 inverted epifluorescence microscope. Cells were analysed for the 
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presence or absence of fluorescence in specific subcellular organelles. Subcellular 
structures were confirmed using specific markers. Calnexin was used as an ER marker 
(the 2h30 time point is shown as an example). 
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RESULTS 
Our previously described model allowed for the monitoring of 
phospohorylation-dependent APP trafficking and processing 13. Briefly, first we mimic 
the phosphorylation and dephosphorylation of APP target residues, allowing the 
evaluation of the functional impact of phosphorylation of those residues. Secondly, the 
constructs were fused in-frame with a reporter gene (GFP) in a mammalian expression 
vector, and used to achieve low level transient transfections. Finally, the addition of 
cycloheximide was particularly useful since it dramatically reduces the background of 
APP-GFP molecules being continuously synthesized. In essence, ‘de novo’ synthesis of 
APP-GFP was blocked and previously synthesized molecules were detected and 
followed over a period of time (Fig. 1). After 5 hours of incubation with cycloheximide, 
APP-GFP turnover was complete and inhibited from further processing given the 
absence of ‘de novo’ protein synthesis. Thus, by using this approach we were able to 
determine the importance of Tyrosine 687 on APP-GFP turnover rate, intracellular 
trafficking, processing and particularly endocytosis and Abeta production 11,12. Hence, 
the retrograde transport of APP was monitored. Removal of CHX, on the other hand, 
should allow the study of the anterograde transport of APP (Fig. 1).  
 
 
 
 
 
 
 
 
 
Figure 1. Modified model system. Schematic representation of the modified model 
system. The vertical arrow indicates the time point when cycloheximide (CHX) was removed.  
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“De novo” protein synthesis was blocked by adding 50 μg/ml CHX for 5 hours. 
After that period, the CHX was removed and fresh medium without CHX was added, 
and the cells were allowed to resume ‘de novo’ protein synthesis (Figs. 1 and 2). Thus, 
transiently transfected COS-7 cells were observed at 1 h, 2 h, 3 h, 4 h and 5h 
following CHX removal and analysed for the presence or absence of fluorescence in 
specific subcellular organelles. At time 0 h no fluorescence was observed. A 
representative example at each time point both for Wt-APP and the phosphorylation 
mimicking mutants (Y687E and Y687F) is presented in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1h                                  2h                          3h                                    4h               5h     
Wt
Y687F
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1h                                  2h                          3h                                    4h               5h     
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Figure 2. Wild-type and mutant (Y687E and Y687F) APP-GFP intracellular 
protein trafficking. Representative epifluorescence microphotographs of transiently 
transfected COS-7 cells at specific time points after CHX removal. 
 
 
One hour after CHX removal we observed that APP-GFP is already being 
abundantly ‘de novo’ synthesized. Indeed, it is already detected in the ER and Golgi 
for wild-type, as well as for the two APP phosphomutants (Fig. 2, 1 h). At the 2h time 
point, it is evident that Wt-APP is already being incorporated into cytoplasmic vesicles 
and clearly reaches the plasma membrane by 3 h (Fig. 2). The nucleus is visible one 
hour later (Fig. 2, 4 h) and is clearer by the end of the experiment (Fig. 2, 5 h). The 
Y687E-APP mutant was also abundantly expressed after one hour of CHX removal. The 
protein, similar to Wt, could be detected in the ER and Golgi (Fig. 2, 1 h). However, 
some differences between the wild-APP and Y687E-APP mutant were already evident 
one hour later (2 h), since few cytoplasmic vesicles are visible with this mutant. 
Additionally, the plasma membrane is already detected in some cells (Fig. 2, 2 h). At 
the 3 h time point once again few cytoplasmic vesicles are present when compared 
with Wt-APP, and the plasma membrane seems to be more intensely marked for the 
phosphorylation mimicking mutant (Y687E-APP). During the last two time points the 
cytoplasmic vesicles as well as the nucleus are well visible (Fig. 2, 4 h and 5 h). 
Contrasting effects were obtained when monitoring ‘de novo’ protein synthesis of the 
dephosphorylation mimicking mutant (Y687F-APP). As with Wt, one hour after CHX 
removal, localization in ER and Golgi was clearly evident. Moreover, the Y687F-APP 
protein trafficking was very similar to Wt-APP at all time points. There was only a 
slight difference between them at the 2 h time point, since the Y687F-APP mutant was 
already visible in the plasma membrane of some cells. Hence, the two phosphorylation 
state mimicking mutants behaved differently and exhibited different distribution 
patterns. 
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Co-localization studies were validated with several markers, in particular 
calnexin which labels the endoplasmic reticulum. An example of co-localization with 
the Y687E-APP phosphorylation mimicking mutant is presented in Figure 3. As 
mentioned above, the Y687E-APP mutant does not produce clearly visible vesicles. In 
fact, it exhibits strong localization to the ER throughout the experiment. In conclusion, 
the reversible use of CHX permitted monitoring anterograde APP transport and 
unravelled the importance of residue Y687 in this process. 
 
 
 
 
 
 
 
Figure 3. Y687E-APP-GFP co-localization with calnexin. COS-7 cells transfected 
with the phosphorylation mimicking mutant (Y687E-APP), were fixed and processed for 
immunocytochemical analysis using a specific antibody to detect endogenous calnexin (an 
endoplasmic reticulum marker). Bar, 10 μm. 
 
 
 
 
 
 calnexinY687E merge
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DISCUSSION 
 
Addressing a specific population of proteins is an important approach to study 
protein turnover. Methionine labeling is often used and certainly provides useful data. 
Here we present an alternative method which is non-radioactive, reversible and 
permits the study of anterograde and retrograde processing. In previous experiments 
11,12 we used CHX, thus inhibiting ‘de novo’ protein synthesis and enabling protein 
turnover to be monitored, in particular endocytosis and subsequent targeting, such as 
to the TGN or the nucleus (Vieira, in preparation). By 5 hours, fluorescent APP protein 
is completely absent from the cell 13. Thus, at this time point we removed the CHX, 
allowing ‘de novo’ synthesis of APP to reinitiate. The CHX inhibition of protein 
synthesis was reversible and cells were able to resume ‘de novo’ protein synthesis. 
The Y687E-APP mutant consistently failed to be incorporated into cytoplasmic vesicles 
under both conditions (in the presence and absence of CHX). Other aspects of 
transport of this mutant were also confirmed. Namely, the Y687E-APP mutant was still 
transported to the cell membrane, even in the absence of visible vesicles. Delivery of 
the Y687E-APP mutant protein to the cell membrane might be supported by the ER, 
consistent with previous findings by other authors 16. 
Considering the data thus far obtained with the Tyr687 mutants, it is possible to 
propose a model of phosphorylation-dependent APP targeting in the cell (Fig. 4). 
Central to the development of this model was the observation that Y687E-APP and 
Y687F-APP exhibited contrasting behaviours, particularly with respect to TGN budding, 
as described above, and endocytosis 11,12. In fact, Y687F-APP apparently incorporates 
more efficiently into vesicular structures than Wt-APP. The fact that the mutants 
behave so differently supports our hypothesis that phosphorylation of this key residue 
may in fact be a central regulatory event. In the model shown in Figure 4, we indicate 
subcellular structures abundant in both the dephosphorylation and phosphorylation 
mimicking mutants (black and white, respectively), and those where only the 
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dephosphorylation mimicking mutant was preferentially detected (black only). Hence, 
it would appear that APP needs to be dephosphorylated at Tyr687 in order to be 
incorporated into vesicular structures, both at the TGN and during endocytosis (Fig. 
4). These are two critical sites for Abeta production 6,17-19 and this may explain why 
the dephosphorylation mimicking mutant produces less Abeta, as previously described 
12. APP export is likely to be mediated by multimeric complexes, the formation of 
which being probably regulated by phosphorylation. Such an example has already 
been described for FE65 binding to APP, which is modulated by phosphorylation of APP 
at Thr668 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Tyrosine 687 phosphorylation/dephosphorylation-dependent APP 
subcellular targeting. N, nucleus; ER, endoplasmic reticulum. 
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One can conclude that the CHX based experimental model is useful to study 
both retrograde and anterograde processing, and that for APP the NPTY domain is 
important in both instances. The exposure to CHX appears to leave the cell machinery 
intact, such that the mutants behave in an identical manner both before and after 
removal of the drug. That is, Y687E-APP failed to be incorporated into vesicles, 
whereas Y687F-APP was incorporated more efficiently than wild-type APP. Another, 
advantage of this method, particularly in comparison to pulse chase methods, is that it 
allows direct real time in vivo monitoring of the GFP-tagged proteins. This is useful for 
Alzheimer’s disease related studies addressing the use of signal transduction based 
therapeutics, where phosphorylation of a single site on a given protein can result in a 
cascade of events and affect other proteins directly or indirectly. By visualizing APP 
directly, and given all the other methodology already evolved, such as measuring 
Abeta levels, such effects on APP metabolism can be easily evaluated. 
We had previously shown that disrupting the NPTY domain dramatically 
impaired endocytosis of APP and affected Abeta production 12. APP turnover was 
monitored in the absence of ‘de novo’ protein synthesis by adding CHX to transfected 
cells in culture. The work presented here modified the previously described model 
system 13 by removing the CHX, thus permitting ‘de novo’ protein synthesis to 
resume. Consequently, all the cellular machinery should become available to permit 
‘normal’ protein targeting. Notably, under these conditions the Y687E-APP mutant still 
fails to be incorporated into visible vesicular structures (Fig. 3). Overall, the method 
described for monitoring intracellular protein targeting has several advantages, and 
can be applied to the study of proteins other than APP. 
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CHAPTER III 
 
TYROSINE 687 DEPENDENT ALZHEIMER’S AMYLOID PRECURSOR 
PROTEIN TRAFFICKING AND PROCESSING 
 
 
 
Protein phosphorylation is a major regulatory mechanism, reversible in nature and 
controlling key events in molecular and cellular biology. It is perhaps not surprising 
that many pathologies exhibit altered protein phosphorylation profiles, among these 
Alzheimer’s disease (AD). Moreover, APP is itself a phosphoprotein with eight putative 
phosphorylation sites on its C-terminal domain (Ser653, Thr654, Ser655, Thr668, Ser675, 
Tyr682, Thr686 and Tyr687). Of these, tyrosine 687 (Y687) of the APP was shown to be 
phosphorylated in the brain of Alzheimer’s disease patients by MALDI-TOF MS (Lee et 
al. 2003).  
Additionally, this residue lies within a typical internalization signal (NPTY) for 
membrane associated receptor proteins, strongly suggesting a potential role for APP in 
signal transduction. Consequently, this chapter describes how phosphorylation of Y687 
may be affecting APP in terms of its proteolytic cleavage and subcellular distribution. 
In the work described, Y687 was mutated to glutamate (Y687E-APP-GFP) to mimic a 
constitutively phosphorylated residue, or to phenylalanine (Y687F-APP-GFP) to mimic 
a constitutively dephosphorylated residue and the results are presented in the next 
two manuscripts (Rebelo et al. 2007a and Rebelo et al. 2007b). For detailed protocol 
information see the appendix.  
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CHAPTER IV 
 
APP PROTEIN-PROTEIN INTERACTIONS MEDIATED BY THE 
NPTY DOMAIN 
 
 
 
The results reported in Chapter III revealed antagonic effects of mutating 
Tyr687 to phenylalanine and glutamate, in comparison to the wild-type protein. It is 
resasonable to deduce that the phosphorylation state of Tyr687 may results in the 
formation of different multimeric complexes which are differently targeted. In fact, 
we have already initiated the analysis of the phosphorylation dependent APP 
interactome. An array of different APP binding proteins have been identified 
(unpublished data). RTN3-B is a novel APP interacting protein that was isolated 
when either the Wt-APP protein or the Y687F mutant protein was used as bait in a 
Yeast Two Hybrid screen. Further details are presented in the first paper of this 
section (Rebelo et al. 2008, in preparation). 
Our conclusions so far, favour the model that interaction of APP with the 
binding proteins may also be mediated by the phosphorylation state of APP itself 
(da Cruz e silva et al. 2004). This is not a surprise if one considers for instance that 
the phosphorylation of APP at Thr668 affects its binding to FE65. Curiously, FE65 
which binds at the 682YENPTY687 domain of APP also depends on the phosphorylation 
state of Thr668 on the 667VTPEER672 domain. When phosphorylated at Thr668, AICD is 
no longer stabilized by FE65, and associates less with the latter. Indeed, the 
phosphorylation of APP at Thr668 had already been shown to affect the interaction 
between APP and FE65, probably because the phosphorylation of this residue 
induces structural changes from trans- to cis-conformations in the C-terminal 
domain of the protein (Ramelot and Nicholson 2001).  
The hypothesis that subcellular targeting, as one might expect, involves APP 
binding proteins, which are in turn regulated by protein phosphorylation, deserves 
further investigation. This is addressed in the second paper of this section where we 
have shown that FE65 binds simultaneously to APP and PP1γ, both in neuronal and 
non-neuronal cell lines. The tri-complex was also detected in adult rat brain. 
Additionally, we demonstrated that FE65 is the bridging protein between APP and 
PP1γ (Rebelo et al. 2008, submitted).  
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ABSTRACT 
 
Alzheimer’s disease (AD) is the most common age-related dementia. The 
amyloid precursor protein (APP) has a central role in the development of the disease, 
although its precise function remains undefined. Unveiling the APP interactome will 
contribute to understanding its function, as well as contributing towards potential 
therapeutic targets for the treatment of AD. In Yeast Two-Hybrid screens using Wt-
APP as well as a dephosphorylation-mimicking mutant (Y687F-APP), Reticulon 3 
(RTN3-B) was identified from a human brain cDNA library. RTN3 is a protein 
associated with the endoplasmic reticulum (ER) and is involved in membrane 
trafficking. This protein had been associated with AD as a negative regulator of BACE-
1 activity. Our results showed that RTN3-B and APP interact both in vivo and in a Y2H 
system and co-localize in human cells lines. We also show that overexpression of 
RTN3-B leads to increased secretion of sAPP along with a decrease in the levels of 
holo-APP. Given that RTN3-B can bind both BACE-1 and APP, a putative functional 
model is proposed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Alzheimer ’s disease, Reticulon 3, Protein interactions, BACE-1, APP 
phosphorylation, Endoplasmic reticulum. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common age-related dementia among 
elderly. World widely it affected aproxiamately 30 million persons in 2006 and is 
estimated to affect 100 million persons in 2050 (Brookmeyer et al. 2007). AD is 
characterized by two major histopathological hallmarks; intracellular neurofibrillary 
tangles and extracellular amyloid plaques. Neurofibrillary tangles contain 
hyperphosphorylated tau protein, while the amyloid plaques are mainly composed of 
Abeta aggregates. Strong evidence suggests that altered processing of the amyloid 
precursor protein (APP) is one of the early events in AD pathogenesis (Roner 2004). 
The amyloid hypothesis predicts that an alteration in the proteolytic processing of APP 
may lead to increased Abeta production, which then leads to its accumulation, a 
primary event in the pathogenesis of AD (Newman et al. 2007). Moreover, APP can be 
processed by various pathways, which can be amyloidogenic or non-amyloidogenic. In 
the non-amyloidogenic pathway, APP is cleaved by an α-secretase, within the Abeta 
sequence, producing the alpha secreted APP fragment (sAPPα) and alpha C-terminal 
fragment (αCTF) or C83. The latter is further cleaved by the γ-secretase complex and 
to produce the p3 fragment and the APP intracellular domain (AICD). In the 
amyloidogenic pathway, APP is cleaved by a β-secretase resulting in two fragments, 
beta secreted APP fragment (sAPPβ) and beta C-terminal fragment (βCTF) or C99. The 
βCTF is further cleaved by the γ-secretase complex producing Abeta and the AICD 
(Kern et al. 2006). 
ADAM10 and ADAM17 metalloproteinases are responsible for α-cleavage 
(Buxbaum et al. 1998; Koike et al. 1999; Lammich et al. 1999), whereas β-cleavage 
at the APP N-terminal was shown to be catalyzed by BACE-1 (Hussain et al. 1999; 
Vassar et al. 1999). This enzyme has been localized in the Golgi apparatus and 
endosomes (Vassar et al. 1999), which are the subcellular compartments where Abeta 
is produced (Roner 2004). The γ-secretase is a macromolecular complex that results 
from the interaction between the presenilins, nicastrin, APH-1 and PEN-2 (Esler et al. 
2002; Francis et al. 2002; Lee et al. 2002). Protein phosphorylation has also been 
shown to play an important role in APP processing (da Cruz e Silva and da Cruz e Silva 
2003). Indeed, intracellular signaling cascades have a central role in the regulation of 
APP cleavage (Gandy et al. 1993). Both protein kinase A (PKA) and protein kinase C 
(PKC) have been shown to phosphorylate proteins associated with the Trans-Golgi 
network. Phorbol esters, which are known to activate PKC, stimulate APP secretion 
while decreasing Abeta production (Buxbaum et al. 1993). Protein phosphatase 1 
(PP1) may also play a role in the production of sAPP, as its inhibition stimulates 
 Chapter IV 
158  Sandra Rebelo 
 
  CBC/UA, 2008 
secretion of sAPP (da Cruz e Silva et al. 1995). Additionally, APP is itself a 
phosphoprotein, with potential phosphorylatable residues located on its cytoplasmic 
domain, namely Tyr653, Ser655, Thr668, Ser675, Tyr682, Thr686 and Tyr687 (Lee et al. 
2003b). Most of these phosphorylatable residues lie within important motifs within the 
AICD, such as the 653YTSI656 basolateral sorting signal, the 667VTPEER672 motif that 
regulates the α-helical structure of the cytoplasmic region and a typical internalization 
signal, 682YENPTY687. Several proteins have been identified as interacting with these 
AICD motifs. Among them the APP tail 1 (PAT1) may be involve in APP translocation 
towards the cell surface and requires Tyr653 located on the YTSI motif for binding 
(Zheng et al. 1998a). The GTP-binding protein G0 binds to a larger domain containing 
the VTPEER motif (De Strooper and Annaert 2000). Particularly well studied are Fe65 
and Mint 1, which bind to the YENPTY motif. The interaction of APP with these binding 
proteins appears to be regulated by protein phosphorylation, as has been described 
for FE65 binding. It was demonstrated that FE65 binding to the 682YENPTY687 domain 
depends on the dephosphorylation of Thr668. Many other proteins contribute directly or 
indirectly to APP processing. For example RTN3-B has been described as a negative 
modulator of BACE-1 activity (He et al. 2006; He et al. 2004; Wakana et al. 2005), to 
participate in the formation of dystrophic neuritis in AD (Hu et al. 2007) and was 
found to be down regulated in AD brains (Yokota et al. 2006). 
Reticulons (RTNs) are a family of membrane-bound proteins with a highly 
conserved C-terminus, found in animals, plants and fungi (Oertle et al. 2003). 
Mammals have four genes, rtn1 to rtn4, which lead to the expression of multiple 
isoforms that share a common 188 amino-acid domain in the C-terminal and is 
referred to as the Reticulon Homology Domain (RHD;Di Scala et al. 2005). Within the 
RHD, there are two stretches (28-36 amino acids) of hydrophobic residues separated 
by a 66-amino acid loop, and each is expected to embed RTNs in the membrane. The 
diverse N-terminal domain among RTNs allows each RTN member to possess a specific 
function. The rtn3 gene transcripts (RTN3-A and RTN3-B) are primarily expressed in 
the brain (Di Scala et al. 2005; Oertle and Schwab 2003). RTN3-B is a splice variant 
bearing exons 1, 4, 5, 6, 7, 8 and 9, resulting in a protein with only 236 amino acids 
(Humans) and an expected molecular mass of 25 kDa. It is expressed in spinal cord, 
cortex and cerebellum (Di Scala et al. 2005). Moreover, RTN3-B is mainly localized to 
the ER and Golgi (He et al. 2004; He et al. 2007; Murayama et al. 2006; Wakana et 
al. 2005), but it is also found in the axons, dendrites and growth cones (Hu et al. 
2007). The localization of RTN3-B in the neuritic region suggests its potential role in 
neuritic function (Hu et al. 2007). RTN3-B plays a role in membrane trafficking 
between the ER and Golgi and may be involved in the retrograde transport from ER-
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Golgi intermediate compartment (ERGIC) to the ER, although it is not excluded that it 
may be implicated in the anterograde transport (Wakana et al. 2005). 
In the work here described, we have demonstrated that APP and RTN3-B 
interact in vivo, and also that the RTN3-B expression level has a marked effect on APP 
processing, namely favouring the non-amyloidogenic pathway. 
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METHODS 
 
Antibodies 
The primary antibodies used were mouse monoclonal antibody 22C11 (Chemicon) to 
detect APP and sAPP, rabbit polyclonal anti-APP C-terminal antibody (Zymed) to detect 
CTFs, mouse monoclonal anti-Myc antibody (Cell Signaling) to detect Myc-RTN3-B and 
rabbit polyclonal anti-calnexin antibody (Stressgen) to detect endoplasmic reticulum 
(ER). Secondary antibodies used were anti-mouse IgG horseradish peroxidase-linked 
whole antibody (Amersham Pharmacia) and anti-rabbit IgG horseradish peroxidase-
linked whole antibody (Amersham Pharmacia) for enhanced chemiluminescence (ECL) 
detection. Texas-Red-conjugated anti-mouse IgG (Molecular Probes), Fluorescein-
conjugated anti-mouse IgG (Molecular Probes) and Alexa 350-conjugated anti-rabbit 
IgG (Molecular Probes) were used for co-localization studies. 
 
Yeast Two-Hybrid screen 
Yeast Two-Hybrid screens were carried out using either the wild type-APP or the 
phosphorylation/dephosphorylation mimicking mutants (Y687E- and Y687F-APP, 
respectively) as baits for a human brain cDNA library (Clontech) using a MATCHMAKER 
GAL4 Two-Hybrid System 2 (Clontech), as previously described (Fardilha et al. 2004). 
The positive clones obtained were sequenced and identified by sequence comparaison 
to the GeneBank database using the BLAST algorithm. 
 
Plasmid construction  
The coding region of the cDNA for RTN3-B (BC105981) was amplified by PCR using 
two primers which insert restriction sites for EcoRI before the initiation codon (RTN3-
FW 5’-CTCGAATTCCCATGGCGGAGCCGTCGG-3’) and Xho I after the stop codon (RTN3-
RV 5’-GTTTCCTCGAGCTTATTCTGCCTTTTTTTTGGC-3’). The amplified product was 
inserted in pCMV-Myc Mammalian Expression Vector (Clontech) and pET-28c (+) 
(Novagen). A similar strategy was used to insert RTN3-B cDNA in pDsRed-Monomer-
N1 vector (Clontech) using a different reverse primer (RTN3-Red 5’-
CCATCCCGGGATTCTGCCTTTTTTTTGGCG-3’) that removed the stop codon and added a 
restriction site for Xma I allowing it to be fused in frame with the N-terminal of the red 
fluorescent protein. The green fluorescent protein (GFP) constructs of wild-type APP, 
Y687E and Y687F phosphomutants have been previously described (da Cruz e Silva et 
al. 2004a). All constructs were verified by DNA sequencing. 
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Cell culture 
HeLa cells were grown in minimal essential medium (MEM) supplemented with 10% 
fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin at 37ºC in 
a controlled atmosphere with 5% CO2/95% air. SH-SY5Y cells were grown in MEM 
supplemented with F-12 Nutrient Mixture (Gibco), 10% FBS, glutamine, 100 U/ml 
penicillin and 100 mg/ml streptomycin at 37ºC, 5% CO2/95% air. Cells were normally 
grown in 100-mm plates at subconfluent conditions before transfection.  
Rat cortical primary cultures were established from embryonic day 18 embryos. 
Briefly, after dissociation with 0.75 mg/ml trypsin, cells were plated on poly-D-lysine-
coated dishes at a density of 1.0x105 cells/cm2 in B27-supplemented Neurobasal 
medium (GIBCO), a serum-free medium combination (Brewer et al. 1993). The 
medium was supplemented with glutamine (0.5 mM), gentamicin (60 μg/ml). Cultures 
were maintained in an atmosphere of 5% CO2 at 37ºC for 10 days before being used 
for experimental procedures. Cell cultures (COS-7, HeLa and SH-SY5Y) and rat cortical 
primary cultures were transiently transfected using LipofectAMINE 2000 (Invitrogen 
Life Technologies) a cationic lipidic transporter, as described by the supplier. After 12-
16 hours of transfection, cells were harvested (processing studies) as described below 
or divided into 6-well plates with coverslips pre-treated with 100 μg/ml polyornithine 
(Sigma), and left to recover for 4 hr (co-localization studies). After this period cells 
were fixed using 4% paraformaldehyde and used in immunocytochemical analysis. 
 
Yeast co-transformation 
The yeast strain AH109 was transformed using the lithium acetate method, with the 
following plasmids: (1) Wt-APP-pAS2-1+ RNT3-B-pACT2; (2) Y687E-APP-pAS2-1 + 
RNT3-B-pACT2; (3) Y687F-APP-pAS2-1 + RNT3-B-pACT2; (4) pAS2-1 + pACT2. Fresh 
yeast colonies expressing the interacting proteins being analyzed, were grown in 4 ml 
of SD TDO medium (-Trp, -Leu, -His). The negative control AH109 (pAS2-1 + pACT2) 
was grown on SD –Trp-Leu. The cultures were incubated overnight at 30ºC with 
shaking at 200 rpm. The optical density of the culture at 600nm was recorded. 1ml of 
the culture was centrifuged for 5 minutes at 14000 rpm, and the supernatant was 
removed for analysis. The assay was performed by combining 8µl of culture 
supernatant with 24µl of Assay Buffer (100mM PNP-α-Gal solution, 1X NaOAc [1:2 
(v/v) ratio]). After incubation for 60 minutes at 30ºC the reaction was terminated with 
960µl of 1X stop solution (0.1M NaCO3) and the optical density at 410nm was 
recorded. The α-galactosidase milliunits were calculated with the following formula, as 
described by the manufacturer (Yeast Protocols Handbook, Clontech) for the 1ml 
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assay format: [milliunits/(ml x cell)] = OD410 x 992 x 1000 / [OD600 x time (min) x 
16.9 x 8]. 
 
Immunoprecipitation 
Cell cultures (COS-7, HeLa and SH-SY5Y) or rat primary neurons were transiently 
transfected with 8 μg of Myc-RTN3-B cDNAs, cells were harvested and extracts were 
prepared in non-denaturating lysis buffer with a protease inhibitor cocktail. The cell 
extracts were immunoprecipitated using either the anti-Myc or 22C11 (or 6E10 in 
COS-7) antibodies overnight under agitation at 4ºC. Agarose beads were then added 
to each sample and the lysate-mixture samples were incubated for 2 hours at 4ºC 
with agitation. Agarose beads were then washed 4 times with washing buffer and 
finally resuspended in LB/SDS 1%. The samples were separated on SDS-PAGE 
followed by immunoblotting using either the 22C11 antibody (samples 
immunoprecipitated with anti-Myc antibody) or the anti-Myc antibody (samples 
immunoprecipitated with 22C11 antibody). 
 
Immunocytochemical analysis 
For Myc-RTN3-B co-localization with APP, HeLa and SH-SY5Y cells were permeabilized 
with methanol for 2 min and washed with phosphate buffer saline (PBS). Cells were 
first incubated with the anti-Myc primary antibody for 2h at room temperature, 
followed by Texas-red-conjugated anti-mouse secondary antibody. After washing with 
PBS, cells were incubated with the second primary antibody, anti-APP C-terminal 
antibody, for 4h at room temperature, followed by Fluorescein anti-rabbit secondary 
antibody. After thorough washing with PBS, preparations were mounted using 
Vectashield mounting media with DAPI (Vector) and visualized using an inverted 
motorized epifluorescence microscope (Olympus). 
For Myc-RTN3-B co-localization with calnexin, SH-SY5Y cells were fixed, permeabilized 
with methanol for 2 min and washed with phosphate buffer saline (PBS). Cells were 
first incubated with the anti-Calnexin primary antibody for 2h at room temperature, 
followed by Alexa 350 conjugated anti-mouse secondary antibody. After thorough 
washing with PBS, preparations were mounted using Vectashield mounting media 
(Vector) and visualized using an inverted motorized epifluorescence microscope 
(Olympus). 
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RTN3-dependent APP processing studies 
For processing studies, SH-SY5Y cells were transiently transfected with increasing 
amounts of Myc-RTN3-B (0-4 µg) and incubated for 13 hours. After that period the cell 
culture medium was replaced by fresh serum-free medium. After 3 hours, the 
conditioned medium was collected and the cell lysates were harvested into 1% SDS 
and processed for SDS-PAGE and immunoblotting as previously described (Rebelo et 
al. 2004). Myc-RTN3-B was detected with anti-Myc antibody, holo-APP and sAPP were 
detected with 22C11 antibody and CTFs were detected using an APP C-terminal 
antibody (Zymed), followed by incubation with horseradish peroxidase-linked 
secondary antibody and detection by enhanced chemiluminescence (Amersham). 
Quantitive analysis was carried out by densitometric analysis using Quantity One 
software (BioRad).  
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RESULTS 
 
RTN3-B isoform characterization 
Positive clones encoding the cDNA for RTN3-B were isolated from the Yeast 
Two-Hybrid (Y2H) screens with either the Wild type-APP (Wt-APP) or 
dephosphorylation mimicking mutant of APP (Y687F-APP). Full sequencing of these 
clones and in silico analysis allows its identification as RTN3-B isoform. This isoform 
was previously described by Di Scala et al. (2005): it comprises exons 1, 4, 5, 6, 7, 8 
and 9 of the rtn3 gene and encodes several interesting domains (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Shematic representation of RTN3-B isoform. Several phosphorylation 
sites and subcellular location signals are represented. The reticulon homology domain (RHD) is 
represented in solid grey and includes two transmembrane domains. 
 
 
The reticulon homology domain (RHD) is a well conserved domain among the 
RTN family, while the N-terminus is specific for RTN3-B. The RHD domain 
encompasses two large transmembrane domains (Fig. 1). Thus, exons 4-9 encode the 
RHD domain and only exon 1 encodes the N-terminus domain. In silico analysis of the 
RTN3-B amino acid sequence, revealed the presence of several potentially interesting 
domains (Fig. 1). These include several phosphorylation sites for various kinases such 
us CK1, CK2 and MAPK. Moreover, the WW domain located at the N-terminus of the 
protein is important for phosphorylation-dependent interactions. An ER retention 
signal is usually found at the C-terminus of type I ER membrane proteins and 
N C
CK1 phosphorylation sites
CK2 phosphorylation site
MAPK phosphorylation site
ER retention signal
Sorting and internalization signal
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WW domainN-terminal domain
RNT3-B
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curiously it is also found at the C-terminus of RTN3-B (Fig. 1). The targeting of RTN3-
B from Trans Golgi network (TGN) to endosomal-lysosomal compartments is mediated 
by the sorting and internalization signal, located between the two transmembrane 
domains.  
 
RTN3-B interacts with APP 
The newly described interaction between the RTN3-B and APP was confirmed in 
vivo using immunoprecipitation assays. COS-7, HeLa, SH-SY5Y and cortical neurons 
were transiently transfected with Myc-RTN3-B and subjected to immunoprecipitation 
using either the anti-Myc antibody or the 22C11 antibody. Additionally, COS-7 cell 
extracts were also IP with the 6E10 antibody (Fig. 2). The immunocomplexes were 
analysed by SDS-PAGE and immunoblotting. In COS-7 cells the presence of a strong 
band at 25 KDa (Fig. 2A, upper blot) indicates that Myc-RTN3-B binds to APP. 
Moreover, when we immunoprecipitate RTN3-B using a specific antibody that 
recognizes the Myc tag, the immunoblot (Fig. 2A, lower blot) revealed the presence of 
bands with the same weight as APP, confirming once again the interaction between 
those proteins.  
Other cells lines were similarly analysed, namely HeLa and SH-SY5Y cells, and 
the results were very similar to the ones obtained with COS-7, indicating that the 
complex is also present in human cellular systems. Finally, when we tested primary 
rat cortical neurons we also observed complex formation between RTN3-B and APP. 
These immunoprecitation studies confirmed that the two proteins interact in vivo, 
because when we IP RTN3-B we detect the presence of several APP isoforms and when 
we IP APP we detect the RTN3-B isoform.  
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Figure 2. In vivo validation of the interaction between RNT3-B and APP. Panel 
A: Different cell lines and primary cultures were transfected with Myc-RTN3-B and tested for 
binding to APP. the cell lysate (L) is the control (left) of the IP with 22C11 and 6E10 (right). In 
the lower panel, the cell lysate (L) is the control (left) of the IP with anti-Myc antibody (right). 
1. Non-transfected cells; 2. IP with 22C11; 3. IP with 6E10. Panel B: HeLa cells were IP using 
22C11 (upper blots) or the anti-Myc antibody (lower blots). Panel C: SH-SY5Y cells were IP 
using 22C11 (upper blots) or anti-Myc antibody (lower blots). Panel D: Rat cortical neurons 
were IP using 22C11 (upper blotsl) or the anti-Myc antibody (lower blots). 
 
 
RTN3-B co-localizes with APP 
In order to address the physiological role of this new interaction, we carried out 
co-localization studies using human cell lines. HeLa and SH-SY5Y cells were transiently 
transfected with Myc-RTN3-B and its distribution, as well as that of the endogenous 
APP, are shown (Fig. 3A). RTN3-B, as expected, is mainly located in the endoplasmic 
reticulum (ER) and endogenous APP and RTN3-B co-localize extensively within the cell 
as indicated by the yellow/orange colour (Fig. 3A, Merge). The ER localization was 
confirmed by transfecting HeLa cells were transiently transfected with both RTN3-B-
Red and APP-GFP constructs, and incubating with an ER marker (anti-calnexin) (Fig. 
3B). In both cases, using either the Myc or Red constructs, we observed very similar 
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subcellular distributions of RTN3-B consistent with ER distributions, as indicated by the 
white color observed (Fig. 3B, Merge). Both endogenous APP and Wt-APP-GFP co-
localized with RTN3-B contructs.  
 
 
 
Figure 3. Co-localization of RTN3-B with APP. Panel A: co-localization of Myc-
RTN3-B with endogenous APP in HeLa and SH-SY5Y cells, using DAPI to detect the nucleus (nu). 
The immunodetection of endogenous APP was carried out using a specific antibody that 
recognises the APP C-terminus (CT-Ab). Panel B: co-localization of RTN3-B-Red, Wt-APP-GFP 
and Calnexin [endoplasmic reticulum (ER) marker]. 
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RTN interacts with APP and APP phosphomutants in the Y2H system 
The AH109 yeast strain was co-transformed with plasmids expressing RTN3-B 
and APP. Prior to α-galactosidase quantitative assays, Wt-APP and APP 
phosphomutants were assayed for positive interaction with RTN3-B in the Yeast Two-
Hybrid system. The positive interactions were was shown by growth on SD/-Trp/-Leu/-
His plates and by the blue color of the colonies, indicating expression of the MEL1 
reporter gene (Fig. 4A). For the α-galactosidase quantitative assays, the yeast cells 
were grown overnight in selective medium, after which cell-free supernatants were 
assayed for α-galactosidase activity (Fig. 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Yeast Two-Hybrid interaction of RTN3-B with Wt-APP, Y687E-APP and 
Y687F-APP. The yeast strain AH109 was co-transformed with the following plasmids: 
pACT2/pAS2-1; pACT2-RTN3-B/pAS2-1-Wt-APP; pACT2-RTN3-B/pAS2-1-Y687E-APP; pACT2-
RTN3-B/pAS2-1-Y687F-APP. Panel A: yeast cells were grown on SD-Trp/-Leu/-His selective 
medium with X-α-Gal to test for the α-galactosidase expression. Panel B: yeast cells containing 
the various two-hybrid constructs were grown overnight in selective medium, after which cell-
free supernatants were assayed for α-galactosidase activity. Data are expressed as mean ± 
SEM of triplicate determinations of three independent experiments. Statistical significance was 
conducted by one-way analysis of variance (ANOVA) with Tukey-Kramer test. Unless other wise 
noted, a level of statistical significance is considered P<0.05. Significant differences against the 
fold induction of α-galactosidase activity compared to the Wt-APP interaction are presented as * 
(P<0,05). + value statiscally different from each other (P<0,05). 
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In order to determine the relative strength of the interaction between RTN3-B 
and Wt-APP and Y687E- and Y687F-APP phosphomutants, a quantitative assay was 
carried out in other to measure the activity of α-galactosidase in yeast culture 
supernatants (Fig. 4B). The α-galactosidase activity was significantly higher with the 
dephosphorylation mimickingmutant, when compared with Wt-APP (P<0,05). In 
contrast, the yeast cultures expressing both Y687E+RTN3-B showed a level of α-
galactosidase activity similar to Wt-APP (Fig. 4B). Hence, RTN3-B interacts with Wt-
APP, as well as with both APP phosphomutants, in the Y2H system. However, the 
interaction is strongest with the dephosphorylation-mimicking mutant.  
 
RTN3-B dependent APP processing  
Thus, we confirmed the interaction between RTN3-B and APP both in vivo and 
ex vivo using several techniques. We also demonstrated that RTN3-B and APP share 
common subcellular localizations and hence we can hypothesize that together they are 
playing important cellular functions, with a possible role in subcellular processing. In 
order to address this, we transiently transfected SH-SY5Y cells with increasing 
amounts of Myc-RTN3-B and the corresponding immunoblot is presented in Fig. 5. It is 
clear that transfecting SH-SY5Y cells with increasing amounts of Myc-RTN3-B results 
in a corresponding increase in expression levels (Fig. 5A). We also analyzed the 
production of sAPP and CTFs, as well as holo APP levels. sAPP and CTFs are produced 
by α- or β-cleavage of APP, and CTFs are then γ-cleaved producing P3 or Abeta, 
respectively. Thus, altered levels in any of these products may be relevant for AD. It 
was observed that with increased amounts of Myc-RTN3-B being expressed there is an 
increasing in the amount of sAPP and CTFs being produced in SH-SY5Y cells (Fig. 5 C, 
D). In fact, sAPP levels 12-fold higher than control were obtained for the higher 
expression level of RTN3-B. Moreover, the same blot was probed with 6E10 (data not 
shown), showing and we verify that almost all sAPP production was alpha sAPP, and 
indicating that the non-amyloidogenic pathway was favoured. Additionally, this 
increase is accompanied by a decrease of the holo APP levels (Fig. 5B).  
 
 Chapter IV 
170  Sandra Rebelo 
 
  CBC/UA, 2008 
 
 
Figure 5. RTN3-B dependent APP processing in SH-SY5Y cells. Panel A: 
expression of Myc-RTN3-B in cells transfected with increasing amounts of Myc-RTN3-B. Panel 
B: immunoblot of APP in cell lysates detected with the 22C11 antibody and the respective 
quantitative data. Panel C: Immunoblot of sAPP production detected with the 22C11 antibody 
and the respective quantitative data. Panel D: immunoblot of total CTFs in cell lysates detected 
with anti-APP (C-terminal) antibody and the respective quantitative data. Quantitative data are 
shown as the fold increase relatively to the control (C - non-transfected cells).  
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DISCUSSION 
 
In this study we show for the first time that RTN3-B binds to APP and, 
therefore, we propose that the two proteins are functionally related. The RTN3 role in 
AD has been so far attributed to its interaction with BACE-1, since RTN3 strongly 
inhibits BACE-1 activity (He et al. 2006; Murayama et al. 2006; Tang and Liou 2007). 
Recently, it has been described as contributing to the formation of dystrophic neurites 
in AD (Hu et al. 2007) and was found down regulated in AD brains (Yokota et al. 
2006). In this respect altered APP processing may be a major contributing factor. 
RTN3-B is targeted from Trans-Golgi network (TGN) to endosomal-lysosomal 
compartments and this is mediated by the sorting and internalization signal. This 
domain is very important if we consider that several APP functions occur in the TGN 
and endocytic pathway, including amyloidogenic processing of APP. Our results 
strongly suggest that this novel RTN3-B: APP interaction is important in targeting the 
complex and influences APP processing. Co-localization of both proteins is consistent 
with this hypothesis. The relevance of this interaction in neuronal systems was evident 
given that the complex could also be immunoprecipitated from neuronal cultures. 
Given that the interaction between the two proteins was stronger for the Y687F 
protein, phosphorylation of APP may play an important regulatory role. 
Having shown that RTN3-B and APP interact in vivo, we were able to 
investigate the physiological relevance of this new interaction, given that RTN3-B 
overexpression affected APP processing. The differences observed in sAPP production 
are consistent with the decrease in holo-APP levels, as well as with an increase in CTFs 
produced, when higher levels of RTN3-B are expressed (Fig. 6). This was 
demonstrated in SH-SY5Y cells, derived from a neuronal cell line, and therefore of 
specific relevance to this field of study. In essence, it appears that RTN3-B is involved 
in targeting APP to specific subcellular locations where proteolytic processing occurs. 
Our results clearly indicate that RTN3-B is directing APP to the non-amyloidogenic 
pathway. Curiously, BACE-1 cleavage was shown to be blocked by enriching the 
expression of RTN3-B (He et al. 2004). Recent data regarding RTN3 topology indicates 
that it forms a ω-shape structure with the N- and the C-termini of RTN3 facing the 
intracellular/cytosolic side (He et al. 2007). The determination of RTN3 topology would 
help to explain not only the interaction of RTN3 and BACE-1 but also the interaction of 
RTN3-B and APP. Because both C-terminal tails face the cytosolic side, the same 
topological orientation makes this binding compatible. So, if RTN3-B is increasing the 
processing of APP, and at the same time blocking BACE-1 cleavage, APP can only be 
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processed via the non-amyloidogenic pathway. Thus, our results are in agreement 
with previous RTN3 studies (He et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of RTN3-B/BACE-1 and RTN3-B/APP 
interactions. A. The conserved QID triplet within the C-terminal tail of RTNs is only critical 
sequence for the interaction between RTNs and BACE-1 (He et al. 2006). B. We hypothesize 
that RTN3-B interacts with APP through its C-terminus domain. 
 
 
Therefore, RTN3-B represents a good candidate as a therapeutic target, given 
that it appears to regulate Abeta production without blocking APP processing, but 
rather favours non-amyloidogenic processing. 
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ABSTRACT 
 
The Alzheimer’s amyloid precursor protein (APP) binds several proteins conferring it 
specific functional significance. In this study we describe a novel tri-complex 
comprising APP, an APP binding protein (FE65) and a Ser/Thr protein phosphatase 
(PP1γ). We show that the trimeric complex (APP/FE65/PP1γ) occurs both in COS-7 cells 
and rat hippocampal and cortical primary neurons, as well as in adult rat hippocampus 
and cortex. The NPTY domain of APP is important for this interaction. FE65 was 
consequently shown to act as the bridging protein in the complex formed and thus we 
simultaneously describe another binding protein for PP1. This is singularly important 
given that PP1 binding proteins confer upon PP1 functional specificity and thus 
regulate its activity. Finally, identification of this complex supports the hypothesis that 
APP is involved in signal transduction pathways yet to be fully characterized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: PP1 binding protein, APP Tri-complex, FE65 
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INTRODUCTION 
 
Several neurodegenerative disorders are associated with altered signal 
transduction pathways. Alzheimer’s disease (AD) is such an example, where abnormal 
protein kinase (Jin and Saitoh 1995) as well as protein phosphatase (Gong et al. 
1993) activities have been reported in affected AD brains. Alterations include altered 
PKC activities and levels, decreased activity of protein phosphatases PP1 and PP2A, 
overexpression of calcineurin mRNA levels and hyperphosphorylation of the protein 
Tau and β-tubulin (Bennecib et al. 2000; Gong et al. 1993; Hata et al. 2001; 
Matsushima et al. 1996; Vijayan et al. 2001). A major consequence of altered 
signalling is the contribution to increased neuronal Abeta load (Nitsch et al. 1992; 
Selkoe 1993). Several studies have demonstrated that protein targeting to specific 
organelles, proteolytic processing and protein-protein interactions can be regulated by 
protein phosphorylation or by phosphorylation-dependent events (Rebelo et al. 2007a; 
Rebelo et al. 2007b). Protein phosphorylation is a dynamic and reversible process 
which involves protein kinases, phosphatases and multiple substrate proteins. It is 
consensual that protein phosphorylation plays a pivotal regulatory role in signal 
transduction cascades. 
Even though many proteins contribute to the AD pathology, the central role of 
the Alzheimer’s amyloid precursor protein (APP) is unquestionable. Several functions 
have been described for APP, including a role as a signal transduction mediator where 
APP phosphorylation may represent a key regulatory mechanism, modulating APP 
binding, traffic and processing. APP is a phosphoprotein in vivo, with several 
phosphorylation sites on its cytoplasmic domain, whose function is not clearly 
understood. The cytoplasmic phosphorylatable Ser/Thr and Tyr residues are located 
within three APP functional domains: 653YTSI656, 667VTPEER672 and 682YENPTY687. These 
domains can be classified according to their attributed functions and are thought to be 
involved in regulating the rate of APP secretion, endocytosis, and Abeta production 
(Ando et al. 2001; Ando et al. 1999; da Cruz e Silva et al. 2004b; Iijima et al. 2000; 
Mueller et al. 2000; Roncarati et al. 2002; Sabo et al. 2001). Of note is the interplay 
which appears to occur between domains. For example, the binding of FE65 protein to 
APP at the 682YENPTY687 domain also depends on the phosphorylation state of Thr668 on 
the 667VTPEER672 domain. Thr668 has been extensively studied, and can be 
phosphorylated by several proline-directed kinases. When phosphorylated on Thr668, 
the APP intracellular domain (AICD) is no longer stabilized by FE65, and associates 
less with the latter (Ando et al. 2001). Indeed, phosphorylation of Thr668 had already 
been shown to affect the interaction between APP and FE65, probably because the 
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phosphorylation of this residue induces structural changes from trans- to cis-
conformations in the C-terminal domain of the protein (Ramelot and Nicholson 2001). 
Recently, it was reported that the Pin1 protein binds to the phosphorylated Thr668 and 
regulates AICD isomerization between the cis-and trans-conformations, affecting the 
processing of APP (Pastorino et al. 2006). In turn, the domain 682YENPTY687 comprises 
not only a typical internalization signal for membrane-associated receptor proteins, 
but also two tyrosine residues; Tyr682 and Tyr687 that can be phosphorylated and 
regulate APP interactions with several PTB-containing adaptor proteins. However, the 
binding of PTB domains to the NPTY sequence can be independent of phosphorylation 
(Borg et al. 1996). Thus far, data strongly suggests an involvement of the 
682YENPTY687 domain, and Tyr682 and Tyr687 in particular, on APP traffic, processing and 
Abeta production.  
The FE65 protein family contains several protein interacting domains, including 
two PTB domains and a WW region. Furthermore, the WW domain binds to MENA 
(mammalian enabled), which binds actin and thus links FE65 and APP to cytoskeletal 
dynamics and cellular motility (Ermekova et al. 1997). The PTB1 domain of FE65 binds 
both the transcription factor complex CP2-LSF-LBP-1c, and the low density lipoprotein 
receptor-related protein (LRP). The PTB2 domain of FE65 binds the APP C-terminus, 
providing a potential scaffold between APP and LRP (Kinoshita et al. 2001). The effect 
of FE65 expression on APP processing is unclear and may be dependent on both the 
cell type and the FE65 family member. FE65 can increase secretion of Abeta and sAPP 
from MDCK-695/FE65 cells (Sabo et al. 1999), and overexpression of FE65L1 leads to 
a decrease in cellular C83 and increased secretion of Abeta1-40, resulting from 
increased processing through the γ-secretase pathway (Chang et al. 2003). FE65L1 
has also been shown to enhance the maturation and secretion of APP (Duilio et al. 
1998; Guenette et al. 1999). Contrastingly the FE65L2 family member has been 
demonstrated to increase secretion of Abeta in HEK 293 cells without affecting the 
production of other fragments of APP (Tanahashi and Tabira 2002).  
Protein phosphorylation is an important regulatory mechanism and PP1 and 
PP2A together are responsible for over 90% of the total mammalian brain protein 
phosphoseryl/phosphothreonyl phosphatase activity. A decrease of about 20% in the 
activities of PP1 and PP2A has been reported in AD brains (Gong et al. 1994a; Gong et 
al. 1995; Gong et al. 1993; Gong et al. 1994c). Furthermore, PP1 was implicated in 
the regulation of APP processing through the use of specific inhibitors with different 
inhibitory potencies against PP1/PP2A (da Cruz e Silva et al. 1995; Henriques et al. 
2007). Interestingly, PP1 is known to be involved in long-term potentiation (LTP) and 
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long-term depression (LTD), thereby influencing learning and memory (Genoux et al. 
2002; Mulkey et al. 1994; Waddell 2003). 
Previous data from our group indicates that Tyr687 appears to be a critical 
residue determining APP targeting and processing via different pathways, including 
endocytosis and retrograde transport (Rebelo et al. 2007a; Rebelo et al. 2007b). 
Moreover, given the antagonic effects on APP targeting and processing obtained by 
mutating Tyr687 to phenylalanine and glutamate in comparison to the wild-type 
protein, it is tempting to deduce that the phosphorylation state of Tyr687 may affect 
the formation of different multimeric complexes which are differentially targeted. The 
hypothesis that subcellular targeting, as one might expect, involves APP binding 
proteins, which are in turn regulated by protein phosphorylation, deserves further 
investigation.Here we show that FE65 binds simultaneously to APP and PP1γ, both in 
COS-7 cells, and hippocampal and cortical neurons. The trimeric complex was also 
detected in adult rat brain. Additionally, we demonstrated that FE65 is the bridging 
protein between APP and PP1γ.  
 
 
 
 Chapter IV 
182  Sandra Rebelo 
 
  CBC/UA, 2008 
EXPERIMENTAL METHODS 
 
Antibodies 
The primary antibodies used were monoclonal antibody 22C11 (Chemicon) to detect 
endogenous APP, the monoclonal JL-8 (BD Biosciences) that recognizes the 
transfected APP695-GFP, a monoclonal antibody against FE65 (Upstate), a monoclonal 
antibody against Synaptophysin (Synaptic systems) and a monoclonal antibody 
(Zymed) to detect β-Tubulin. Rabbit polyclonal CBC3C recognizes PP1γ. Secondary 
antibodies used were anti-mouse and anti-rabbit horseradish peroxidase-linked whole 
antibody (GE Healthcare) for enhanced chemiluminescence (ECL/ECL plus) detection 
and Texas-Red-conjugated anti-mouse IgG (Molecular Probes) and Alexa 350-
conjugated anti-rabbit IgG (Molecular Probes) for co-localization studies. 
 
APP695 Expression Vectors 
APP695-GFP cDNA constructs (Wt and phosphorylation/dephosphorylation mimicking 
mutants: Y687E and Y687F, respectively) have been previously described (da Cruz e 
Silva et al. 2004a; da Cruz e Silva et al. 1993; Rebelo et al. 2007a; Rebelo et al. 
2007b). 
 
Yeast Tri-Hybrid Screen 
The vector used to insert the BD-Bait (APP) and the inducible protein (PP1γ1) cDNAs, 
was the Yeast Tri-hybrid (Y3H) vector. The bait cDNA coding for human APP695 was 
PCR amplified (forward primer 5’-CCGCGCACCATGGCGATGCTGCCCGGTTTGG-3’; 
reverse primer 5’-GTGGCCCCGGGCTAGTTCTGCATCTGCTCAAAG-3’). The bait cDNA 
was inserted into the Y3H vector using NcoI/SmaI restriction enzyme sites, in frame 
with the GAL4 DNA-BD. The cDNA coding for the inducible protein (PP1γ1) was PCR 
amplified from pAS2-1-PP1γ1 (Fardilha et al. 2004) with appropriate primers (forward 
primer 5’-ATTCGCGGCCGCGAGCCGGCG-3’; reverse primer 5’-
GTTACGGATCCCGACTAGGCAGTG-3’), and inserted into the MCSII (NotI/BglII) of the 
Y3H vector. 
The vector allows for the expression of two proteins: a DNA-binding domain fusion (in 
our screen the cDNA for APP was used) and an additional protein under the control of 
an inducible methionine promoter (in our screen the cDNA for PP1γ was used). This 
constructed plasmid was transformed into AH109 strain by the lithium acetate method 
(according to the manufacturer’s instructions, Clontech). By mating the transformed 
AH109 (Mat a) strain with an activation domain (GAL4-AD) fusion (expressing the 
cDNAs from a human brain library) and reporter strain (Y187, Mat α) with an opposite 
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mating type from the GAL4-based two-hybrid system (Clontech), a tri-hybrid system 
was established for the identification of tri-complexes (Fardilha et al. 2004). Half of 
the diploid mixture was plated on SD/QDO/-Met (SD without Leu, Trp, Ade, His and 
Met), and the other half on SD/TDO/-Met (SD without Leu, Trp, His and Met). All 
plates were incubated at 30ºC until colonies appeared. The transformants were 
assayed for HIS3, ADE2 and MEL1 reporter genes. All positive clones were replated 
twice in SD/QDO medium containing X-α-Gal and incubated at 30ºC for 3-8 days. 
Yeast plasmid DNA was extracted from the positive clones using the breaking buffer 
method and the AD-library plasmids were rescued by transformation of E. coli. Library 
inserts were sequenced using the GAL4 AD primer (Clontech). A search for similar 
sequences in the GenBank database was performed using the BLAST algorithm.  
 
Plasmid Construction 
The human FE65 cDNA (Accession Nº BC010854) was PCR amplified (forward primer 
5’-GGGGATCCCTTCATGGGGTATGGG-3’; reverse primer 5’-
GCTGGGATCCCCATGTCTGTTCCATC-3’) and inserted into the pACT2 (Clontech, 
Enzifarma) vector, using BamHI restriction endonuclease (New England Biolabs), in 
frame with the GAL4 activation domain. The APP intracellular domain (AICD) of human 
APP695 cDNA (Accession Nº NM_201414), corresponding to aminoacids 645-695, was 
PCR amplified (forward primer 5’-ATCACCATGGTGATGCTGAAGAAG-3’; reverse primer 
5’-GTGGCCCCGGGCTAGTTCTGCATCTGCTCAAAG-3’) and was inserted into the pAS2-1 
using vector NcoI/SmaI restriction sites, in frame with the GAL4 DNA-BD. Similar 
constructs were prepared with AICD cDNAs carrying the mutations Y687E and Y687F. 
 
Quantitative α-Galactosidase activity assay 
Yeast strain AH109 was transformed using the lithium acetate method, with the 
following plasmids: (1) pACT2-FE65/pAS2-1-Wt-AICD; (2) pACT2-FE65/pAS2-1-
Y687E-AICD; (3) pACT2-FE65/pAS2-1-Y687F-AICD; (4) pACT2/pAS2-1. Fresh yeast 
colonies expressing the pairs of interacting proteins being analyzed were grown in 4 
ml of SD TDO (-Trp, -Leu, -His). The negative control AH109 (pAS2-1 + pACT2) was 
grown on SD –Trp-Leu. The cultures were incubated overnight at 30ºC with shaking at 
200 rpm. The optical density of the culture at 600nm was recorded. The culture (1 ml) 
was centrifuged for 5 minutes at 14000 rpm, and the supernatant was removed for 
analysis. The assay was performed by combining 8µl of culture supernatant with 24µl 
of Assay Buffer (100mM PNP-α-Gal solution, 1X NaOAc [1:2 (v/v) ratio]). After 
incubation for 60 minutes at 30ºC the reaction was terminated with 960µl of 1X stop 
solution (0.1M NaCO3) and the optical density at 410nm was recorded. The α-
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galactosidase activity (milliunits) were calculated with the following formula, as 
described by the manufacturer (Yeast Protocols Handbook, Clontech) for the 1ml 
assay format: [milliunits/(ml x cell)] = OD410 x 992 x 1000 / [OD600 x time (min) x 
16.9 x 8]. 
 
Cell Culture  
COS-7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 3.7 g/l 
NaHCO3 (Complete DMEM) and maintained as previously described (Rebelo et al. 
2004) at an atmosphere of 5% CO2 at 37ºC. 
Transient transfections of either COS-7 or primary rat cortical and hippocampal 
neurons were performed using LipofectAMINE 2000 (a cationic lipid transporter; 
Invitrogen Life technologies). After 12-16 hours of transfection, cells were harvested 
as described below or divided into 6-well plates with coverslips pre-treated with 100 
μg/ml polyornithine (Sigma), and left to recover for 4 hours (colocalization studies). 
After this period cells were fixed using 4% paraformaldehyde and processeded for 
immunocytochemical analysis. 
Rat cortical and hippocampal primary cultures were established from embryonic day 
18 embryos. Briefly, after dissociation with 0.75 mg/ml trypsin for hippocampus and 
0.45 mg/ml trypsin for cortex, cells were plated on poly-D-lysine-coated dishes at a 
density of 1.0x105 cells/cm2 in B27-supplemented Neurobasal medium (GIBCO), a 
serum-free medium combination (Brewer et al. 1993). The medium was supplemented 
with glutamine (0.5 mM), gentamicin (60 μg/ml) and glutamate (only for hippocampal 
neurons; 25 μM). Cultures were maintained in an atmosphere of 5% CO2 at 37ºC for 
10 days before being used for experimental procedures. 
 
Immunocytochemical analysis 
After fixing, COS-7 cells were permeabilized with methanol for 2 min and washed with 
phosphate buffer saline (PBS). Cells were first incubated with the anti-FE65 primary 
antibody for 3 hours at room temperature, followed by Texas-red-conjugated anti-
mouse secondary antibody. After washing with PBS, cells were subsequently incubated 
with a second primary antibody [anti-PP1γ (CBC3C)] for 3 hours at room temperature, 
followed by Alexa 350-conjugated anti-rabbit secondary antibody. After thorough 
washing with PBS, preparations were mounted using Vectashield mounting media 
(Vector) and visualized using a LSM510-Meta confocal microscope (Zeiss). 
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Immunoprecipation analysis 
Cells transfected with 8 μg of Wt or either phosphorylation mimicking mutant (Y687E 
and Y687F) cDNAs were harvested, and cell extracts were prepared in non-denaturant 
lysis buffer with a protease inhibitor cocktail. The cell extracts were immunoprecipited 
with either the anti-FE65, CBC3C or 22C11 antibodies overnight with agitation at 4ºC. 
Agarose beads were then added to each sample and the lysate-mixture samples were 
incubated for 2 hours at 4ºC with agitation. The agarose beads were washed 4 times 
and finally resuspended into LB/SDS 1%. The samples were further analyzed by SDS-
PAGE and immunoblotted using the antibodies indicated.  
 
SDS-PAGE and Immunobloting 
Samples were separated on 10% SDS-PAGE and electrophoretically transferred onto 
nitrocellulose, followed by immunological detection with the indicated antibodies. 
Membranes were saturated in 5% non-fat dry milk in TBS-T for 4 hours and incubated 
overnight with monoclonal antibody 22C11, recognizing the APP N-terminus, the anti-
GFP JL-8 antibody, to detect the APP-GFP fusion product. Detection was carried out 
using horseradish peroxidase-conjugated anti-mouse IgGs as secondary antibody and 
proteins visualized by enhanced chemiluminescence (GE Healthcare). 
 
Blot Overlay Analysis 
FE65 and APP695 proteins were generated by in vitro transcription (IVT) from pET-FE65 
and pET-APP695 expression vectors, respectively using the TnT-coupled 
transcription/translation kit (Promega), according to the manufacture’s instructions. 
The radioactive detection of proteins was carried by taking advantage of the 
incorporated [35S]-methionine. For the overlay assays, two samples of 250 ug of 
purified recombinant PP1γ protein were separated on a 12% SDS-PAGE. The proteins 
were transferred to nitrocellulose membranes and one was overlaid for 1h30 with the 
[35S]-APP-IVT (as a control), while the second sample was overlaid with FE65-IVT. 
After washing to remove excess binding protein, the latter was then overlaid with the 
[35S]-APP-IVT. Blots were washed thoroughly and then exposed to X-ray film, the 
resulting signal was quantified. 
 
Quantification and Statistic Analysis 
Immunoreactive bands were quantified by densitometric analysis and QuantityOne 
software (Biorad, Portugal). Data are expressed as mean ± SEM of triplicate 
determinations, from at least three independent experiments. Statistical significance 
was determined by one way analysis of variance (ANOVA), followed by Tukey-Kramer 
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post-hoc test. Unless otherwise noted, a level of statistical significance is considered 
P<0.05. 
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RESULTS 
 
A new trimeric complex (APP/PP1γ/FE65) was identified using the Yeast Tri-
Hybrid system 
Our present knowledge of signalling cascades and multimeric complexes 
formed, as well as the previously described role of PP1 in APP processing, led us to 
perform a Yeast Tri-Hybrid screen of a human brain library as previously described 
(Fardilha et al. 2004). The system allows for the simultaneous expression of two 
proteins: the bait cDNA fused to a Gal4-DNA binding domain (BD-Bait) and an 
additional protein under the control of an inducible methionine promoter (Inducible 
protein). In this screen, the bait fused to Gal4-DNA BD was APP695 cDNA and the 
inducible protein was PP1γ. A total of 7x107 library clones were screened and 563 
positives were obtained (Table 1). So far, all clones analyzed encoded FE65, 
demonstrating the existence of a new tri-complex APP/PP1γ/FE65.  
 
Table 1. Yeast Tri-hybrid Screen. 
 
BD-Bait Inducible protein Positive clones Screened clones
APP PP1γ 563 7x107
 
 
 
Moreover, using in silico analysis of the FE65 sequence we verified the 
presence of an additional interesting domain, besides the three previously mentioned 
(WW domain, PTB1 domain and PTB2 domain). Particularly, the presence of a 
consensus PP1 binding motif (RVGW) was revealed, confirming the interaction 
between FE65 and PP1. 
 
Expression profile of the proteins in the trimeric complex 
Given the importance of APP in neuronal systems, the expression pattern of the 
proteins involved in this trimeric complex described above was analyzed in neuronal 
cultures using specific antibodies (Fig. 1). Synaptophysin and β-tubulin were used as 
controls. The expression of the three proteins increased with time in culture (Fig. 1 A-
C). However, while PP1γ expression levels increase up to 6 DIV and remained constant 
thereafter, the levels of expression of APP and FE65 appeared to increase over the 
entire period of the experiment, reaching a maximum level of expression at 14 DIV.  
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Figure 1. FE65, APP and PP1γ expression profile in primary rat cortical neurons. 
The expression pattern of the three proteins was determined using specific antibodies for each 
protein: 22C11 was used to detect the APP expression pattern (A); CBC3C to detect the PP1γ 
(B); and anti-FE65 to detect the FE65 (C). The quantitative data for A, B and C are presented 
on the right. As controls the expression patterns of synaptophysin (D) and β-tubulin (E) were 
also analyzed. 
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FE65 interaction with APP is phosphorylation dependent 
Previous work showed that FE65 binds APP in the 682YENPTY687 domain, and it is 
dependent on the phosphorylation state of Thr668. Here we addressed if the 
phosphorylation state of the Tyr687 could also play a role in this interaction. Yeast 
strain (AH109) was co-transformed with the following pairs of plasmids: pACT2-
FE65/pAS2-1-Wt-AICD; pACT2-FE65/pAS2-1-Y687E-AICD; pACT2-FE65/pAS2-1-
Y687F; and the control pACT2/pAS2-1. Prior to α-galactosidase quantitative assays, 
Wt AICD and AICD phosphorylation mimicking mutants (Y687E and Y687F) were 
assayed for interaction with FE65 in the Yeast Two-Hybrid system. FE65 was shown to 
interact with Wt AICD, as described before, and also with both phosphorylation 
mutants. Positive interactions were shown by growth on SD/-Trp/-Leu/-His plates and 
by the blue colour of the colonies, indicating expression of the MEL1 reporter gene 
(data not shown). In order to assess the relative strength of the interaction of FE65 
with Wt-AICD, and with the Y687E and Y687F phosphomutants, a quantitative assay 
measuring the activity of α-galactosidase was carried out in yeast culture 
supernatants. The α-galactosidase activity of the Y687F-AICD-FE65 co-transformants 
showed a 1.36-fold induction, in relation to the wild-type (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Yeast Two-hybrid interaction of FE65 with Wt AICD, Y687E AICD and 
Y687F AICD. The yeast AH109 strain was co-transformed with the following plasmids: pACT2-
FE65/pAS2-1-Wt-AICD; pACT2-FE65/pAS2-1-Y687E-AICD; pACT2-FE65/pAS2-1-
Y687F; and the control pACT2/pAS2-1. The yeast cells were grown overnight in selective 
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medium, after which cell-free supernatants were assayed for α-galactosidase activity. Data are 
expressed as mean ± SEM of triplicate determinations of three independent experiments. 
Statistical significance was assessed by one-way analysis of variance (ANOVA) with Tukey-
Kramer test. Unless otherwise noted, a level of statistical significance is considered P<0.05. 
Significant differences of the fold induction of α-galactosidase activity compared to the Wt 
AICD+FE65 interaction are presented as (**), for p<0,01 and (***), for P<0,001. 
 
 
Consequently, the interactions were further validated by co-
immunoprecipitation. COS-7 cells were transfected with either the wild-type APP or 
the two Tyr687 phosphorylation mimicking mutants (Y687E and Y687F). Homogenates 
were prepared as described above, endogenous FE65 was immunoprecipitated and 
FE65 binding proteins were detected by immunoblot analysis. As expected, FE65 
immunoprecipitated wild-type APP695-GFP protein, but it also immunoprecipitated the 
phosphorylation mimicking mutant (Y687E and Y687F; Fig. 3A). However, compared 
to Wt and Y687E, FE65 immunoprecipitated more efficiently the dephosphorylation 
mimicking mutant (Y687F). which is in agreement with the previously obtained data 
(Fig. 2). Consequently, we tested if FE65 could also co-immunoprecipitate PP1γ. Figure 
3B shows unequivocally that the FE65 immunoprecipitate also contained the PP1γ 
isoform. This seems to correlate with the preferential APP binding, given that the APP 
Y687F mutant immunoprecipitated more FE65 and more PP1γ, compared to the Wt 
and the Y687E mutant. (Fig. 3).  
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Figure 3. Tricomplex detection in COS-7 cells. COS-7 cells not transfected (NT) or 
transfected with either the Wt or the phosphorylation mimicking mutants (Y687E and Y687F) 
were homogenized and immunoprecipitated with anti-FE65. FE65 binding proteins were 
detected by immunoblot analysis using either the anti-GFP JL-8 antibody (A) or the anti-PP1γ 
CBC3C antibody (B). The respective quantitative data are also presented. 
 
 
Immunocytochemistry studies further confirmed the association between APP, 
FE65 and PP1γ, in COS-7 cells transfected with either the Wt or the two phospho-state 
mimicking mutants (Fig. 4). PP1γ and FE65 were found distributed throughout the 
cytoplasm, diffuse and in vesicular structures. Extensive colocalization of the two 
(violet colour) was evident. APP exhibited a somewhat different distribution, being 
found mainly in the ER, Golgi and vesicular structures, as previously described. 
However, strong co-localization of the three proteins was evident in ER, Golgi and 
vesicular structures, as indicated by the white colour (Fig. 4; merge).  
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Figure 4. APP, FE65 and PP1 subcellular distribution. Following COS-7 cells 
transfection with either the Wt or the phosphorylation mimicking mutants (Y687E and Y687F) of 
APP, cells were fixed and processed for immunocytochemical analysis using specific antibodies 
to detect endogenous FE65 and PP1γ. 
 
 
 
Wt FE65 MergePP1γ
Y687E FE65 MergePP1γ
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Validation of the trimeric complex in neuronal cultures 
To test whether the putative tri-complex (APP, FE65, PP1γ) is also present in 
neurons, rat cortical and hippocampal cultures were established and maintained for 10 
days, after which they were transfected with either the Wt or the two APP 
phosphomutants. The interactions between FE65-PP1γ and FE65-APP, both in cortical 
and hippocampal neurons (Fig. 5) were also evident. Moreover, in cortical neurons 
(Fig. 5, panel I) Wt-APP, as well as the phosphorylation (Y687E) and 
dephosphorylation (Y687F) mimicking mutants, interact with FE65 and this binding is 
more intense with the Y687F mutant. The binding of PP1γ to FE65 was also detected. 
As with COS-7 cells, FE65 co-immunoprecipitates more Y687F, which also produces a 
stronger band for PP1γ. These results suggest that in neurons the two proteins bind to 
FE65. An identical set of experiments was carried out, but instead of using cortical 
neurons, hippocampal neurons were used and the results are presented in Fig. 5, 
Panel II. Results are identical for both types of neuronal cultures.  
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Figure 5. Trimeric complex validation in neurons. Cortical (Panel I) and 
hippocampal (Panel II) neurons were transfected with either the Wt or the phosphorylation 
mimicking mutants (Y687E and Y687F). Homogenates were prepared and endogenous FE65 was 
immunoprecipitated. FE65 binding proteins were detected by immunoblot analysis using either 
the anti-GFP JL-8 antibody (A) or the anti-PP1γ CBC3C antibody (B). The respective quantitative 
data are also presented. 
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The tri-complex is present in vivo in adult rat brain 
Adult rat hippocampus and cortex were isolated and immediately lysed using a 
buffer supplemented with a cocktail of protease inhibitors. Following complete 
homogenization, immnoprecipitations (IPs) were carried out with specific antibodies 
and results are presented in Figure 6. Homogenates were immunoprecipitated with 
each of the three antibodies and each immnoprecipitate was tested for the other two 
putative binding proteins. Similar results were obtained for adult rat hippocampus and 
cortex, as presented in Figure 6 panel I and II, respectively. Hence, for hippocampus, 
when we IP with FE65 (Fig. 6; panel I A) we can detect the other two proteins: PP1γ 
and APP, suggesting that the three proteins form a tri-complex. Additionally, we 
detected both FE65 and APP when we IP with PP1γ (CBC3C antibody) and when we IP 
with APP (22C11 antibody) we can detect FE65 and PP1γ (Fig. 6, Panel I). Similar 
results were obtained using adult rat cortex revealing a similar relationship between 
these three endogenous proteins (Figure 6, Panel II). 
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Figure 6.Tri-complex presence in adult rat brain. Adult rat hippocampus (Panel I) 
and cortex (Panel II) were isolated and immediately lysed. After complete homogenization, 
immnoprecipitations (IPs) were carried out using specific antibodies. Panel I A. 
Immunoprecipitation using the FE65 antibody (FE65). B. Immunoprecipitation using the PP1γ 
antibody (CBC3C). C. Immunoprecipitation using the APP antibody (22C11). Panel II A. 
Immunoprecipitation using the FE65 antibody (FE65). B. Immunoprecipitation using the PP1γ 
antibody (CBC3C). In each case Westen Blot (WB) analysis was carried out to detect specific 
proteins in the putative tri-complex; for PP1g (CBC3C antibody), for APP (22C11 antibody) and 
for FE65 (FE65 antibody). 
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FE65 is the bridge protein between APP and PP1γ 
The results obtained so far demonstrated that both APP and PP1γ bind to FE65 
in COS-7 cells, in cortical and hippocampal neurons, as well as in adult rat brain 
(cortex and hippocampus). Taken together these results suggest that FE65 is probably 
the bridging protein. In order to prove unequivocally that FE65 is the bridging protein 
between APP and PP1γ an in vitro assay was used. Briefly, two samples of purified 
recombinant PP1γ protein were separated by 12% SDS-PAGE. The resulting blot was 
divided in two, one half was overlaid with the [35S]-APP-IVT (Figure 7A) while a 
second one was overlaid with FE65-IVT (Figure 7B). After washing to remove excess 
binding protein, the latter was subsequently overlaid using the [35S]-APP-IVT. The 
results are presented in the Figure 7A and B. Figure 7A clearly shows that the APP 
does not bind to PP1γ directly. Alternatively, when we first overlay the membrane with 
FE65-IVT (Fig. 7B) and then with [35S]-APP-IVT, we verify that APP does bind to the 
complex. A clear band is evident (Fig. 7B) indicating the presence of complex 
anchoring onto the PP1γ originally loaded and transferred onto the blot. From these 
results we can conclude that FE65 is the bridging protein between APP and PP1γ, 
suggesting that in vivo FE65 brings together these two proteins, allowing them to 
interact in signaling pathways.  
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Figure 7. FE65 is the bridging protein between APP and PP1γ. Two samples of 
purified recombinant PP1γ protein (A and B) were separated by SDS-PAGE and the resulting blot 
was overlaid with other proteins. A. The blot was overlaid using the [35S]-APP-IVT. B. The blot 
was overlaid with FE65-IVT, washed to remove excess binding protein, and then overlaid using 
the [35S]-APP-IVT. C. Schematic representation of the novel tri-complex formed by 
APP/FE65/PP1γ. The arrows indicates the regions through which the FE65 binds specifically to 
APP and PP1γ. 
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DISCUSSION 
 
In this study we show for the first time a clear relationship between protein 
phosphatase PP1γ, APP and FE65. We propose that the three are functionally related 
given that they interact simultaneously. The new tricomplex was first identified using 
the Yeast Tri-hibrid system (Table 1). Furthermore, using in silico analysis we 
recognized a consensus PP1 binding motif in the FE65 sequence and therefore this 
interaction was further validated using other in vivo methodologies.  
As already reported by others, FE65 binds to APP. In this study, we went on to 
analyze the effect of Tyr687 phosphorylation on this interaction. We demonstrated that 
both phosphorylation mimicking mutants (Y687E and Y687F) interact with FE65, but 
that the interaction is strongest with the dephosphorylated mimicking Y687F mutant 
(Fig. 2), indicating that when Tyr687 is dephosphorylated it recruits more FE65.  
Immunoprecipitations were essential for in vivo validation of the tricomplex 
(APP/FE65/PP1γ). Having shown that FE65 preferentially immunoprecipitated Y687F, 
we went on to show that PP1γ also preferentially immunoprecipitated with Y687F, thus 
presenting a consistent correlation for the putative complex. Differential interaction 
with the phosphorylation mimicking mutants was not surprising, given that differences 
of subcellular targeting, namely endocytosis, of these mutants have been previously 
described. From the data it appears that the mutant that is more efficiently 
endocytosed (Y687F) and produces more Abeta (Rebelo et al. 2007b), also binds more 
efficiently to FE65. The interaction is consistent and in agreement with previously 
published data (Sabo et al., 1999).  
Immunoprecitations of adult rat brain demonstrated that the tri-complex is also 
present in brain (Figure 6). This data is of importance and of relevance in terms of AD 
therapeutics. FE65 is the bridging protein between the APP and PP1γ, meaning that 
FE65 is responsible for mediating their interaction. PP1 and PP2A together account for 
over 90% of the total mammalian brain protein phosphoseryl/phosphothreonyl 
phosphatase activity and any alteration in the activity of these two phosphatases may 
significantly affect the phosphorylation state of tau or of other phosphorylated 
proteins. A decrease of about 20% in the activities of PP1 and PP2A has been reported 
in AD brains (Gong et al. 1994a; Gong et al. 1995; Gong et al. 1993; Gong et al. 
1994c). In vitro studies demonstrated that hyperphosphorylated tau from AD brain 
(ADP-tau) can be dephosphorylated by PP1, PP2A and PP2B, but not by PP2C (Gong et 
al. 1994a; Gong et al. 1994b; Gong et al. 1994c). Moreover, Lee et al. (2003b) 
demonstrated that 7 of the 8 potentially phosphorylatable residues in the intracellular 
domain of APP were phosphorylated in AD patients, namely Tyr653, Ser655, Thr668, 
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Ser675, Tyr682, Thr686 and Tyr687. A very attractive hypothesis is that FE65 is promoting 
the interaction between APP and PP1γ, and that PP1γ, in turn, is responsible for the 
dephosphorylation of APP at one or more of the previously mentioned residues or 
another protein relevant for APP processing. The exact mechanism needs to be further 
addressed.  
Several studies suggest a role for the AICD/FE65 complex as a transcriptional 
activator. Moreover, other reports also identified PP1γ as nuclear protein with an 
important role in the transcriptional machinery (Bennett 2005; Moorhead et al. 2007). 
Given the trimeric complex (APP/FE65/PP1γ) identified and co-localization of the three 
proteins we may have a potential regulatory mechanism for transcription activation. 
Our experiments proved unequivocally that FE65 is the bridging protein 
between APP and PP1γ. Taken together, all the results are consistent with this 
hypothesis. Therefore, FE65 is included in the group of proteins known as “scaffold” or 
“bridge” proteins. These proteins are molecular intermediaries that help cell signaling 
proteins to interact and are also responsible for the recruitment of some effectors in 
the pathway. Furthermore, the idea of APP as a signal transduction molecule becomes 
stronger and gains more support. Thus, signal transduction based diagnostics and 
therapeutics represent important future strategies of relevance to AD and other 
neurodegenerative diseases. The future identification of the kinases and phosphatases 
that act upon each of the APP phosphorylatable residues will likely prove useful in this 
respect. One powerful candidate is PP1γ. 
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CHAPTER V 
 
DISCUSSION 
 
 
 
5. 1 OVERVIEW 
 
AD is multifactorial in its etiology and the complex cause-consequence 
mechanisms are still not completely understood. In the last few years, the cellular 
mechanisms by which APP is regulated have started to be unravelled. Related research 
has characterized APP binding proteins, identified some of the domains involved in 
these interactions, as well as their physiological relevance. APP is a transmembranar 
protein processed via the secretory and endocytic pathways (see Chapter I) and, as 
part of population is cleaved during its subcellular translocation, regulation of APP 
trafficking is thus of paramount importance. APP proteolytic cleavages may be 
regulated by temporal APP substrate/enzyme co-distribution, and by substrate and 
enzyme activation. A possible scenario would involve APP substrate targeting to 
specific subcellular microdomains in order to perform a specific cellular function, as for 
example activation of gene expression, being cleaved or not during the process. 
Several factors have been described to regulate APP trafficking and proteolysis, among 
them protein phosphorylation. Moreover, APP phosphorylation and APP protein-protein 
interactions are found to be intimately related (Ando et al. 2001; Scheinfeld et al. 
2002; Taru et al. 2004), with APP phosphorylation now emerging as a regulatory 
mechanism of APP binding to other proteins. Interestingly AD patients exhibit not only 
impairment of cellular phosphorylation equilibria (Fisher et al. 1996) but also 
alterations of the APP phosphorylation state (Lee et al. 2003b). Additionally, Abeta 
phosphorylated on serine residue 26 was reported in AD brains and this 
phosphorylation was putatively implicated in Abeta toxicity (Milton 2005). 
Nonetheless, little is known regarding the role of APP phosphoresidues, namely the 
Tyr687 located in the NPTY domain.  
 
 
 Chapter V 
208  Sandra Rebelo 
 
  CBC/UA, 2008 
5.2 THE NPTY DOMAIN 
 
The asparagiNe-Proline-any-tYrosine (N-P-X-Y) motif in the cytoplasmic domain 
of type I transmembrane proteins was identified as an evolutionary conserved sorting 
signal that targets proteins for clathrin pit localization and transport via clathrin-
coated vesicles from the cell surface to endosomes (Chen et al. 1990). Likewise, the 
clathrin coat complex transports type-I transmembrane proteins from the TGN to 
endosomes. Moreover, this highly conserved domain (NPTY) was identified in the APP 
cytoplasmic domain, allowing for specific predictions regarding its sorting itinerary. 
Additionally, the sorting D-X-X-L-L dileucine motif, present in the cytoplasmic tail of 
BACE, is a separate type of sorting signal involved with clathrin-coat transport 
between the TGN and endosome (He et al. 2005; Wahle et al. 2005). More recently, 
cell biology studies identified and characterized a novel coat complex, the retromer, 
involved primarily in retrograde transport from the endosome (Bonifacino and Rojas 
2006; Seaman 2004) to the TGN. The retromer was further implicated in APP and 
BACE sorting (He et al. 2005; Small et al. 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Coat complexes in Alzheimer’s disease. The clathrin coat (left). The 
clathrin coat complex transports type-I transmembrane proteins to the endosome from the TGN 
or from the cell surface. The adaptor proteins impose cargo and itinerary specificity. The NPTY 
motif found in APP binds a wide-range of adaptor proteins engaged in clathrin-mediated 
transport from the cell surface to the endosome. The retromer (centre and right). The 
retromer coat complex transports type-I transmembrane proteins from the endosome to the 
TGN. VPS35 is the core of the retromer and binds directly to the to-be-transported type-I 
transmembrane protein cargo (grey bar). VPS26, VPS29, and sortin nexins (SNX) 1 and 2 
assemble onto VPS35 to generate the complete functional retromer complex. Recent findings 
suggest that the retromer sorts APP and BACE, by direct binding either to the retromer or by 
Clathrin Retromer (direct) Retromer (indirect) 
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indirect binding to the transmembranar adptor protein sorLA (blue) (taken from Small and 
Gandy 2006). 
 
 
Based on the sorting motifs described above for both APP and BACE, it is 
plausible to deduce that the clathrin coat complex transports these proteins 
(Bonifacino and Traub 2003). Each clathrin molecule is composed of three clathrin 
light chains (CLC) and three heavy chains (CHC) (Hirst and Robinson 1998). Clathrin 
does not bind directly to its cargo, but rather, the globular tail of each CHC binds to 
“adaptor” proteins which, in turn, bind to the transmembrane cargo proteins to be 
sorted (Hirst and Robinson 1998; Morris et al. 1999). The adaptor proteins determine 
cargo and itinerary specificity. Clathrin coats are involved in two main sorting routes, 
the endocytic pathway connecting the cell surface to the endosome, and the pathway 
connecting the TGN to the endosome (Traub 2005).  
As mentioned above, the cytoplasmic tail of APP contains the NPTY amino acid 
motif, a motif which governs the targeting of cargo to clathrin-coated vesicles (Chen 
et al. 1990). Motifs such as this are important for generating predictions about sorting 
events. However, direct experimental proof of these predictions is required before 
these sorting itineraries are established. Indeed, mutagenesis studies have been used 
to assess and confirm that each amino acid within the NPXY motif plays some role in 
transport of APP from the cell surface to endosomes. A number of families of adaptor 
proteins have been found to mediate the binding of the NPTY motif to clathrin coats. 
Hence, a number of clathrin adaptor proteins have been described to bind APP through 
the NPTY motif and therefore serve as regulators of APP endocytosis. 
 
 
5.3 DEVELOPMENT OF MODEL SYSTEMS TO STUDY APP TRAFFICKING AND 
PROCESSING 
 
In order to determine the functional impact of phosphorylation at specific 
amino acids we mutated target residues. Thus, mimicking constitutive phosphorylation 
and dephosphorylation and allowing for the in vivo and in vitro evaluation of the 
functional impact of phosphorylating specific amino acids, without the potential 
interference of cellular phosphatase and/or kinase activities that may act upon those 
sites (Bibb and da Cruz e Silva 1997). 
The model system established consisted of the combined usage of site-directed 
mutagenesis, with an in-frame fusion to a reporter gene (GFP) in a mammalian 
expression vector. It was also important to ensure low levels of expression, and 
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inhibiting ‘de novo’ protein synthesis, thus allowing the monitoring of an APP protein 
pool in a time-dependent manner using either epifluorescence microscopy or/and 
immunoblotting analysis. A significantly novel aspect to the method described is 
provided by the fact that we can mimic a constitutively phosphorylated and contrast it 
to a dephosphorylated residue and so analyse its impact on APP trafficking and 
processing. The inhibition of expression upon by addition of cycloheximide 
dramatically reduced the background of fluorescence typically obtained when proteins 
are continuously synthesized. Hence, we were able to follow the 
disappearance/turnover of a specific protein population. This drug has been previously 
used to study the importance of other posttranslational protein modifications (Parat 
and Fox 2001). 
The use of this methodology represents an attractive model to study APP 
metabolism, including not only the tracking of its subcellular localization and targeting 
but also rates of processing and degradation. The usefulness of our model system was 
entirely validated by the results obtained where the APP wild type and the different 
mutants of the same residue were processed differently with time (Fig. 6, Pag. 110). 
The results also indicated that the phosphorylation state of specific amino acids in the 
APP intracellular domain are of extreme importance for targeting APP to specific 
subcellular locations, deciding its processing and metabolic fate. The model system 
developed not only represents a powerful tool in the study of intracellular protein 
trafficking, but also provides a useful method for studying the role that some specific 
amino acid residues and/or specific posttranslational modifications may have in a 
protein’s intracellular fate.  
In order to determine the consequence of APP Tyr687 site specific 
phosphorylation, located with the NPTY domain, in the dynamic process of APP 
targeting and processing, the methology described above was employed. The results 
obtained are discussed in the previous chapters and are now object of an integrative 
analysis. 
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5.4 TYROSINE 687 DEPENDENT APP SUBCELLULAR TRAFFICKING 
 
ER exit. As a secretory protein, APP is synthesized in the ER, where it suffers its first 
maturation process, and is translocated to the cis-Golgi. The ER to Golgi translocation 
of the Y687E mutant is delayed (Fig. 3, Pag. 138), since at the beginning of the 
experiment 100% of cells analysed showed intense ER fluorescence and this dropped 
to 40% of cells by the end of the experiment, while with the other two APP-GFP 
species (Wt and Y687F) it dropped to virtually 0%. Moreover, the rate of 
disappearance of its immature form was slower (Fig. 1, Fig.3 and Table 1, Pag. 135, 
136 and 138), with Y687E-APP having a half-life of 2.58 ± 0.04 h, while the Wt- and 
Y687F-APP have half-lives of 2.23 ± 0.13 and 0,81 ± 0.02, respectively (Table 1, Pag. 
135). The mature APP-GFP also disappears with time, presumably due to normal 
turnover and processing. Y687F-APP has a faster maturation rate as compared to Wt- 
and Y687E-APP. The last two possess identical maturation rates (Fig. 1 and Table 1, 
Pag. 135 and 136). Hence, it is that seems that when APP is phosphorylated at Tyr687 
it experiences delays exiting the ER and this is consistent with the observed decreased 
rate of disappearance for the immature species. However, once mature Y687-APP has 
normal rate of turnover and processing. 
 
Golgi/TGN exit. Difficulties in being exported are evident for the Y687E-APP mutant, 
since a large percentages of cells exhibit Golgi fluorescence (80-100%) at all 
experimental time points (Fig.3, Pag. 138). These results indicate that this mutant is 
not only retained in the ER but also in the Golgi. Consistent with this failure to be 
exported from Golgi is the almost complete absence of visible vesicular structures for 
this mutant. Thus, we can hypothesize that this mutant is not so efficiently packeged 
into post-TGN vesicles. On the other hand, the Y687F-APP mutant behaves similarly to 
Wt-APP and exhibited an apparently normal TGN/Golgi exit dynamics.  
 
Cell surface endocytosis. The differences observed in increased GFP fluorescence 
and increased APP retention for the Y687E-APP mutant at the plasma membrane, 
suggested that Y687E-APP was less efficiently endocytosed (Fig. 1, Pag. 145). The 
APP-GFP/transferrin co-localization assay (Fig. 1, Pag. 145) also indicated that Y687E-
APP could not be incorporated into endocytic vesicles. Further support was obtained 
from the antibody uptake assays, either from microscopy analysis of the differential 
cell surface APP (Fig. 2, Pag. 146), or from directly scoring the number of surface 
internalized APP-GFP vesicles (Fig. 2, Pag. 146). In sharp contrast, the Wt- and 
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Y687F-APP co-localization with transferrin allowed us to conclude that these two 
species are readily endocytosed. In summary, this significant novel finding shows that 
the Y687 phosphorylation state is critical for APP endocytosis, and is consistent with 
the 682YENPTY687 domain being a consensus signal for internalization. In fact, in 1990, 
it was pointed out that the cytoplasmic domain of APP contained a tetrapeptide 
sequence, NPTY, which is a consensus sequence required for rapid endocytosis of the 
low density lipoprotein receptor (LDLP, Chen et al. 1990). This observation raised the 
possibility that APP might participate in receptor-mediated endocytosis and that 
membrane trafficking of APP might influence the generation of Abeta.  
In conclusion, Y687 dephosphorylation seems to promote APP cell surface 
internalization by increasing APP endocytosis. Moreover, when Y687 is phosphorylated 
it is not efficiently targeted for endocytosis. Another possibility is that the rates of cell 
surface APP recycling (back to plasma membrane) may also be increased for this 
mutant. Hence, tyrosine 687 is a critical residue for APP targeting to the endocytic 
pathway.  
 
Plasma membrane-TGN retrograde transport. Once at the plasma membrane, 
APP can be internalized (endocytic pathway), recycled back to the plasma membrane. 
The cell membrane is a structure which is clearly visible during almost all experimental 
time points with Y687E-APP, reaching a maximum of 70% for the Y687E-APP, 40% for 
the Y687F-APP and 30% for the Wt-APP. The antibody uptake assay allows us to 
monitor once again the internalization of APP (Fig. 2, Pag. 146). At time point 0, all 
cells revealed 22C11-staining at the cell surface (red fluorescence). Moreover, during 
the time of the experiment (30 min) we determined that the Y687E-APP mutant was 
not efficiently endocytosed, a no co-localization was observed between red and green 
vesicles (APP-GFP and endogenous APP). However, both the Y687F- and Wt-APP were 
well endocyosed and it seems that Y687F is more efficiently targeted to TGN than the 
Wt protein. Indeed, retrograde transport of endocytosed APP to the TGN was found to 
be enhanced for Y687F. Dephosphorylation of APP at the cytoplasmic Y687 residue 
appears to function as a signal for endocytosis, as well as a targeting signal for APP 
retrieval to the trans-Golgi network.  
From the analysis of the APP-GFP trafficking and catabolism results, we 
conclude that the APP NPTY domain must be involved in the targeting of APP at several 
sorting stations, and that Y687 phosphorylation regulates the protein sorting and/or 
the kinetics at each specific stage. At the TGN and cell surface, Y687 
dephosphorylation seems to lead to higher transport efficiencies, as for example, a 
preference for Y687F-APP to be vesicle-incorporated. Upon internalization, different 
           
The role of the NPTY functional domain on APP trafficking and processing 213 
 
 
scenarios are possible, depending where APP sorting towards the TGN occurs. If it 
occurs at the early/sorting endosomes, the Y687 phosphorylation state would be 
decisive for membrane recycling, APP late endosomes delivery, for TGN recycling and 
possibly even in the targeting to lysosomes.  
 
 
5.5 TYROSINE 687 DEPENDENT APP PROTEOLYTIC PROCESSING 
 
The different subcellular targeting of the APP-GFP phosphomutants in COS-7 
cells had important effects on the rate of APP-GFP cleavage by α- and β-secretases. 
Indeed, given the data available it seems reasonable to deduce that APP proteolytic 
cleavages may not to be directly dependent on the APP Y687-phosphorylation state, 
but being that the latter influences APP subcellular targeting, it may have 
consequences on APP availability for subsequent cleavages. That is, the 
phosphomutants are differentially targeted subcellularly and this affects APP cleavage 
events which occur in specific organelles. 
 
α-secretase processing. In terms of total sAPP production, Wt- and Y687E-APP 
yielded similar rates of secretion (Fig. 2 and Table 2, Pag. 137). The Y687F-APP 
mutant, however, revealed a faster rate of total sAPP production. Interestingly, when 
alpha sAPP secretion was monitored it became evident that the Y687E mutant was 
favoured for α-secretase cleavage because at the 5h time point it exhibits a 1.63-fold 
increase in total sAPP production, while alpha sAPP increased even more (1.90-fold). 
The opposite was observed for the Y687F-APP mutant, which was relatively favoured 
for β-secretase cleavage at the same time point, with a total sAPP increase of 2.50-
fold, but alpha sAPP increased only 2.10 fold (Fig. 2 and Table 2, Pag. 137). The Abeta 
production values are in agreement with these results and will be discussed below. 
 
β-secretase processing. Studies from Klafki el at. (1996) and Wiltfang et al. (1997) 
were able to demonstrate the electrophoretic baseline separation of Abeta peptides, 
differing in length by only one single amino acid, could be achieved using an urea-
based multiphasic bicine/sulphate SDS-PAGE system (Wiltfang et al. 2001). A quintet 
of Ct-truncated Abeta peptides (Abeta1-37, Abeta1-38, Abeta1-39, in addition to Abeta1-40 
and Abeta1-42) are normally observed. We applied this technique in collaboration with 
Prof. Jens Wiltfang, and were able to further characterize APP Y687-phosphorylation 
state-dependent processing and correlate with Abeta production. Different Abeta 
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species produced were quantified. The Y687F-APP mutant and Wt-APP yielded a 
similar profile of Abeta production, namely Abeta1-37, Abeta1-38, Abeta1-39 and Abeta1-40. 
However, Y687E-APP produced significantly lower levels of all Abeta species analysed. 
Another truncated Abeta specie present was Abeta2-40, which was almost absent in the 
phosphotylation-mimicking mutant. Thus, it would appear that APP phosphorylation is 
also an important regulatory mechanism determining Abeta production. The 
processing data are in agreement with the previously discussed subcellular targeting 
results, because the two reported main subcellular locations of Abeta production, 
namely the TGN and endosomes, are subcellular organelles enriched in β-secretase 
and γ-secretase. Although both Y687 mutants were found at the TGN, only Y687F-APP 
is targeted to the endosomes. However, Y687E-APP has a higher time of residence at 
the Golgi, and this seems insufficient for cleavage by the β-secretase, in fact it seems 
to favour α-secretase cleavage. In addition, some competition between the Y687 
phosphorylation-dependent sorting/α-secretase and β-secretase cleavage may exist.  
One hypothesis may be the preference of phospho Y687 APP to be target to the 
plasma membrane where it will be α-secretase cleaved, while dephospho Y687 APP 
would have an efficient vesicle incorporation (increased endocytosis) and targeting to 
TGN and so could be more available for β-secretase and γ-secretase cleavage. Thus, 
APP phosphorylation on Y687 could indirectly affect Abeta production. 
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5.6 SCHEMATIC REPRESENTATION OF Y687 PHOSPHORYLATION-DEPENDENT 
APP SUBCELLULAR TARGETIG AND PROCESSING  
 
 
A schematic summary of the results obtained for the cellular fate of Y687 
phosphomutants in COS-7 cells is presented in Figure 1. These schemes show the 
main subcellular compartments of residence for both the Y687E-APP and Y687F-APP 
mutants, and the observed alterations in terms of their cellular sorting and targeting.  
 
    A. Y687E-APP-GFP 
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     B. Y687F-APP-GFP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of Y687 phosphorylation state-dependent 
APP cellular traffic and proteolytic processing. Summary of APP Y687 phosphomutants (A: 
Y687E; B: Y687F) subcellular traffic and processing. ER, endoplasmic reticulum; TGN, trans-
Golgi network; PM, plasma membrane; N, Nucleus; Note: endosomes are not a single 
organelle, but rather comprise multiple subtypes including early endosomes, sorting 
endosomes, recycling endosomes, late endosomes and multivesicular bodies. Nevertheless, for 
clarity, we used the term endosome to encompass all subtypes. 
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Taken together, all results support that Y687 phosphorylation is a cellular 
mechanism which favours APP to be preferentially cleaved through the α-secretase 
pathway and to generate its derived physiological active fragments: αsAPP and AICD. 
This is accomplished by targeting it to the subcellular compartments where α-
secretase cleaves APP, namely the TGN and the plasma membrane. Another 
interesting aspect that is in agreement with this idea of preferential cleavage, isthat 
this mutant resides at the plasma membrane accompanied and does nor suffer 
endocytic targeting. One possible explanation is that the Y687 phosphorylation 
enables faster protein recycling to the plasma membrane where it can be further 
cleaved by α-secretase.  
In sharp contrast, Y687 dephosphorylation is important for APP endocytosis 
and also appears to be a target signal for APP retrieval to the TGN (retromer). We 
believe that the increase of this mutant in the endocytic pathway is responsible for its 
increased Abeta production. 
Our results showing that Abeta production can be modulated by direct APP 
phosphorylation may be of specific therapeutic relevance. It is interesting to note that 
the retrograde transport of BACE-1, responsible for β-secretase activity, is also 
regulated by the phosphorylation state of the protease (Wahle et al. 2005). In 
addition, our conclusions favour a model where interaction of APP with its binding 
proteins may also be mediated by the phosphorylation state of APP itself (da Cruz e 
Silva et al. 2004b).  
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5.7 APP PROTEIN-PROTEIN INTERACTIONS MEDIATED BY Y687 
PHOSPHORYLATION/DEPHOSPHORYLATION 
 
 
Phosphorylation of APP at its C-terminus is believed to regulate binding of APP 
to other cellular proteins that participate and mediate APP cellular processing and 
function. Ando et al (2001) showed that the phosphorylation state of Thr668 regulates 
APP interactions at the 682YENPTY687 motif. XL11 and mDab1 bind APP regardless of 
the phosphorylation state of APP Thr668, while FE65 interaction with the APP 
recognition motif is weaker upon Thr668 phosphorylation. In addition, phosphorylation 
at this residue is associated with a preference for APP to be cleaved in the β-secretase 
pathway (Lee et al. 2003a; Muresan and Muresan 2005a). Nonetheless, it is still a 
matter of controversy if Thr668 phosphorylation results in higher or decreased AICD 
nuclear targeting and transactivation (Kimberly et al. 2005; Muresan and Muresan 
2004; Zheng et al. 2003).  
The targeting of APP to the α-secretase pathway by APP direct phosphorylation 
prior to our findings had not been observed. The underlying Tyr687 
phosphorylation/dephosphorylation regulatory mechanisms most probably include 
controlling APP binding to specific proteins. For example, Tyr687 phosphorylation may 
induce alterations in the APP affinity for specific APP interacting proteins with a role 
such as coat proteins resulting in enhanced APP targeting to post-TGN and endocytic 
vesicles. For example, S498 phosphorylation enhances BACE-1 binding, through the 
S498-containing sorting motif, to the adaptor protein GGA (Shiba et al. 2004). This 
protein is involved in TGN anterograde transport and GGA-BACE-1 binding was later 
shown to be responsible for the phosphorylation-dependent BACE-1 retrograde 
transport (Wahle et al. 2005). A similar mechanism, involving a serine residue 
immediately upstream a sorting motif, occurs for the cation independent MRP protein 
(Kato et al. 2002). In a similar manner APP Tyr687 phosphorylation may t accelerate 
specific vesicle traffic steps such as APP cargo packaging, vesicle release, or vesicle 
targeting. The proteins that interact with these domains/sequences are the best 
candidates to be the putative APP binding proteins, interacting with APP in a Tyr687 
phosphorylation-dependent manner. The known proteins to fall into this group are so 
far: ARH (Noviello et al. 2003), Numb (Berdnik et al. 2002; Roncarati et al. 2002), 
disabled family member (Dab) 1 and 2 (Homayouni et al. 1999; Yun et al. 2003), 
c-Jun N-terminal kinase interaction (Jip1b) protein (Inomata et al. 2003; 
Matsuda et al. 2001; Scheinfeld et al. 2002; Taru et al. 2002), SHC (Russo et al. 
2002; Russo et al. 2001; Tarr et al. 2002; Zambrano et al. 2001), Grb2 (Venezia et 
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al. 2004; Zhou et al. 2004), c-Abl (Russo et al. 2001; Tarr et al. 2002; Zambrano et 
al. 2001), members of X11 family, namely X11α (Borg et al. 1996; McLoughlin et al. 
1999; Tomita et al. 1999) and members of FE65 family (including FE65, FE65L1 
and FE65L2) (Borg et al. 1996; Bressler et al. 1996; Duilio et al. 1998; Fiore et al. 
1995; Guenette et al. 1996; Tanahashi and Tabira 1999b; Zambrano et al. 1997). 
Figure 3 summarizes putative Y687 phosphorylation-dependent bindings of the 
APP C-terminus to proteins with which it may form signalling complexes 
physiologically relevant in APP cellular fate and processing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Proteins that interact with the cytoplasmic tail of APP. The X11 family, 
FE65 family, JIP family, Dab1 and 2 and ARH all contain PTB domains that interact with the 
YENPTY domain in the intracellular C-terminus of APP. FE65 may also require Thr668 for binding. 
The crystal structure of the X11α PTB domain bound to a YENPTY with additional residues 
essential for stabilization. SHC and Abl may be recruited to the YENPTY domain when the first 
tyrosine residue is phosphorylated. 
 
 
FE65  
 
Members of the FE65 family contain several protein interacting domains, 
including two PTB domains and a WW region. The interaction between APP and FE65 
involves binding of the YENPTY domain and non-phosphorylated Thr668 in APP. 
Furthermore, the WW domain binds to MENA (mammalian enabled), which binds actin 
and thus links FE65 and APP to cytoskeletal dynamics and cellular motility . The PTB1 
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domain of FE65 binds both the transcription factor complex CP2-LSF-LBP-1c, and the 
low density lipoprotein receptor-related protein (LRP). The PTB2 domain of FE65 binds 
the APP C-terminus, providing a potential scaffold between APP and LRP (Kinoshita et 
al. 2001). Additionally, in silico analysis of the FE65 sequence reveals the presence of 
a well conserved Ser/Thr protein phophatases type 1 (PP1) binding motif (RVGW), 
suggesting that hypothetically FE65 binds to PP1. In vivo studies confirmed this 
interaction. Thus, the hypothesis that subcellular targeting, involves APP binding 
proteins, which are in turn regulated by protein phosphorylation, becomes stronger 
and deserves further investigation.  
In this work we demonstrate that both phosphorylation state mimicking 
mutants (Y687E and Y687F) interact with FE65, but that the interaction is strongest 
with the dephosphorylation mimicking mutant (Fig. 3 and 5, Pag. 191 and 194). Hence 
the idea of a tri-complex was forthcoming and became stronger with the fact that PP1γ 
is preferentially immunoprecipitated with the Y687F mutant. Differential interaction 
between the phosphorylation mimicking mutants was not unexpected given the 
previously discussed differences on subcellular targeting, namely endocytosis, as 
described for these mutants. Interestingly, the Y687F mutant that is readily 
endocytosed and produces more Abeta, also binds more efficiently to FE65 that is in 
agreement with previously described data (Sabo et al. 1999). The Yeast Two-Hybrid 
data also support the immunoprecipitation data indicating that FE65 binds significantly 
more to the Y687F mutant. The occurrence in vivo of the tri-complexformat  suggests 
that the three proteins are interacting. Moreover, we demonstrate that FE65 binds 
simultaneously to APP and PP1γ both in neuronal and non-neuronal cell lines. It seems 
that FE65 is the bridging protein between APP and PP1γ meaning that FE65 is 
responsible for mediating this interaction.  
In vitro studies demonstrated that hyperphosphorylated tau in AD brains (ADP-
tau) can be dephosphorylated by PP1, PP2A and PP2B, but not by PP2C (Gong et al. 
1994a; Gong et al. 1994b; Gong et al. 1994c). PP1 and PP2A together account for 
over 90% of the total mammalian brain protein phosphoseryl/phosphothreonyl 
phosphatase activity and any alteration in the activity of these two phosphatases may 
significantly affect the phosphorylation state of tau or of other phosphorylated 
proteins. A decrease of about 20% in the activities of PP1 and PP2A has been reported 
in AD brains (Gong et al. 1994a; Gong et al. 1995; Gong et al. 1993; Gong et al. 
1994c). Moreover, Lee et al (2003b) demonstrated that 7 of the 8 potentially 
phosphorylatable residues in the intracellular domain of APP were phosphorylated in 
AD patients, namely Tyr653, Ser655, Thr668, Ser675, Tyr682, Thr686 and Tyr687. 
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One very attractive model is that FE65 is promoting the interaction between 
the APP and PP1γ, and that PP1γ in turn is responsible for the dephosphorylation of APP 
at one of the previously mentioned residue or another protein relevant in APP 
processing. However, the exact mechanism needs further investigation. Using overlay 
experiments, we proved unequivocally that FE65 is thebridge protein between FE65 
and PP1γ, given that in the absence of FE65, APP and PP1γ were no longer able to 
interact. Taken together, the results are consistent with this hypothesis. Therefore, 
FE65 is included in the group of proteins known as “scaffold” or “bridge” proteins. 
These proteins are molecular intermediaries that help cell signaling proteins to interact 
and are also responsible for the recruitment of some effectors in the pathway. 
Furthermore, the idea of APP as a signal transduction molecule becomes stronger and 
gains additional support. Thus, signal transduction based diagnostics and therapeutics 
(discussed later) represent important future strategies of relevance to AD and other 
neurodegenerative diseases. The future identification of the kinases and phosphatases 
that act upon each of the APP phosphorylatable residues will likely prove useful in this 
respect.  
 
RTN3 
 
Prior to the work here presented, RTN3 had been linked to AD given that it 
interacts with BACE-1 and inhibits its activity (He et al. 2006; Tang and Liou 2007) 
(Murayama et al. 2006). Recently, RTN3 it has been described as contributing to the 
formation of dystrophic neurites in AD (Hu et al. 2007) and was found down regulated 
in AD brains (Yokota et al. 2006). We described a novel interaction between RTN3-B 
and APP, and therefore propose that these two proteins are functionally related. 
Evidence of the potential functional roles of RTN3-B have emerged from in silico 
analysis. Besides the reticulon homology domain (RHD) located at C-terminal tail 
which encompasses two large transmembrane domains, it contains a WW domain 
located at the N-terminus of the protein, important to mediate phosphorylation-
dependent interactions (Fig. 1, Pag. 164). Moreover, it contains several 
phosphorylation sites for various kinases, including CK1, CK2 and MAPK, suggesting 
that this protein can be regulated by protein phosphorylation. The targeting of RTN3-B 
from the trans-Golgi network (TGN) to the endosomal-lysosomal compartments is 
mediated by protein sorting and the internalization signal. This domain is of extreme 
importance if we consider that APP processing can occur during its residence in the 
TGN and in the endocytic pathway, including amyloidogenic processing. Our results 
strongly suggest that there is a role involving a direct interaction between RTN3-B and 
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APP and the former may be responsible for altered APP targeting and processing. Co-
immunoprecipitations and co-localization studies confirmed this interaction. 
Recent data concerning the RTN3 topology indicates that it forms a ω-shape 
structure with the N- and the C-terminal of RTN3 facing the intracellular/cytosolic side 
(He et al. 2007). The determination of RTN3 topology helps to explain not only the 
interaction of RTN3 and BACE-1 but also the interaction of RTN3-B and APP, because 
both C-terminal tails face the cytosolic side, the same topological orientation makes 
this binding compatible. These results confirm that the interaction proposed above is 
topologically possible. 
The APP:RTN3-B interaction also caused increases in αsAPP and CTFs (Fig. 5, 
Fig. 170). These results suggest that RTN3-B seems to be involved in targeting APP to 
specific subcellular locations where its α-secretase proteolytic processing occurs, and 
directing it to the non-amyloidogenic pathway. This finding is particularly important in 
terms of AD therapy, because RTN3-B seems be a good target for therapeutic 
intervention, sincein its presence we are able to diminish the Abeta production. 
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5.8 AD PATHOPHYSIOLOGY AND THERAPY 
 
 
Alzheimer’s disease is the most common form of dementia in the industrialized 
countries. If more effective therapies are not developed that either prevent AD or 
block progression of the disease in its very early stages, the economic and socital 
coats of treating AD patients will be devastating.  
There is now consensus that protein misfolding, aggregation, amyloid 
formation, or some combination of these events triggers many types of 
neurodegenerative diseases, including AD. Genetic studies of mutations that cause 
early onset AD provide tremendous support for the notion that preventing Abeta 
aggregation will prevent AD. All genetic alterations linked to AD alter Abeta in a way 
that increases it propensity to aggregate (Golde et al. 2000; Hardy and Selkoe 2002; 
Younkin 1998). Similarly, genetic evidence from frontal temporal dementia showing 
that mutations in tau lead to abnormal tau accumulation in NFT and possible other 
smaller aggregates suggest that the abnormal accumulation of tau is also linked to 
neurodegeneration. Thus, Abeta and tau are prime targets for disease therapeutics. 
Preventing the abnormal misfolding, aggregation and accumulation of Abeta, tau or 
both, should result in a disease modifying AD therapy. AD could be prevented or more 
effectively treated by: (1) decreasing Abeta and tau production; (2) preventing 
aggregation or misfolding of these proteins; (3) neutralizing or removing the toxic 
aggregate or misfolded forms of these proteins or (4) combination of these 
modalities. Despite the huge investment in research and development, only a few 
anti-Abeta therapies are being clinically evaluated and there are even fewer human 
trials targeting tau (Golde 2003, 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter V 
224  Sandra Rebelo 
 
  CBC/UA, 2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Abeta based therapeutic targets. A. Targets based on altering 
production of APP. In the α-secretase pathway, the Abeta sequence is cleaved in two and so 
is called non-amyloidogenic and therefore protective. Thus, increasing α-secretase cleavage is a 
possible therapeutic option. Multiple ways to interfere in amyloidogenic pathway (β-secretase 
processing of APP) have been identified and are summarized in this figure. Promising 
therapeutic targets include the aspartyl protease β-secretase, γ-secretase inhibitors that target 
presenilin and modulators that selectively alter Abeta1-42 production.   B. Targets based on 
altering Abeta clearance or aggregation. Abeta aggregation is thought to be a 
concentration dependent seeded polymerization reaction that proceeds through a nucleation 
event. As Abeta aggregates, it undergoes a structural conversion to a highly ordered β-sheet 
conformation that is characteristic of an amyloid deposit. At the moment is it not clear whether 
oligomeric species that have been identified are ‘on’ or ‘off’ pathway intermediates in the 
amyloid deposition process. Generic strategies for perturbing this pathway are shown and 
include aggregation inhibitors, antibody based therapies and methods to activate clearance of 
monomeric Abeta or Abeta aggregates (taken from Golde 2006). 
A
B
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Figure 5. Tau based therapeutic targets. Tau binding to microtubules (MT) stabilizes 
the microtubule. Phosphorylated tau does not bind the microtubules as well, leading to the 
hypothesis that phosphorylation regulates tau binding to MT. Some soluble normally 
phosphorylated tau is present in the cell, but hyperphosphorylated tau accumulates in NFTs. It 
is thought that abnormal soluble aggregates of abnormally folded tau contribute to degenerative  
disease processes, though such small soluble tau assemblies have not been identified. In any 
case, soluble misfolded tau is thought to contribute to the disease process. Although tangles are 
often not thought of asd amyloid they are in fact amyloid structures within the cell. General 
strategies for altering tau accumulation are identified. These include microtubule stabilizing 
agents, kinase inhibitors, aggregation inhibitors and methods to enhance clearance of either 
soluble tau or tau aggregates via chaperones (e. g. HSPs, CHIP) or proteases (e. g. the 
proteasome) (taken from Golde 2006). 
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5.8.1 CURRENT THERAPY FOR AD 
 
 
Currently approved drugs for the treatment of AD target the metabolic deficits 
observed in the disease, associated with reduced brain function and include two 
classes of drugs: the acetyl cholinesterase inhibitors (AchEI) (tacrine, donepizil, 
rivastigmine, galantamine) and the N-methyl-D-aspartate (NMDA) receptor antagonist 
memantine. These drugs appear to provide short-term benefits to patients based on 
enhancement of remaining cognitive functions. However, they do not provide a 
significant delay of disease progression Because of the limited efficacy of these drugs, 
the main focus of medical management of AD patients is therefore monitoring of 
progress of their disease and providing an appropriate level of supportative care 
 
5.8.2 EXPERIMENTAL THERAPY FOR AD 
 
As research into the onset and progression of AD has progressed over the last 
decade, an expanding range of potential mechanisms of intervention has emerged 
with the goal of developing disease-modifying therapies that will slow, if not reverse, 
the progression of disease. Experimental therapies based on modulation of APP/Abeta 
pathways can be broadly described as being based on three types of approaches: 
preventing the production of Abeta, preventing the formation of toxic forms of Abeta, 
preventing the toxic effects of Abeta. Representative experimental therapeutics 
targeting Abeta for the treatment of AD, which have reached clinical trials are 
described in Table 1. Antiamyloid strategies fall into three basic categories: 
immunotherapy agents, antiaggregants, and secretase modulators. 
 
Immunotherapy agents. The most advanced of these approaches is that of 
immunotherapy based on vaccination with Abeta. The potential importance of 
immunotherapy approaches to AD was first demonstrated by Salomon et al. (1997) 
using antibodies raised against Abeta28 which bound to and disaggregated premade 
Abeta fibrils. Antibodies were also shown to block the toxic effects of fibrillar Abeta on 
cells. Subsequent and somewhat speculative experiments with active vaccination with 
Abeta produced rather extraordinary positive results in transgenic mice (Janus et al. 
2000; Morgan et al. 2000; Schenk et al. 1999). Following this observation, these 
effects were obtained using passive vaccination, the direct administration of antibodies 
raised against Abeta (DeMattos et al. 2001). Even brief administration of anti-Abeta 
antibodies was found to produce a cognitive benefit in the absence of a significant 
effect on amyloid burden (Dodart et al. 2002). Because of robust effects in animal 
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models, this approach has entered clinical trials and has provided evidence of efficacy 
in a small number of patients. While the first vaccine appeared to be safe and could 
elicit an immune response in a majority of subjects, with repeated injections (Bayer et 
al. 2005)(, this first trial was put on hold because of significant side effect of 
meningoencephalitis in a small subset of patients (Mathews and Nixon 2003; 
Orgogozo et al. 2003) which raised concerns with immunotherapy approaches 
(McGeer and McGeer 2003).  
 
Table 1. Experimental therapeutics targeting Abeta for the treatment of AD in clinical 
development. 
 
MECHANISM OF 
ACTION 
COMPANY, PRODUCT,                     
(STAGE OF DEVELOPMENT) 
Abeta aggregation inhibitor Neurochem, AlzhemedTM (tramiprosate; Phase III) 
γ-secretase modulators 
Myriad Genetics, Flurizan (tarenflurbil; Phase III) 
Eisai, E2012 (Phase I) 
γ-secretase inhibitors 
Lilly, LY450139 (Phase I) 
Wyeth, GSI-953 (Phase I) 
Passive immunization against 
Abeta 
Wyeth/Elan. Bapineuzumab (AAB-001; Phase III) 
Lilly, humanised m266 (LY206430; Phase I) 
Wyeth/Elan, AAB-002 (Phase 0) 
Pfizer/Rinat RN1219 (Phase I) 
Active immunization against 
Abeta 
Novartis/Cytos, anti-Abeta fragment (Phase I) 
Wyeth/Elan, ACC-001 (Phase I) 
Abeta-ROS-directed metal 
chelator 
Prana, PBT1 (cliquinol, Phase IIa, discontinued) 
PBT2 (Phase IIa) 
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Antiaggregants. Similarly advanced is the effort to develop an antagonist of Abeta 
aggregation. Numerous reports have been published describing a range of compounds 
that inhibit the transition of monomeric Abeta to toxic oligomers and/or polymers. 
Neurochem is developing a compound mimicking the glycosaminoglycans that inhibits 
Abeta aggregation. Their compound for AD, 3-aminopropane-1-sulfonate also named 
AlzhemedTM, is now in Phase III clinical trials (Aisen, 2005). At least two other 
aggregation inhibitors are known to have entered clinical trials, the peptidic compound 
ApanTM of Praecis Pharmaceuticals (Findeis, 2002), and scyllo-inositol at Transition 
Therapeutics (McLaurin et al. 2000). 
 
Secretase modulators. Despite difficulties encountered in the development of drug-
like selective β-secretase inhibitors, it is almost certain, given the investment by 
pharmaceutical companies and others in this area, that brain penetrant, orally 
bioavailable, selective β-secretase inhibitors will be developed in the next few years. It 
remains to be determined whether long-term treatment with β-secretase inhibitors will 
be tolerated.  
Potent inhibitors that target the multicomponent γ-secretase enzyme, have 
been developed and even entered into Phase I human clinical trials (Golde and 
Eckman, 2003; Siemers et al. 2005). These inhibitors appear to target presenilin 1 or 
2, which are apparent catalytic components of the γ-secretase complex. However, the 
continued development of these inhibitors as AD therapeutics is controversial due to 
target-based toxicities attributable to effects on other γ-secretase substrates such as 
Notch (De Strooper et al. 1999; Saxena et al. 2001). Targeting γ-secretase cleavage 
with non-steroidal anti-inflammatory compounds (NSAIDs) and their derivatives is 
being used. These types of compounds modulate γ-secretase by shifting cleavage from 
Abeta1-42 to shorter Abeta peptides and do not result in substrate accumulation or 
functional impairment of other g-secretase substrates (Weggen et al. 2001). A 
selective Abeta1-42 lowering agent, R-Flurbiprofen (Flurizan) is currently being 
evaluated in a Phase II human trial. Notably, one year randomized, placebo-
controlled, double-blind Phase 2 study of R-flurbiprofen (MPC-7869, Myriad 
Pharmaceuticals, Inc.), in 2007 subjects with mild to moderate AD subjects receiving 
the highest dose of MPC-7869, a statistically significant benefit was observed in 
activities of daily living and global function with positive trends in cognition (Black et 
al. 2006). 
Muscarinic agonist, hormone replacement and statins have all been tested as 
possible AD therapies in clinical trials (Nitsch 1996; Sparks et al. 2005). Whether such 
agents could work in AD by altering α-secretase activity is not clear. They clearly have 
multiple pharmacologic targets. Indeed, a recent study in AD mouse model that 
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develops both amyloid deposition and neurobibrillary pathology using the M1 agonist 
AF267B suggest that inhibitors of this type increase α-secretase cleavage of APP and 
may also decrease GSK3β activity and thus reduce tau pathology (Caccano et 
al.2006).  
Another approach that has reached human clinic trials is that of modulating the 
aparent ability of Abeta to promote the generation of toxic reactive oxygen species 
(ROS). Certain metal chelators have been shown to reduce the toxicity associated with 
Abeta. An initial trial with clioquinol provided evidence of efficacy (Ritchie et al. 2003) 
and a second generation compound, PBT2, is now in the clinic trials 
(http://www.pranabio.com/research/clinical_trials.asp). 
 
 
5.9 Y687 PHOSPHORYLATION IN AD PATHOPHYSIOLOGY AND THERAPY  
 
APP abnormal cleavage may arise from various sources including altered APP 
trafficking. For example, a major FAD gene (Barinaga 1995) encodes a protein 
homologous to the C. elegans Spe4, a protein that plays a role in membrane sorting 
(L'Hernault and Arduengo 1992), raising the possibility that missorting of APP may 
contribute to some forms of AD. The high Abeta levels observed in AD patients may 
lead to altered protein traffic, and many authors now defend impaired APP-dependent 
secretory traffic as a possible mechanism of AD pathogenesis. Hence, it would be 
desirable to transiently set a cellular system in which APP could still perform its 
nuclear signalling but where Abeta levels would not be significantly enhanced and APP 
traffic would not be inhibited. Our results suggest that APP Y687 phosphorylation is 
suitable for all these purposes, and further work will be carried out to clarify its the 
role in neuronal cells.  
Nowadays, combination therapy is believed to be the future therapeutic 
strategy for AD that gives maximum results. Not all studies favour the superior 
efficacy of combination therapy, but some studies show some evidence for synergistic 
combination effects of symptomatic therapy, including delay or prevention of disease 
progression (Schmidt et al. 1997). Results discussed above highlight the possible 
benefits of a combined strategy of targeting APP to the α-secretase processing, even 
in a background of high β-secretase processing. Considering this APP processing 
pathway, several drugs with brain protective beneficial effects and that lower Abeta 
production, such as NSAIDs, statins and flavonoids, were recently found to channel 
APP to non-amyloidogenic processing (review in Tang 2005). Anti-AChE drugs 
increasing acetylcholine brain levels also lead to an up-regulation in the αsAPP 
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processing through M1 receptors. The benefit of neurotrophic factors in dementia has 
been highlighted (Levy et al. 2005), and αsAPP is one such factor. Besides having 
synaptogenic properties, this APP fragment counteracts Abeta toxicity and glutamate-
induced excitotoxicity and dendrite outgrowth inhibition, through modulation of cGMP 
and intracellular calcium levels (reviewed in Mattson and Chan 2003). Y687 
phosphorylation seems to ‘activate’ the APP molecule to be targeted to subcellular 
sites of α-secretase processing. In speculative terms, favouring the cerebral 
production of the neuroprotective αsAPP through Y687 phosphorylation looks 
appealing, as it could also potentially maintain Abeta levels low. The development of 
therapeutic drugs targeting APP Tyr687 phosphorylation could also involve protein 
phosphatases and selective targets of these proteins may be accomplished by 
identifying protein phosphatase interacting which can be tissue-specific and provide 
ideal target proteins for therapeutics. (da Cruz e Silva and da Cruz e Silva 2003; da 
Cruz e Silva et al. 2004b). 
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APPENDIX I 
 
REAGENTS AND SOLUTIONS 
 
 
1. DNA Manipulation 
 
Solutions for bacterial cultures, transformation and DNA extraction 
? SOB (Fluka)      25.5 g/L 
? SOC 
- SOB      49 ml 
- 1 M Glucose stock solution    1 ml  
? Competent cells solutions 
Solution I (1 L): 
- MnCl2.4H2O     9.9 g  
- CaCl2.2H2O      1.5 g  
- Glycerol      150 g   
- KHAc      30 ml (1 M) 
Adjust pH to 5.8 with HAc, filter through a 0.2 μm filter and store at 4ºC. 
Solution II (1 L): 
- MOPS (0.5 M, pH 6.8)    20 ml  
- RbCl      1.2 g  
- CaCl2.2H2O      11 g  
- Glycerol      150 g 
Filter through a 0.2 μm filter and store at 4 ºC.   
? LB (Luria-Broth) medium (Sigma)  20 g/L 
? LB agar plates 
For a final volume of 1 L, add 12 g of agar to 950 ml of LB medium. Mix until the 
solutes have dissolved. Adjust the volume of the solution to 1 litre with LB medium 
and sterilize by autoclaving. When at cooled splite the medium into plates (∼ 20 
ml/ 100 mm plate). 
 
? 100 mg/ml Antibiotics stock solutions (Ampicilin or Kanamycin)  
Dissolve 1 g of the antibiotic in 10 ml of deionized H2O. Mix until the solutes 
have dissolved, filter through a 0.2 μm filter, aliquot and store at -20 ºC. 
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? DNA extraction (‘mini and maxi preps’) 
Solution I (‘resuspension’):  
- Glucose      50 mM 
- Tris.Cl (pH 8.0)    25 mM 
- EDTA (pH 8.0)    10 mM 
Solution II (‘alkaline lysis’): 
- NaOH     0.2 N 
- SDS         1 % 
Solution III (‘neutralization’): 
- 5 M Potassium acetate   3 M 
- Glacial acetic acid    2 M 
? 50X TAE solution (1 L) 
- Tris base      242 g 
- Glacial acetic acid     57.1 ml 
- EDTA (pH 8.0)     100 ml  
? TE buffer, pH 7.5 
- Tris-HCl (pH 7.5)     10 mM 
- EDTA (pH 8.0)     1 mM 
? RNase stock solution     10 mg/ml 
? 10 mM dNTPs solution (100 µl) 
- dATP      10 µl 
- dTTP      10 µl 
- dCTP      10 µl 
- dGTP      10 µl 
- H2O         60 µl 
aliquot and keep at -20 ºC. 
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2. Cell Culture and Rat primary neuronal cultures 
 
Cells seeding, maintenance and experiments 
 
? DMEM medium (COS-7 cells) 
For a final volume of 1 L, dissolve one pack of DMEM powder (with L-
glutamine and 4500 mg glucose/L, Sigma Aldrich) in deionised H2O and add: 
- NaHCO3 (Sigma-Aldrich)    3.7 g 
adjust to pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4 
ºC.  
? Complete DMEM (COS-7 cells) 
For a final volume of 1 L, when preparing DMEM medium adjust to pH 7.4 and 
before sterilizing add: 
- Fetal Bovine Serum (FBS) (Gibco BRL, Invitrogen) 100 ml (10% v/v) 
Notes: FBS is heat-inactivated for 30 min at 56 ºC. For cells maintenance, 
prior to pH adjustment add 100 U/ml penicillin and 100 mg/ml streptomycin 
[10 ml Streptomycin/ Penicilin/ Amphotericin solution (Gibco BRL, 
Invitrogen)]. 
DMEM Components:     (g/L) 
L-Arginine•HCl      0.084 
L-Cystine•2HCl      0.0626 
L-Glutamine      0.584 
Glycine       0.03 
L-Histidine•HCl• H2O     0.042 
L-Isoleucine      0.105 
L-Leucine       0.105 
L-Lysine•HCl      0.146 
L-Methionine      0.03 
L-Phenylalanine      0.066 
L-Serine       0.042 
L-Threonine      0.095 
L-Tryptophan      0.016 
L-Tyrosine 2Na•2H2O     0.10379 
L-Valine       0.094 
Choline Chloride      0.004 
Folic Acid       0.004 
myo-Inositol      0.0072 
Niacinamide      0.004 
D-Pantothenic Acid hemicalcium    0.004 
Pyridoxal•HCl      0.004 
Riboflavin       0.0004 
Thiamine•HCl      0.004 
Calcium Chloride [Anhydrous]    0.2 
Ferric Nitrate•9H2O     0.0001 
Magnesium Sulfate [Anhydrous]    0.09767 
Potassium Chloride     0.4 
Sodium Chloride      6.4 
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Sodium Phosphate Monobasic [Anhydrous]   0.109 
Glucose        4.5 
Phenol Red•Na       0.0159 
? PBS (1x) 
For a final volume of 500 ml, dissolve one pack of BupH Modified 
Dulbecco’s Phosphate Buffered Saline Pack (Pierce) in deionised H2O. 
Final composition: 
- Sodium Phosphate      8 mM 
- Potassium Phosphate    2 mM 
- NaCl            140 mM 
- KCl              10 mM 
Sterilize by filtering through a 0.2 μm filter and store at 4 ºC. 
? Complete Neurobasal medium (Cortex primary cultures) 
This serum-free medium (Neurobasal; Gibco, BRL) is supplemented 
with: 
- B27 supplement (Gibco, BRL)   2% 
- L-glutamine (Gibco, BRL)    0.5 mM  
- Gentamicine (Gibco, BRL)    60 μg/ml  
- Phenol Red (Sigma Aldrich, Portugal)  0.001% 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 μm filter and store 
at 4 ºC. 
? Complete Neurobasal medium (Hippocampus primary cultures) 
This serum-free medium (Neurobasal; Gibco, BRL) is supplemented 
with: 
- B27 supplement (Gibco, BRL)   2% 
- L-glutamine (Gibco, BRL)    0.5 mM  
- L-glutamate (Gibco, BRL)    0.5 mM  
- Gentamicine (Gibco, BRL)    60 μg/ml  
- Phenol Red (Sigma Aldrich, Portugal)  0.001% 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 μm filter and store 
at 4 ºC. 
? Hank’s balanced salt solution (primary neuronal cultures) 
This salt solution is prepared with deionised H2O. Final composition: 
- NaCl       137 mM  
- KCl        5.36 mM  
- KH2PO4         0.44 mM 
- Na2HPO42H2O       0.34 mM 
- NaHCO3        4.16 mM 
- Glucose       5 mM 
- Sodium pyruvate      1 mM 
- HEPES       10 mM 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4 
ºC. 
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3. Cells fixation and Imunocytochemistry: 
 
? 1 mg/ml Poly-L-ornithine solution (10x) (COS-7 cells) 
To a final volume of 100 ml, dissolve in deionised H2O 100 mg of poly-L-
ornithine (Sigma-Aldrich, Portugal).  
? 10 mg/ml Poly-D-lysine stock (100x) (rat primary neuronal cultures) 
To a final volume of 10 ml, dissolve in deionised H2O 100 mg of poly- D-lysine 
(Sigma-Aldrich).  
? Borate buffer (at primary neuronal cultures) 
To a final volume of 1 L, dissolve in deionised H2O 9.28 g of boric acid 
(Sigma-Aldrich). Adjust to pH 8.2, sterilize by filtering through a 0.2 μm filter, 
and store at 4 ºC. 
? Poly-D-lysine solution (neuronal cells) 
To a final volume of 100 ml, dilute 1 ml of the 10 mg/ml poly-D-lysine stock 
solution in borate buffer.  
? 4% Paraformaldehyde Fixative solution 
For a final volume of 100 ml, add 4 g of paraformaldehyde to 25 ml deionised 
H2O. Dissolve by heating the mixture at 58 ºC while stirring. Add 1-2 drops of 
1 M NaOH to clarify the solution and filter (0.2 μm). Add 50 ml of 2X PBS and 
adjust the volume to 100 ml with deionised H2O. 
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4. Proteins Manipulation 
 
SDS-PAGE 
 
? LGB (Lower gel buffer) (4x) (1 L) 
- Tris       181.65 g 
- SDS       4 g 
Shake until the solutes have dissolved. Adjust the pH to 8.9 with HCl and 
adjust the volume to 1 L with deionised H2O. 
? UGB (Upper gel buffer) (5x) 
Per litre, to 900 ml of deionised H2O add 75.7 g of Tris base. Shake until the 
solute has dissolved. Adjust the pH to 6.8 with HCl and adjust the volume to 1 
L with deionised H2O. 
? 30 % Acrylamide / 0.8 % Bisacrylamide solution 
Per 100 ml, to 70 ml of deionised H2O add: 
- Acrylamide      29.2 g  
- Bisacrylamide      0.8 g 
Shake until the solutes have dissolved. Adjust the volume to 100 ml with 
deionised H2O. Filter through a 0.2 μm filter and store at 4 ºC. 
? 10 % APS (ammonium persulfate) 
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use. 
? 10 % SDS (sodium dodecilsulfate) 
In 10 ml of deionised H2O dissolve 1 g of SDS. 
? Loading (sample) buffer (4x) (10 ml) 
- 1M Tris  solution (pH 6.8)   2.5 ml (250 mM) 
- SDS      0.8 g (8%) 
- Glicerol      4 ml (40%) 
- β-Mercaptoetanol     2 ml (2%) 
- Bromofenol blue     1 mg (0.01%) 
Adjust the volume to 10 ml with deionised H2O. Store in darkness at RT. 
? 1 M Tris (pH 6.8) solution 
For a final volume of 250 ml, dissolve 30.3 g of Tris base in 150 ml of 
deionised H2O, adjust pH to 6.8, and adjust final volume to 250 ml.  
? Running buffer (10x) (1 L) 
- Tris       30.3 g (250 mM) 
- Glycine      144.2 g (2.5 M) 
- SDS      10 g (1%) 
Dissolve in deionised H2O, adjust pH to 8.3, and adjust volume to 1 liter.  
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(1.5 mm gels) 
 
? Resolving (lower) gel solution (60 ml) 7.5%  12%  6.5% 
- H2O     29.25 ml 20.7 ml 31.25ml 
- 30% Acryl/0.8% Bisacryl solution 15.0 ml 24.0 ml 13.0 ml 
- LGB (4x)     15.0 ml 15.0 ml 15.0 ml 
- 10% APS     300 μl  300 μl   300 μl 
- TEMED     30 μl  30 μl    30 μl 
? Stacking (upper) gel solution (20 ml) 3.5% 
- H2O             13.2 ml 
- 30% Acryl/0.8% Bisacryl solution  2.4 ml 
- UGB (5x)     4.0 ml 
- 10% SDS     200 μl 
- 10% APS     200 μl 
- TEMED        20 μl 
 
Immunoblotting solutions 
 
? Electrotransfer buffer (1x) 
Per litre, to 700 ml of deionised H2O add:  
- Tris      3.03 g (25 mM) 
- Glycine       14.41 g (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the 
volume to 800 ml with deionised H2O. Just prior to use add 200 ml of methanol 
(20%). 
 
? TBS (Tris Buffered Saline) (10x) 
Per litre, to 700 ml of deionised H2O add  
- Tris       12.11 g (10 mM) 
- NaCl       87.66 g (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised 
H2O. 
? TBS-T (Tris Buffered Saline + Tween) (10x) 
For a final volume of 1 L, to 700 ml of deionised H2O add  
- Tris       12.11 g (10 mM) 
- NaCl       87.66 g (150 mM) 
- Tween 20       5 ml (0.05%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised 
H2O. 
? Blocking solution (100 ml) 
- TBS-T stock solution (10x)   10 ml 
- non-fat milk (dry powder)   5 g 
Dissolve in deionised H2O and adjust volume to 100 ml.  
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? Antibody solution (25 ml) 
- TBS-T stock solution (10x)   2.5 ml 
- non-fat milk (dry powder)   0.75 g 
Dissolve in deionised H2O and adjust volume to 25 ml. Add antibody, mix 
gently without vortex, and store at -20 ºC. 
? Alkaline Phosphatase (AP) Reaction Solution (1 L) 
- Tris-HCl (pH 9.5)      12.11 g (100 mM) 
- NaCl       5.85 g (100 mM) 
- MgCl2       1.02 g (5 mM) 
Dissolve Tris base in deionised H2O and adjust solution to pH 9.5 with HCl. 
Dissolve the other solutes and adjust volume to 1 L. 
? AP Stop Solution (1 L) 
- Tris-HCl (pH 9.5)     2.42 g (20 mM) 
- EDTA      1.86 g (5 mM)   
Dissolve Tris in deionised H2O and adjust with HCl to pH 9.5. Add EDTA after 
and adjust volume to 1000 ml. 
? Membranes Stripping Solution (500 ml) 
- Tris-HCl (pH 6.7)     3.76 g (62.5 mM) 
- SDS      10 g (2%) 
- β-mercaptoethanol    3.5 ml (100 mM)  
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the 
mercaptoethanol and adjust volume to 500 ml.  
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APPENDIX II 
 
METHODS AND KITS 
 
 
1. DNA Manipulation 
 
PCR (polymerase chain reaction) for mutant and wt APP cDNAs amplification 
 
PCR was performed using Pfu DNA polymerase (Promega), and the amplification 
reactions were set up according to the manufacturer instructions. The standard 
amplification reactions were performed in 0.2 ml microtubes as follows (Table 
AII.1) 
    
Table AII.1. Reagents mixtures used in APP isoform 695 cDNAs PCR amplification. 
Total volume: 50 μl 
Tube 
Template 
0.1 ng 
Template 
1.0 ng 
Negative 
Control  1 
(w/primers, 
w/o template) 
Negative 
Control  2 
(w/o primers, 
w/ template) 
10x Pfu 
buffer 
5 μl 5 μl 5 μl 5 μl 
dNTPs (10 
mM) 
1.5 μl 1.5 μl 1.5 μl 1.5 μl 
Primer NAPN 1.5 μl (10 pmol) 1.5 μl (10 pmol) 1.5 μl (10 pmol) - 
Primer S1 1.5 μl (10 pmol) 1.5 μl  (10 pmol) 1.5 μl  (10 pmol) - 
APP cDNA 
(template) 
1 μl 10 μl - 1 μl  Wt APP cDNA 
Pfu 
polymerase 
1 μl 1 μl 1 μl 1 μl 
H2O 38.5 μl 29.5 μl 39.5 μl 41.5 μl 
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? PCR amplification program   
1 min 94 ºC   1x (Denaturation) 
30 sec 94 ºC       
30 sec 67 ºC   5x   (Denaturation, Annealing, Polymerization)  
1 min 72 ºC      
30 sec 94 ºC   25x (Denaturation, Polymerization)   
3 min 72 ºC  
7 min 72 ºC   1x (Polymerization; “Extension” step)    
The annealing temperature depends on the primers melting temperatures (Tm) and 
it should usually be =(Tm – 8) ºC.  For some reactions it was necessary to undergo 
further amplification cycles: more 20 cycles (30 sec 94 ºC, 3 min 72 ºC) followed 
by another extension step of 1x 7 min 72 ºC. Amplification was confirmed by 
resolving a PCR reaction aliquot (10 μl) in a 1.2% agarose gel electrophoresis. 
 
PCR cDNA products digestion with restriction enzymes 
 
The amplified APP cDNA fragments were sequentially digested with the restriction 
endonucleases Nru I and Age I to allow further insertion into the EGFP-N1 plasmid. 
APP cDNAs were inserted between the Sma I and Age I sites of the pEGFP-N1 
vector, upstream of the enhanced green fluorescent protein (EGFP) cassette and in 
the correct open reading frame. For a typical DNA digestion, the following 
components were added to the following concentrations: 
100 μg/ml cDNA 
1X reaction buffer (specific for each restriction enzyme)  
1U restriction enzyme /μg cDNA 
 
The mixture was incubated at the appropriate temperature for a few hours (or 
overnight if convenient). When sequential digestions with different enzymes were 
carried out the DNA was purified between the two reactions (see below). Table 
AII.2 presents the restriction enzymes and specific mixtures used in the APP-GFP 
translational fusions production and previous confirmation before sequencing. Prior 
to sequencing, the plasmid DNA extracted from transformants and the EGFP-N1 
vector (for control), were sequentially digested with Xba I, EcoR I, and Pst I.  
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Table AII.2. Mixtures used in APP695 and EGFP vector cDNAs digestion with restriction 
enxymes. Restriction enzymes: Nru I and Age I (NEB); Sma I, Xba I and EcoR I(Fermentas). 
Objective: APP subcloning into the EGFP vector Confirmation of APP-GFP fusion  
Restriction 
Enzyme / 
Mixture 
Components 
Nru I 
(APP 
cDNAs, 
PCR 
products) 
Age I 
(APP 
cDNAs, 
PCR 
products) 
Sma I 
(N1 
vector) 
Age I 
(N1 
vector) 
Xba I 
(putative 
APP-GFP 
clones) 
EcoR I 
(putative 
APP-GFP 
clones, after 
Xba I 
confirmation) 
Pst I 
(putative 
APP-GFP 
clones, after 
Xba I 
confirmation) 
Buffer 10x 10 μl 5 μl 10 μl 10 μl 1 μl 1 μl 1 μl 
Enzyme 2 μl 1 μl 3.5 μl 3.5 μl 1 μl 1 μl 1 μl 
DNA 
40 μl of 
PCR 
product 
Pellet of 
purified 
cDNA pre-
cuted with 
NruI  
20 μl 
(± 12 
μg) of 
gel 
extracted 
N1 
t  
Pellet of 
purified 
cDNA 
pre-cuted 
with 
SmaI 
3 μl of the 
clone 
miniprep 
3 μl of the clone 
miniprep 
3 μl of the clone 
miniprep 
H2O 48 μl 44 μl 66.5 μl 86.5 μl 5 μl 5 μl 5 μl 
Final 
Volume 
100 μl 50 μl 100 μl 100 μl 10 μl 10 μl 10 μl 
Temperature  37 ºC  25 ºC  30 ºC  25 ºC  37 ºC  37 ºC 37 ºC 
Reaction 
Time 
4 h Overnight 4 h Overnight 2 h 4 h 4 h 
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DNA purification 
 
? Method 1: QIAquick PCR Purification Kit Protocol (QIAgen # 28706) 
This kit was used to purify DNA fragments from PCR and other enzymatic reactions. 
It allowed purification from primers, nucleotides, DNA polymerases and salts by 
using QIAquick spin columns in a microfuge tube. The manufacturer’s protocol was 
used as follows: 5 volumes of buffer PB were added to 1 volume of the reaction to 
be purified, and mixed. The QIAquick spin column was placed in a provided 2 ml 
collection tube and the sample was applied to the column and centrifuged for 1 min 
at 14,000 rpm to allow for DNA binding. The first flow-through was discarded and 
the column washed with 0.75 ml of buffer PE and centrifuged for 1 min at 14,000 
rpm. The second flow-through was discarded, the column placed back in the same 
tube and centrifuged again to remove traces of washing buffer. The column was 
finally placed in a clean microtube, 50 μl of H2O were added and let to stand for 1 
min. To elute the DNA, the column was centrifuged for 1 min at 14,000 rpm.  
 
? Method 2: DNA precipitation with ethanol 
This method was used to concentrate nucleic acids as well as to purify them (e.g. 
for cell culture transfection). Approximately 1/10 volume of 3 M sodium acetate (pH 
5.2) was added to the DNA solution to adjust the salt concentration, followed by 2 
volumes of ice-cold ethanol. The solution was mixed thoroughly and stored at –20 
ºC for 30 min to allow the DNA precipitate to form. DNA was recovered by 
centrifugation at 4 ºC for 15 min at 14,000 rpm. The supernatant was carefully 
removed without disturbing the pellet. The microtube was half filled with ice-cold 
70% ethanol and re-centrifuged using the same conditions as above for 5 min. The 
supernatant was again removed and the pellet allowed to dry before being 
resuspended in sterile water. 
 
 
Electrophoretic analysis of DNA 
 
An electrophoresis apparatus was prepared and the electrophoresis tank was filled 
with enough 1X TAE to cover the agarose gel. The appropriate amount of agarose 
(to a final percentage of 0.8 – 1.2%) was transferred to an Erlenmeyer with 50 ml 
1X TAE, and this slurry was heated until agarose dissolution and allowed to cool to 
60 ºC before adding ethidium bromide to a final concentration of 0.5 μg/ml. The 
agarose solution was poured into the tray and a comb was positioned on it. After 
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the gel was completely set, the comb was carefully removed and the gel mounted in 
the tank. DNA samples were mixed with the 6X DNA loading buffer (DNA LB) 
(0.25% bromophenol blue/30% glycerol in water) and the mixture was loaded into 
the slots of the submerged gel. Marker DNA (λ-Hind III fragments or Invitrogen 1 
Kb ladder) of known size was also loaded into the gel. The lid of the gel tank was 
closed and the electrical leads were attached so that the DNA migrated towards the 
anode. The gel was run at 100 V, and finally examined by UV light and 
photographed, or analysed on a Molecular Imager (Biorad).   
 
DNA Gel Extraction kit (QIAgen) 
 
For the EGFP-N1 cDNA extraction, 0.8% gels were set as described above with 
some differences. 10 μl of non-cutted and 90 μl of Sma I/Age I cutted EGFP-N1 
vector cDNA were loaded and resolved. The DNA standard and 10 μl lanes were UV 
exposed and the migration distance of the digested cDNA band registered. The 90 
μl band was finally extracted from the gel (without being exposed to UV light) with 
a clean spatula. The destination microtube was weighted, before and after receiving 
the extracted band, to calculate the cDNA weight. EGFP-N1 cDNA was further 
purified by using the QIAquick Gel Extraction Kit protocol. Briefly, 3 volumes of 
Buffer QG were added to 1 volume of gel (100 mg ∼100 μl). This mixture was 
incubated at 50 ºC for 10 min (or until the gel slice was completely dissolved), 
while inverting the microtube every when. After the gel slice complete dissolution, 
pH was confirmed to be ≤ 7.5, and 1 gel volume of isopropanol was added to the 
sample and mixed. This sample was applied to a QIAquick spin column, previously 
placed in a 2 ml collection tube, and the tube centrifuged at 10,000 x g or 1 min. 
The flow-through was discarded, 0.5 ml of Buffer QG were applied to the column 
and a further 1 min centrifugation was performed. 0.75 ml of Buffer PE were used 
to wash the column by two sequential centrifugations at 10,000 x g, and the flow-
through discarded. The column was placed in a clean 1.5 ml tube and the DNA 
eluted with 50 μl of deionised H20 after 1 min standing in the column and a last 1 
min centrifugation. 
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Ligation of cohesive termini and blunt ended DNA 
 
Digested fragments (Sma I/Age I EGFP-N1 plasmid and the Nru I/Age I APP-GFP 
cDNA fragment to be inserted) were separated by gel electrophoresis and purified. 
0.1 μg of vector DNA were transferred to a microtube with an equimolar amount (or 
more) of insert DNA. Ligations were performed using the bacteriophage T4 DNA 
ligase (Promega), in a total volume mixture of 20 µl, and were carried out for 4 h at 
room temperature or overnight at 16 ºC. Additional control reactions were also set 
up (Table AII.3). 
 
 
Table AII.3 – APP/GFP bacteriophage T4 DNA Ligations. 
 Ligations Ligations Controls 
Tube 
1 
(2 μl of Nru 
I/Age I 
PCR 
product) 
2 
(6 μl of Nru 
I/Age I 
PCR 
product) 
Control 1 
(w/o cDNA) 
Control 2 
(non-cutted 
EGFP 
vector ) 
Control 3 
(cutted 
EGFP 
vector ) 
10x T4 
ligase 
buffer 
2 μl 2 μl 2 μl 2 μl 2 μl 
EGFP 
vector 
cDNA 
3.5 μl 
(100 ng) 
3.5 μl 
(100 ng) - 
1 μl 
(1 ng) 
3.5 μl 
(100 ng) 
APP PCR 
products 
2.5 μl 
(± 20 ng) 
6.0 μl 
(± 50 ng) - - - 
T4 DNA 
ligase 
1.0 μl 1.0 μl 1.0 μl 1.0 μl 1.0 μl 
H2O 13.5 μl 11 μl 17 μl 16 μl 14.5 μl 
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Bacteria Transformation 
 
? Preparation of competent cells 
A single colony of E. coli XL1-Blue was incubated overnight in 10 ml SOB medium 
at 37 ºC. 1 ml of this overnight culture was used to incubate 50 ml SOB until 
OD550= 0.3. This culture was incubated on ice for 15 min and centrifuged at 4,000 
rpm (4 ºC) for 5 min. The supernatant was discarded and 15 ml of Solution I were 
added. After allowing standing on ice for 15 min, cells were centrifuged at 4,000 
rpm (5 min, 4 ºC) and 3 ml of Solution II were added to the pellet. Cells were 
immediately divided in 0.1 ml aliquots and stored at -80 ºC. 
 
? Bacteria transformation with plasmid DNA 
Competent cells (50 μl) were thawed on ice and 2 or 5 μl of each ligation product 
(0.1 - 50 ng of DNA) were added to the cells with gentle swirling. The microtubes 
were incubated on ice for 20 min and heat shocked at 42 ºC for 60 sec. Further 
incubation on ice for 2 min was performed, and 0.9 ml of SOC medium was added. 
The tubes were incubated at 37 ºC for 1 hour with shaking at 225 rpm. 1/10 and 
9/10 of this cells solution were plated on the appropriate antibiotic (100 μg/ml 
kanamycin) agar medium plates (pre-heated) and incubated at 37 ºC for ∼16 h 
until colonies appeared. Control transformations were also performed in parallel, 
which always included a negative control transformation without DNA and a positive 
control transformation with 0.1 ng of the control plasmid.  
 
Amplification and isolation of plasmid DNA from bacteria 
 
? Alkaline lysis mini-prep 
This method was used to screen the bacterial plates for transformant colonies. A 
single positive (transformant) bacterial colony was transferred to a tube containing 
5 ml of LB plus antibiotic medium and incubated overnight at 37 ºC with vigorous 
shaking. After overnight culture growth, 1 ml of the 5 ml culture was centrifuged at 
14,000 rpm and 4 ºC for 1 min. The medium was removed by aspiration and the 
bacterial pellet ressuspended in 100 μl of ice-cold solution I (‘ressuspension’ 
solution) by vigorous vortexing. Afterwards, 200 μl of Solution II was added 
(‘alkaline lysis’), and the content of the tube mixed by inverting it several times. 
The microtube was placed on ice, 150 μl of ice-cold solution III (‘neutralization’ 
solution) was added and the tube gently vortexed. After standing on ice for 5 min, 
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a 10 min centrifuge at 14,000 x g and 4 ºC was performed, and the supernatant 
transferred to a clean microtube. The DNA was precipitated with 2 volumes of 
ethanol at RT and this mixture was allowed to stand for 10 min at RT. After this 
period, the microtube was centrifuged at 14,000 x g and 4 ºC for 5 min. The 
supernatant was completely removed and the pellet washed with 70% ethanol and 
allowed to air-dry for 10 min. Purified DNA was dissolved in 20 μl H2O containing 
DNAse-free pancreatic RNAse (20 μg/ml) and stored at -20 ºC. 
 
 
? Mega-prep (Promega) 
The Promega kit WizardTM Plus Megapreps DNA purification System # A7300 
was used in this procedure. One litre of a single-transformant cell culture was 
pelleted by centrifugation at 1,500 x g for 20 min at RT. The cell pellet was 
resuspended in 30 ml of cell resuspension solution [50 mM Tris-HCl (pH 7.5)/10 mM 
EDTA/100 μg/ml RNAase A] by manually disrupting the pellet with a pipette. 
Afterwards, 30 ml of cell lyses solution (0.2 M NaOH/ 1% SDS) were added to the 
cells and the solution mixed gently by tube inversion until it became clear and 
viscous. 30 ml of neutralization solution [1.32 M potassium acetate (pH 4.8)] were 
added and the tube immediately mixed by inversion. After centrifugation at 14,000 
x g for 15 min at RT the clear supernatant was transferred by filtering it through 
gauze swabs into a new tube, and the supernatant volume was measured. At this 
stage 0.5 volumes of RT isopropanol were added and the solution mixed by 
inversion. This solution was centrifuged at 14,000 x g for 15 min at RT, the 
supernatant discarded and the pellet resuspended in 4 ml of TE buffer. 20 ml of 
Wizard TM Megapreps DNA purification Resin were added to the DNA and mixed by 
swirl. A Wizard TM Megacolumn was inserted into the vacuum manifold port and the 
DNA/resin mix was transferred onto the Megacolumn. Vacuum was applied to pull 
the mix into the Megacolumn. Two washes with 25 ml of column wash solution (80 
mM potassium acetate/8.3 mM Tris-HCl/40 μM EDTA/55% ethanol) were performed 
and the resin was rinsed with 10 ml of 80% ethanol. The Megacolumn was inserted 
into a 50 ml screw cap tube and centrifuged at 2,500 rpm for 5 min using a 
swinging bucket rotor centrifuge. The Megacolumn was removed from the tube and 
placed in a clean tube, and 3 ml of pre-heated water (70 ºC) were added to the 
column. After 1 min standing, the DNA was eluted by centrifugation at 2,500 rpm 
for 5 min. The DNA was stored at –20 ºC, and a 400 μl DNA aliquot was purified by 
ethanol (and kept sterile) and its concentration and 260/280 nm purity ratio 
calculated by densitometry measurements at the indicated wavelengths. 
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APP-GFP DNA sequencing 
 
All the DNA samples to be sequenced followed the same protocol. In a microtube 
the following components were added: 1 ng dsDNA (column purified) 
4 μl of Ready Reaction Mix* 
15 pmol primer (1.5 μl  of 10 pmol/μl) 
H2O to a final volume of 20 μl 
* Ready Reaction Mix is composed of: dye 
terminators, deoxynucleoside triphosphates, 
AmpliTaq DNA polymerase, FS, rTth 
pyrophosphatase, magnesium chloride and 
buffer (Applied Biosystems).  
This reaction mixture was vortexed and spun down for a few seconds. PCR was 
then performed using the following conditions: 
 
  96 ºC 30 sec 
  42 ºC 15 sec           25 cycles 
  60 ºC   4 min 
Afterwards, samples were purified by ethanol precipitation (as described above). 
Briefly, 2.0 μl of 3 M sodium acetate (pH 5.2) and 50 μl of 95% ethanol were added 
to the reaction microtube. The microtube was vortexed and incubated at RT for 15 
min to precipitate the extension products. The microtube was then centrifuged at 
14,000 rpm for 20 min at RT. After discarding the supernatant, 250 μl of 70% 
ethanol were added, the microtube was briefly vortexed and re-centrifuged for 5 
min at 14,000 rpm at RT. The supernatant was again discarded and the pellet 
dried. After this procedure the samples were loaded in the ABIPRISM (Applied 
Biosystems) Automated DNA Sequencer.    
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2. Cell culture and Rat primary cultures 
 
 
COS-7 cell culture maintenance 
 
COS-7 cells were grown in complete DMEM medium (DMEM medium supplemented 
with 10% FBS) to which 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco 
BRL, Invitrogen) were added. Cells were plated in 100 mm diameter plates or 6-
well plates (35 mm diameter), and grown in a humidified incubator at 37 ºC and 
5% CO2. Cells were subcultured whenever ∼95% confluence was reached.  
 
Rat cortical/hippocampal primary cultures 
 
Rat cortical neurons were isolated from cortex of Wistar Hannover 18 days rat 
embryos whose mother was killed by rapid cervical dislocation. After cortex 
dissection, tissues were treated for 10 min at 37 ºC with a 0.45 mg/ml trypsin/0.18 
mg/ml deoxyribonuclease solution in Ca2+- and Mg2+-free HBSS (Gibco, BRL), 
supplemented with BSA (Merck, VWR International). Cells were washed with HBSS 
supplemented with 10% FBS to stop trypsinization, centrifuged at 1,000 rpm for 3 
min, and further washed and centrifuged with HBSS for serum withdraw. Cells 
pellet was ressuspended in complete Neurobasal medium, which is supplemented 
with 2% B27. Viability and cellular concentration were assessed by using the 
Trypan Blue excluding dye [0.4% Trypan Blue solution (Sigma)], and cells with 
(dead) or without (living) intracellular blue staining were counted in a 
hemocytometer chamber. Cellular viability was calculated and normally higher than 
95%. These neuronal cells were plated at 9.0 x 104 cells/cm2 on 100 μg/ml poly-D-
lysine pre-coated glass coverslips that were placed in six-well plates. Cells were 
maintained in 2 ml of complete Neurobasal medium in a humidified incubator at 37 
ºC and 5% CO2. Three and seven days after plating, 500 μl of cultured medium was 
replaced with 750 μl of gentamicine-free complete Neurobasal medium.  
 
Rat cortex isolation 
 
Young (1-2 month old) adult male rats were sacrificed by cervical dislocation and 
decapitation. Cerebral cortex was rapidly dissected on ice-cold 0.32 M sucrose/10 
mM HEPES (pH 7.4) solution and weighted. Boiling SDS was added to a final 1% 
SDS solution (at ≅ 10% w/v solution), samples were homogenised with a Potter-
Elvehjem type homogenizer and further boiled for 10 min. 
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Cells cDNA Transfection with Lipofectamine 2000 
 
Lipofectamine 2000 (Invitrogen) is a cationic liposome formulation that functions by 
complexing with nucleic acid molecules, allowing them to overcome the 
electrostatic repulsion of the cell membrane and to be taken by the cell. The 
method of DNA delivery in culture cell lines and primary neurons is well described 
in Dalby et al. (2004), from where the following protocols were based: 
 
? COS-7 cell line (Table AII.4) 
Cells were grown in complete DMEM until 85 - 95% confluence and at the 
transfection day the culture medium was replaced for complete medium 
(antibiotic/antymicotic-free). The appropriate amount of DNA for each plate/well 
was diluted in DMEM (serum- and antibiotic/antymicotic-free). The Lipofectamine 
2000 reagent was diluted at the appropriated amount in the same medium, and 
the tubes were left to rest for 5 min. The DNA solution was added to the 
Lipofectamine solution drop by drop, and the solution was mixed by gentle 
bubbling with the pipette. In order to form the DNA-lipid complexes, the tube was 
left to rest at for 25 - 30 min RT, after what the complexes solution was directly 
added onto the cells medium, drop by drop and with gentle rocking of the plate. 
The cells were further incubated at 37 ºC/5% CO2 for the indicated transfection 
time prior to cell collection or fixation. 
 
 
Table AII.4 – COS-7 cells transfection reagents  
Culture 
Plates 
Medium  
w/ serum 
DNA (µg) 
Lipofectamine 
2000 (µl) 
Medium  
w/o serum  
100 mm 15 ml 8 50 1500 µl 
60 mm plate  5.0 ml 4 15 500 µl 
35 mm 6- 2.0 ml 2 10 250 µl 
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? Primary Neuronal cultures  
Replace the culture medium in each 35 mm well for 0.8 ml of fresh gentamicine-
free complete Neurobasal medium. Per each 35 mm well to transfect, 8 μl of 
Lipofectamine 2000 were diluted in 100 μl of DMEM, and the microtube was left to 
rest at RT for 5 min. 2 μg of APP-GFP cDNA were also diluted in 100 μl of DMEM, 
and this solution was added drop by drop to the Lipofectamine solution. The final 
solution was mixed by gentle bubbling with the pipette, and left to rest for 25 - 30 
min at RT in order to form the DNA-lipid complexes. This 200 μl DMEM complexes 
solution was directly added onto the cells medium, drop by drop and with gentle 
rocking of the plate. Neuronal cells were further incubated at 37 ºC and 5% CO2 for 
5 h, after what medium was substituted by fresh complete neurobasal medium and 
left for 24 h prior to cell collection or fixation. 
 
Culture cells Fixation and Immunocytochemistry 
 
COS-7 and neuronal primary cells were grown in 1M HCl pre-treated glass 
coverslips pre-coated with 100 μg/ml poly-L-ornithine or poly-D-lysine, 
respectively. After the experimental procedures, cells were washed three times with 
1 ml of the serum-free DMEM, after which 1 ml of a 1:1 DMEM/4% 
paraformaldehyde fixative solution was gently added and allowed to stand for 1-2 
min. Subsequently, 1 ml of fixative solution was gently added for 25 minutes. 
Finally, cells were washed 3 times with PBS for 10 min, being ready for 
immunocytochemistry procedures or to be directly mounted with 1 drop of anti-
fading reagent (Fluoroguard, BioRad) on glass microscope slides for epifluorescence 
microscopy analysis. For immunocytochemistry procedures, a permeabilization step 
with methanol was taken (2 min at RT) and cells were immediately washed four 
times with PBS. Afterward, cells were incubated with primary antibody diluted in 
3% BSA in PBS for 2-4 h at RT. The primary antibody was removed by washing the 
coverslips 3 times with PBS and a secondary antibody (also diluted in 3% BSA in 
PBS) was added for 2 h at RT. After washing three times with PBS the coverslips 
were mounted with one drop of the antifading reagent on a glass slide.  
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3. Proteins Manipulation 
 
Protein Assay kit (BCA, Pierce) 
 
Samples total protein measurements were performed with Pierce’s BCA protein 
assay kit, following the manufacturer’s instructions. The method combines the 
reduction of Cu2+ to Cu+ by protein in an alkaline medium (the biuret reaction) with 
a sensitive colorimetric detection of the Cu+ cation using a reagent containing 
bicinchoninic acid (BCA). The purple-coloured reaction product of this assay is 
formed by the chelation of two molecules of BCA with one Cu+ ion. This water-
soluble complex exhibits a strong absorbance at 562 nm that is linear with 
increasing protein concentration over a working range of 20 μg/ml to 2000 μg/ml.  
? Working Reagent (W.R.) 
The W.R. was prepared by mixing X ml of BCA reagent A with Y ml of BCA reagent 
B in the proportion of 50:1.  
? Samples preparation 
A microtube per sample was prepared to be assayed with 25 μl of each sample plus 
25 μl of the solution in which the sample was collected (1% SDS).  
? Standard curve 
Microtubes with standard protein concentrations were prepared as described below 
(Table AII.5).  
Table AII.5 – Standards used in the BCA protein assay method. BSA, Bovine 
serum albumin solution (2 mg/ml). 
Standard BSA (μl) 10% SDS H2O (μl) Protein mass W.R. (ml) 
P0 - 5 45 0 1 
P1 1 5 44 2 1 
P2 2 5 43 4 1 
P3 5 5 40 10 1 
P4 10 5 35 20 1 
P5 20 5 25 40 1 
P6 40 5 5 80 1 
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? Incubation and absorbance measurement 
1 ml of W.R. was rapidly added to each microtube (standards and samples) and the 
microtubes were incubated at 37 ºC exactly for 30 min. Tubes cool to RT and 
immediately measure their absorbance at 562 nm.  
? Samples concentration 
A standard curve is prepared by plotting BSA standard absorbance vs. BSA 
concentration, and used to determine the total protein concentration of each 
sample. 
 
SDS-PAGE (for Western blotting) 
 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) separations were carried out 
using well established methods (Laemmli, 1970), where proteins are separated by 
their molecular weight and negative net charge due to SDS-amino acid binding. The 
gels percentage and size chosen depend on the molecular weight of the proteins to 
be separated in the gel. Gels were prepared by mixing several components 
(Appendix I). The resolving gel solution was immediately and carefully pipetted 
down the spacer into the gel sandwich, leaving free space for the stacking gel. 
Water was carefully added to cover the top of the gel and the gel was allowed to 
polymerize for 1 h. Stacking gel solution was prepared according to Appendix I. The 
water was poured out and the stacking gel was added to the gel sandwich; a comb 
was inserted and the gel allowed to polymerize for 1 h. In parallel, samples were 
prepared by adding to the protein sample solution ¼ volume of 4X LB (Loading 
Buffer). Samples microtubes were boiled and spinned down, the combs removed 
and the gels wells filled with Tris-Glycine running buffer. The samples were carefully 
loaded into the wells, and electrophoretically separated using a 90 mA electric 
current. Molecular weight markers (Kaleidoscope Prestained Standards or 
Prestained SDS-PAGE Standards – Broad Range, Bio Rad) were also loaded and 
resolved side-by-side with the samples. 
 
Proteins Electrotransfer 
 
Through the Western Blotting technique, proteins that were electrophoretically 
separated by SDS-PAGE can be transferred to membranes (nitrocellulose 
membranes, for instance), while keeping their positions. 3MM blotter papers and a 
nitrocellulose membrane were used to build up the transfer sandwich. The gel was 
removed from the electrophoresis device and the stacking gel discarded. A transfer 
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sandwich was assembled under transfer buffer, in the following order: sponge, 3MM 
blotter paper, gel, nitrocellulose membrane, 3MM paper, sponge. The cassette was 
placed in the transfer device, previously filled with transfer buffer, oriented so that 
the negatively charged proteins migrate towards the anode. Electrotransfer was 
allowed to proceed for 18 h at 200 mA, after what the membrane was allowed to 
dry on a clean paper. 
 
Immunoblot analysis 
 
After proteins electrotransfer, the nitrocellulose membranes could be used 
immediately, and membranes were initially soaped in 1X TBS for 10 min. Blocking 
of possible non-specific binding sites of the primary antibody was performed by 
immersing the membrane in 5% (w/v) non-fat dry milk in 1X TBST solution for 1 - 
4 h. Further incubation with primary antibody was carried out for the specified 
times, ranging from 2 h to overnight incubation at 4 ºC with agitation. After three 
washes with 1X TBS-T, of 10 min each, the membrane was further incubated with 
the appropriate secondary antibody for 2 h with agitation. All primary and 
secondary antibodies used were diluted in 1X TBS-T/non-fat dry milk (3% w/v) at 
the dilutions specified in Chapters II, IV and V (Table II.1, IV.1 and V.1). 
Membranes were additional washed three times with 1X TBST, before being 
submitted to one of the following detection methods: 
? Colorimetric detection (NBT/BCIP, Pierce) 
Each 15 cm membrane was developed by adding to it a solution of 66 µl NBT and 
33 µl BCIP in 10 ml Alkaline Phosphatase reaction buffer. When a coloured signal 
was achieved, the developing reaction was stopped by adding 20 ml of AP stop 
solution. Membrane was washed twice with deionised water and air dried at RT. 
? Enhanced chemiluminescence detection (ECL and ECL+ Kits, Amersham 
Pharmacia) 
ECLTM Western blotting from Amersham Pharmacia Biotech is a light emitting non-
radioactive method for detection of immobilised specific antigens, conjugated 
directly or indirectly with horseradish peroxidase-labelled antibodies (Fig. A.II.1). 
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Figure A.II.1. The ECL analysis system detects the presence of an antibody 
labelled with horseradish peroxidase by catalysing the oxidation of luminol, leading 
to the emission of light, which can be detected by an autoradiography film (From 
the manufacturer datasheet). 
 
 
The membrane was incubated for 1 min at RT with the ECL detection solution or for 
5 min with the ECL+ detection solution. These solutions were prepared fresh 
following the manufacturer’s instructions. ECL/ECL+ detection solution in excess 
was drained by touching the edge of the membrane against tissue paper and the 
membrane was gently wrapped in cling-film, eliminating all the air bubbles. In a 
dark room, an autoradiography film (XAR-5 film, Kodak, Sigma Aldich) was placed 
on the top of the membrane, inside a film cassette. The cassette was closed and the 
blot exposed for an appropriate period of time. The film was then removed and 
developed in a developing solution (Kodak, Sigma Aldrich), washed in water, and 
fixed in a fixing solution (Kodak, Sigma Aldrich).  
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APPENDIX III 
 
SEQUENCES AND TECHINICAL DATA  
 
 
 
 
APP695 sequences (GenBank Acession NM_201414)    
? cDNA sequence 
 
 1 atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta cccactgatg 
 71 gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga ctgaacatgc acatgaatgt 
 141 ccagaatggg aagtgggatt cagatccatc agggaccaaa acctgcattg ataccaagga aggcatcctg 
 211 cagtattgcc aagaagtcta ccctgaactg cagatcacca atgtggtaga agccaaccaa ccagtgacca 
 281 tccagaactg gtgcaagcgg ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg 
 351 cttagttggt gagtttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 
 421 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgag aagagtacca 
 491 acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga ggggtagagt ttgtgtgttg 
 561 cccactggct gaagaaagtg acaatgtgga ttctgctgat gcggaggagg atgactcgga tgtctggtgg 
 631 ggcggagcag acacagacta tgcagatggg agtgaagaca aagtagtaga 
agtagcagaggaggaagaag 
 701 tggctgaggt ggaagaagaa gaagccgatg atgacgagga cgatgaggat ggtgatgagg 
tagaggaaga 
 771 ggctgaggaa ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac 
caccaccaca 
 841 gagtctgtgg aagaggtggt tcgagaggtg tgctctgaac aagccgagac ggggccgtgc cgagcaatga 
 911 tctcccgctg gtactttgat gtgactgaag ggaagtgtgc cccattcttt tacggcggat gtggcggcaa 
 981 ccggaacaac tttgacacag aagagtactg catggccgtg tgtggcagcg ccatgtccca aagtttactc 
1051 aagactaccc aggaacctct tgcccgagat cctgttaaac ttcctacaac agcagccagt acccctgatg 
1121 ccgttgacaa gtatctcgag acacctgggg atgagaatga acatgcccat ttccagaaag ccaaagagag 
1191 gcttgaggcc aagcaccgag agagaatgtc ccaggtcatg agagaatggg aagaggcaga 
acgtcaagca 
1261 aagaacttgc ctaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa tctttggaac 
1331 aggaagcagc caacgagaga cagcagctgg tggagacaca catggccaga gtggaagcca 
tgctcaatga 
1401 ccgccgccgc ctggccctgg agaactacat caccgctctg caggctgttc ctcctcggcc tcgtcacgtg 
1471 ttcaatatgc taaagaagta tgtccgcgca gaacagaagg acagacagca caccctaaag catttcgagc 
1541 atgtgcgcat ggtggatccc aagaaagccg ctcagatccg gtcccaggtt atgacacacc tccgtgtgat 
1611 ttatgagcgc atgaatcagt ctctctccct gctctacaac gtgcctgcag tggccgagga gattcaggat 
1681 gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg attagtgaac 
1751 caaggatcag ttacggaaac gatgctctca tgccatcttt gaccgaaacg aaaaccaccg tggagctcct 
1821 tcccgtgaat ggagagttca gcctggacga tctccagccg tggcattctt ttggggctga ctctgtgcca 
1891 gccaacacag aaaacgaagt tgagcctgtt gatgcccgcc ctgctgccga ccgaggactg accactcgac 
1961 caggttctgg gttgacaaat atcaagacgg aggagatctc tgaagtgaag atggatgcag aattccgaca 
2031 tgactcagga tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 
2101 gcaatcattg gactcatggt gggcggtgtt gtcatagcga cagtgatcgt catcaccttg gtgatgctga 
2171 agaagaaaca gtacacatcc attcatcatg gtgtggtgga ggttgacgcc gctgtcaccc cagaggagcg 
2241 ccacctgtcc aagatgcagc agaacggcta cgaaaatcca acctacaagt tctttgagca gatgcagaac 
2311 tag 
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? Amino acid sequence 
 
L P G L A L L L L A A W T A R A L E V P T D G N A G L L A E P Q I A M F C G R L N M H 
M N V Q N G K W D S D P S G T K T C I D T K E G I L Q Y C Q E V Y P E L Q I T N V V 
E A N Q P V T I Q N W C K R G R K Q C K T H P H F V I P Y R C L V G E F V S D A L L V 
P D K C K F L H Q E R M D V C E T H L H W H T V A K E T C S E K S T N L H D Y G M L 
L P C G I D K F R G V E F V C C P L A E E S D N V D S A D A E E D D S D V W W G G A 
D T D Y A D G S E D K V V E V A E E E E V A E V E E E E A D D D E D D E D G D E V E 
E E A E E P Y E E A T E R T T S A I T T T T T T T E S V E E V V R V P T T A A S T PD AV 
D K Y L E T P G D E N E H A H F Q K A K E R L E A K H R E R M S Q V M R E W E E A E 
R Q A K N L P K A D K K A V I Q H F Q E K V E S L E Q E A A N E R Q Q L V E T H M A 
R V E A M L N D R R R L A L E N Y I T A L Q A V P P R P R H V F N M L K K Y V R A E Q 
K D R Q H T L K H F E H V R M V D P K K A A Q I R S Q V M T H L R V I Y E R M N Q S 
L S L L Y N V P A V A E E I Q D E V D E L L Q K E Q N Y S D D V L A N M I S E P R I S 
Y G N D A L M P S L T E T K T T V E L L P V N G E F S L D D L Q P W H S F G A D S V P 
A N T E N E V E P V D A R P A A D R G L T T R P G S G L T N I K T E E I S E V K M D A 
E F R H D S G Y E V H H Q K L V F F A E D V G S N K G A I I G L M V G G V V I A T V I 
V I T L V M L K K K Q Y T S I H H G V V E V D A A V T P E E R H L S K M Q Q N G 682Y 
E N P T Y687 K F F E Q M Q N 
Legend:   
Italic – Abeta sequence 
Bold – Cytoplasmic sequence  
 
 
Oligonucleotides  
 
? Primers used for APP-GFP constructs engineering 
NAPN (N-terminal APP primer with NruI consensus sequence). Length: 32 nts; 
Melting Temperature: 102 ºC. 
5’ – CTT AAG CTT CGC GAT GCT GCC CGG TTT GGC AC – 3’ 
S1 (C-terminal APP primer without STOP codon and with AgeI consensus 
sequence). Length: 38 nts; Melting Temperature: 114 ºC. 
5’ – ATG GTA CCG GTG GGT TCT GCA TCT GCT CAA AGA ACT TG – 3’ 
? Primers used for APP-GFP constructs sequencing 
NAPN (above). 
APP 500 (at the beginning of APP exon 5, nucleotide 478 - APP695 numbering). 
Length: 24 nts; Melting Temperature: 70 ºC. 
5’ – GAG AAG AGT ACC AAC TTG CAT GAC – 3’     
APP 1100 (at the beginning of APP exon 9, nucleotide 866 - APP695 numbering). 
Length: 14 nts; Melting Temperature: 42 ºC. 
5’ – TCC TAC AAC AGC AG – 3’     
APP 1500 (at the end of APP exon 11, nucleotide 1204 - APP695 numbering). 
Length: 14 nts; Melting Temperature: 44 ºC. 
5’ – ATC ACC GCT CTG CA – 3’     
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APP 1800 (at the beginning of APP exon 14, nucleotide 1507 - APP695 numbering). 
Length: 16 nts; Melting Temperature: 46 ºC. 
5’ – GCC AAC ATG ATT AGT G – 3’    
APP 2000 (at the end of APP exon 16, nucleotide 1806 - APP695 numbering). 
Length: 22 nts; Melting Temperature: 60 ºC. 
5’ – TGA CTC AGG ATA TGA AGT TCA T – 3’  
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pEGFP-N1 Plasmid 
- pEGFP-N1 (Clontech, BD Biosciences; GenBank Accession #U55762 ) 
 
 MCS: 
  
Restriction Map and Multiple Cloning Site of pEGFP-N1. (Unique restriction 
sites are in color or bold.) The Not I site follows the EGFP stop codon. The Xba I 
site (*) is methylated in the DNA provided by CLONTECH. If you wish to digest 
the vector with this enzyme, you will need to transform the vector into a dam- 
host and make fresh DNA.  
http://www.bdbiosciences.com/clontech/techinfo/vectors/vectorsE/pEGFP-N1.shtml - 
top#topDescription: pEGFP-N1 encodes a red-shifted variant of wild-type GFP (1-
3) which has been optimized for brighter fluorescence and higher expression in 
mammalian cells. (Excitation maximum = 488 nm; emission maximum = 507 
nm.) The MCS in pEGFP-N1 is between the immediate early promoter of CMV 
(PCMV IE) and the EGFP coding sequences. Genes cloned into the MCS will be 
expressed as fusions to the N-terminus of EGFP if they are in the same reading 
frame as EGFP and there are no intervening stop codons. SV40 polyadenylation 
signals downstream of the EGFP gene direct proper processing of the 3' end of 
the EGFP mRNA. A bacterial promoter upstream of this cassette (Pamp) expresses 
kanamycin resistance in E. coli. The pEGFP-N1 backbone also provides a pUC19 
origin of replication for propagation in E. coli and an f1 origin for single-stranded 
DNA production.  
http://www.bdbiosciences.com/clontech/techinfo/vectors/vectorsE/pEGFP-N1.shtml - top#topUse: 
Fusions to the N-terminus of EGFP retain the fluorescent properties of the native 
protein allowing the localization of the fusion protein in vivo. The target gene 
should be cloned into pEGFP-N1 so that it is in frame with the EGFP coding 
sequences, with no intervening in-frame stop codons. The inserted gene should 
include the initiating ATG codon. The recombinant EGFP vector can be transfected 
into mammalian cells using any standard transfection method. If required, stable 
transformants can be selected using G418 (7). pEGFP-N1 can also be used simply 
to express EGFP in a cell line of interest (e.g., as a transfection marker).   
 
 The role of APP functional domains on protein trafficking and processing        267 
 
 
? Bacteria strain (plasmid DNA amplification) 
E. coli XL1- blue:  
recA endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac[F’ proAB lacZΔM15 Tn10(Tetr)] 
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Protein Markers of Subcellular Compartments 
 
? Monoclonal Antibody anti-Syntaxin 6 (BD Transduction Laboratories) 
Syntaxin 6 is a 255 amino acid member of the Syntaxin family. It contains a C-
terminal transmembrane domain and is located at the Golgi apparatus. 
 
? Policlonal Antibody Anti-Calnexin (StressGen Biotechnologies) 
Calnexin is a ∼90 KDa unglycosylated molecular chaperone and a resident ER 
transmembrane protein.  
 
 
Fluorophores Excitation and Emission Spectra 
 
? EGFP-N1 (pEGFP encoded) (Clontech, BD Biosciences). Excitation and Emission 
Spectra for BD Living Colors™ Fluorescent Proteins: 
 
 
? Secondary Fluorescent Antibodies:  
A. Fluorescein goat anti–mouse IgG antibody/pH 8.0 (Molecular Probes) 
(fluorescence absorption and emission spectra in pH 8.0 buffer) 
B. Texas Red-X goat anti–mouse IgG antibody/pH 7.2 (Molecular Probes) 
(fluorescence excitation and emission spectra in pH 7.2 buffer) 
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Protein Markers Epifluorescence filter cubes (Chroma):     
  
Set ID: 41020                             
Fluorophore: EGFP. Narrow-band GFP for eliminating auto-fluorescence 
 
 Exciter 
 
HQ480/20x 
 Dichroic  
 Q495LP 
 Emitter  
 
HQ510/20m  
Set ID: 41004  
Fluors: Texas Red. Other: Alexa 568™ Alexa 594™ Bodipy TR Calcium Crimson™ 
Cy3.5™ DsRed  Rhodamine Mitotracker Red 580 Mitottracker Red Mitottracker Red 
580 Rhodamine Red Tetramethylrhodamine Texas Red™ X-Rhodamine 
A.                                       B. 
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Exciter 
HQ560/55x  
Dichroic  
Q595LP  
Emitter  
HQ645/75m   
 
 
 
 
 
